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Abstract 
Charlotte Louise Evans 
The biological and therapeutic significance of tumour necrosis 
Identification and characterisation of viable cells from the necrotic core of multicellular 
tumour spheroids provides evidence of a new micro-environmental niche that has 
biological and therapeutic significance. 
Key Words: Necrosis, Multicellular Tumour Spheroids, Tumour Microenvironment, 
Autophagy, Metabolism, Chemoresistance. 
Tumour necrosis has long been associated with poor prognosis and reduced survival in 
cancer. Hypotheses to explain this include the idea that as aggressive tumours tend to 
grow rapidly, they outgrow their blood supply leading to areas of hypoxia and 
subsequently necrosis. However whilst this and similar hypotheses have been put 
forward to explain the association, the biological significance of the cells which make 
up necrotic tissue has been largely ignored. This stems from the belief that because a 
tumour is more aggressive and fast growing it develops areas of necrosis, rather than, 
the tumour is more aggressive because it contains areas of necrosis. Which came first 
like the egg and chicken is yet to be determined, however to date most research has only 
considered the possibility of the former. Viable cells were found in the necrotic core of 
Multicellular Tumour Spheroids. When examined these cells were found to be different 
to the original cell line in terms of proliferation, migration, and chemosensitivity. A 
proteomic analysis showed that these phenotypical changes were accompanied by 
changes in a large number of proteins within the cells, some of which could be potential 
therapeutic targets. Furthermore this has led to a new hypothesis for tumour necrosis 
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and its association with poor prognosis. Necrotic tissue provides a microenvironemental 
niche for cells with increased survival capabilities. Protected from many 
chemotherapeutics by their non-proliferative status once conditions improve these cells 
can return to proliferation and repopulate the tumour with an increasingly aggressive 
population of cells. 
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Introduction 
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1 The Cancer Problem 
Cancer is a disease caused by the uncontrolled division of abnormal cells. In 2012 an 
estimated 14.1 million people were diagnosed with cancer worldwide with the four most 
common cancers being lung, breast, bowel and prostate. In the same year the number of 
cancer related deaths reached 8.2 million with the majority of deaths as a result of lung, 
liver, stomach or bowel cancer.1 Over the past 4 decades there have been significant 
developments not only in the treatment of cancer but also in our understanding of the 
pathogenesis of cancer. In 2000 the landmark paper by Hannahan and Weinberg 2 
characterised cancer as the acquisition of 6 different traits or ‘hallmarks’ that are 
essential for carcinogenesis. These hallmarks include self-sufficiency in growth signals, 
insensitivity to growth inhibitory signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis. More recently in 
2011 a further paper was published which added two emerging hallmarks, deregulated 
cellular energetics and avoiding immune destruction and two new enabling 
characteristics, genome instability and mutation, and tumour promoting inflammation to 
the list.3 
The treatment of cancer involves a team of multidisciplinary specialists including 
surgeons, radiotherapists and oncologists who administer chemotherapeutic agents. The 
history of chemotherapy goes back to the effects of mustard gas used during World War 
I on white cell counts and the subsequent application of nitrogen mustard as a treatment 
for haematological malignancies.4, 5 While significant advances have been made in the 
treatment of certain cancers such as lymphoma, leukaemia, and testicular carcinomas 
are now treatable, the response of lung, colorectal, oesophageal, pancreatic and prostate 
cancers remains poor and is often only palliative.6 Toxicity to normal tissue and the 
emergence of drug resistant cells are two of the key reasons why classical cytotoxic 
3 
 
drugs fail to reduce mortality rates7 and the need for new therapies that selectively target 
tumours as opposed to normal tissue and circumvent drug resistance has been 
recognised for many years. As the molecular basis for cancer continues to be 
unravelled, novel therapeutics that target key hallmarks of cancer are emerging. One 
particularly successful example is the Philadelphia chromosome discovered in chronic 
myelogenous leukaemia8 which led to the development of Imatinib targeted against the 
fusion protein Bcr-Abl.9 Additional advances have been made in several areas and a 
new generation of targeted therapeutics have emerged.10 These developments underpin 
the perceived wisdom that understanding the biology behind cancers is the real driving 
force leading to the development of new targeted therapies for cancer treatment. As 
more targeted therapeutics progress into the clinic, it has become increasingly clear that 
they also have their problems. New mechanisms of resistance have emerged and despite 
initial good responses to therapy, overall survival is frequently extended for periods of 
months not years. This phenomena has been attributed to the fact that tumours are 
genetically heterogenous and new ‘strains’ of aggressive cells emerge following the 
suppression of specific pathways.11 Understanding how tumours escape chemotherapy 
and re-emerge as an aggressive tumour is essential if long-term remissions are to be 
obtained.   
On this theme, the hypoxic tumour microenvironment is a known cause of resistance to 
therapy and is a marker of poor prognosis. Hypoxia is  a phenomenum whereby a tissue 
is deprived of adequate levels of oxygen leading to biochemical changes within the 
cells. Hypoxia is known to promote the emergence of a more aggressive phenotype via 
several mechanisms including selection of p53 mutant cells that don’t undergo 
apoptosis under hypoxic conditions.12 In addition to hypoxia, solid tumours are known 
to contain regions of necrosis and the extent of necrosis has been shown to be a marker 
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of poor prognosis in several cancer types. The mechanistic basis underpinning this 
relationship is not known. This thesis will focus on the tumour microenvironment with a 
specific focus on tumour necrosis as a ‘niche’ where cells can still survive very hostile 
conditions leading to resistance to therapy and the emergence of a resistant and 
increasingly aggressive population of cells. Initially however, it would be pertinent to 
review the literature focusing on the biological origins of tumour necrosis and the 
current understanding of how necrosis may lead to poor prognosis.  
2 Necrosis 
2.1 Types of Cell Death 
Cell death can generally be divided into two distinct types, apoptosis, a type of 
programmed cell death which involves a distinct combination of signalling pathways 
and has characteristic morphological changes and necrosis which has traditionally been 
considered as an uncontrolled and passive form of cell death. Where apoptosis can be 
likened to a form of cell suicide which requires energy in the form of ATP, necrosis is 
more cataclysmic, accidental and uncontrollable cell death which results in the release 
of the cellular contents into the extracellular space.13 Necrosis is also characterised by 
certain morphological changes such as disruption and breakdown of the plasma 
membrane and induction of inflammation in the surrounding tissue as a result of the 
release of the cellular contents into the extracellular space. Karyolyis occurs which 
entails DNA being degraded leading to the chromatin of the nucleus fading, making the 
dark blue nuclei seen in H&E staining less visible. As the chromatin condenses the 
nucleus itself starts to shrink, a phenomenon known as pyknosis. Then the nucleus 
begins to fragment and the nuclear material is distributed throughout the cytoplasm in a 
process called karyorrhexis. Necrosis occurs due to a catastrophic energy shortage 
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where the levels of cellular ATP become incompatible with the cell's survival. This 
energy shortage can be the result of a number of external stimuli including toxins, 
pathogen infection, physical and heat damage and a critical lack of oxygen or 
nutrients.14  
There are many lesser known forms of cell death other than apoptosis and necrosis. 
Cells can die via mitotic catastrophe which tends to be defined by cell death which 
occurs as a result of aberrant mitosis and occurring during or shortly after mitosis 
itself.15, 16 Entosis is described as a non-apoptotic cell death as a result of detachment 
from the ECM which leads to the unusual phenomenon of invasion of one cell into 
another. This cell internalisation leads to one cell containing another still living cell and 
can result in either degradation of the internalised cell termed entosis or release of the 
cell.17 Panthanatos is used to describe a particular subtype of cell death which involved 
the poly ADP ribose polymerase (PARP) DNA damage response enzymes, in particular 
PARP1. Whilst normally PARP1 is involved in the repair of single strand DNA breaks 
in order to ensure genomic homestasis in response to minor DNA damage. However 
overactivation of PARP1 can cause depletion of NAD+ and ATP.18, 19 
2.2 Morphological patterns of tissue necrosis 
There are three types of tissue necrosis, coagulative, colliquative and caseous, each type 
has a different macroscopic presentation (see Figure 1).20 Coagulative necrosis presents 
as firm tissue, almost as if it has been cooked due to the production of a gel-like 
substance, in this case the architecture of the tissue is maintained. Denaturation of 
protein within the cell leads to coagulation as the albumin within the cells becomes firm 
and gel like.21 Colliquative necrosis also known as liquefactive necrosis is more liquid-
like in presentation, as digestion of the dead cells transforms the tissue into a viscous 
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mass. Whilst this commonly occurs as a result of a bacterial or fungal infection, hypoxic 
infarcts in the brain can cause this type of necrosis due to the tissues lack of connective 
tissue and high levels of digestive enzymes. 22 Caseous necrosis appears like a 
combination of colliquative and coagulative, with a structure more often described in 
layman's language as cottage cheese. The tissue appears white and friable as the dead 
cells are only partly digested leaving behind granular particles (Figure 1).23 In the case 
of necrosis found in tumour tissue this presents as coagulative necrosis.24 
 
Figure 1. Types of Necrosis. Panel A Caseous Necrosis in the lymph nodes, Panel B 
Coagulative necrosis in the liver, Panel C Liquifactive necrosis in the lung the small area of 
necrosis is denoted by an arrow. 25 
2.3 Necrosis: a type of programmed cell death? 
Recent evidence has shown that in some cases necrosis may be more regulated than 
previously thought. It is thought it may function as a backup mechanism of cell death 
which is avoided where possible due to the consequences of the process on the 
A B 
C 
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surrounding tissue, but can be activated in cases of emergency.26  It has been discovered 
that in certain cases where necrosis is not triggered by very extreme conditions the 
process has been documented as a regulated event. Multiple signalling pathways 
involving death receptors,27 the mitochondria28 and certain kinase cascades29 have been 
showed to play a part in necrosis. Indeed by inhibiting certain molecules in these 
pathways a cell can be influenced towards either apoptosis or necrosis.30, 31, 32 Anti 
apoptotic molecules such as Bcl-2/Bcl-x proteins and heat shock proteins have been 
found to prevent not just apoptosis but in some cases necrosis as well.33, 34 In some 
cases caspases were required for the initiation of necrotic process.35, 36 Inhibition of 
caspases such as caspase-3 and caspase-8 inhibited not only apoptosis but also 
necrosis.37, 38, 39 Furthermore necrosis has been found to be involved in various 
physiological processes throughout the body. Renewal of the cells lining the small 
intestine has been shown to involve necrosis as well as apoptosis,40 and similar findings 
have been seen in the large intestines.41  During oogenesis, necrosis has been discovered 
to play a role in follicular development,42 and natural selection in the immune system 
specifically the activation dependant death of T-cells is both caspase independent and 
has necrotic morphology.43  
Necroptosis is the term used to describe regulated necrosis which involves distinct 
molecular signalling including death receptor signalling, caspase inhibition and RIP1 
(receptor interaction protein 1) and/or RIP3 activation.44 Necroptosis has been 
implicated in a number of different disease types including myocardial infarction, stroke 
and inflammatory bowel disease.45, 46 The process has been found to be stimulated by 
multiple triggers such as alkylating DNA damage47 and excitotoxins.48 The kinase RIP1 
is known to play an integral part in the initiation of necroptosis as necrostatin-1 an 
inhibitor of necroptosis has been to exert its anti necroptosis effect through the 
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inhibition of RIP1 sernine/threonine kinase activity.49 A number of death receptors have 
been identified which can stimulate necroptosis including TNFα, FasL and Trail.50 
Whilst some of the stimulators of necroptosis have been uncovered the executioner 
proteins further downstream remain more elusive. Proposals have been made for the 
involvement of Reactive oxygen species (ROS) based upon the evidence that the ROS 
scavenger, butylated hydroxyanisole, inhibited TNFα-induced necrotic cell.51 
Autophagy has also been implicated in the execution of necroptosis due to the 
observation that autophagosomes are often present in cells known to be undergoing 
necroptosis. Further research into autophagy’s role has shown that knockdown of 
beclin1 and Atg7, two autophagy related genes, was sufficient to inhibit necroptosis in 
murine fibrosarcoma cell line.52 However this has yet to be demonstrated in human cell 
lines. Necroptosis may activate autophagy, hence making autophagy a response to 
necroptosis as opposed to part of the process itself.53 Whilst research is still ongoing in 
order to fully understand the process and implications of necroptosis in disease, 
neurostatin could be a potential new treatment for diseases involving inflammation as a 
result of necroptosis. 
2.4 Necrosis as a pathological indicator of prognosis in cancer 
In solid tumours areas of necrotic tissue are found where the tumour has outgrown its 
current blood supply. The location of necrosis is thought to correspond with intra 
tumour hypoxia.54 Increased tumour necrosis has long been associated with increased 
aggressiveness of the tumour.55 It has been noted that a reduction in necrosis is seen in 
tumours in elderly patients compared to younger patients. Specifically this has been 
found in breast cancer where tumours in younger patients (<39yrs) were found to show 
increased tumour necrosis compared to tumours found in older patients. This is 
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suggestive of necrosis being correlated with increased tumour aggressiveness as 
tumours in younger patients are significantly more aggressive than those seen in older 
patients.56 More recently in colorectal cancer, the presence of necrosis was found to be 
associated with poor differentiation, large tumour size, advanced stage and venous 
invasion.57 Further studies have found that necrosis in colorectal tumours is linked to 
poor survival.58 
Figure 2. Kaplan-Meier Survival Plots. Detailing 
the differences in survival time between pancreatic 
cancer patients with tumour necrosis and without at 
different stages of progression. As the disease 
progresses the effect of necrosis upon survival time 
lessens.59 
This data has been backed up in a number of 
other solid tumour types. Necrosis has been 
linked to poor prognosis in renal cell carcinoma, 
where it was also associated with other 
prognostic indicators like lymph node disease, 
metastases, high grade and tumour size.60 What 
this study also showed however was that only 
necrosis in primary tumours was an indicator of 
poor prognosis and reduced overall survival. 
When the patient sample was separated into two 
groups, those with localised disease and those 
with metastatic, necrosis was found to be a 
predictor of prognosis only in those with localised disease. While it is not known 
exactly why this is theories have been put forward to explain it.  Such as, tumours with 
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necrosis have been shown to be more aggressive therefore it is not surprising that these 
aggressive tumours are capable of metastasising, and the development of metastases is 
clearly an indicator of poor prognosis. As opposed to patients who already have 
metastatic deposits, their prognosis is already determined far more by the presence of 
metastases rather than any necrosis in the primary tumour. The same phenomenon has 
also been document in prostate cancer (see Figure 2). Necrosis has also been recently 
found to be of prognostic value in upper urinary track transitional cell carcinoma,61 
gastrointestinal tract tumours62 and Ewing's sarcoma amongst others.63 Also in non 
small cell carcinoma extensive tumour necrosis was found to correlate with an 
aggressive tumour phenotype64 and poor prognosis.65 However one large study showed 
that tumour necrosis in NSCLC (non small cell lung cancer) was not correlated with 
micro vessel density, 66 leading to the question if necrosis does not reflect the 
angiogenic capacity of the tumour then how and why is it correlated with tumour 
aggression and poor prognosis?   
2.5 Investigating the link between necrosis and tumour aggression 
Whether the high levels of necrosis directly cause the tumour to be more aggressive, or 
it is an indirect association between rapidly growing, aggressive tumours that outgrow 
the blood supply leading to necrosis, is unclear.67  
There are many theories to explain the link between necrosis and tumour 
aggressiveness. Such as the tendency to see more necrosis in highly angiogenic 
tumours, which at first seems counterintuitive, however angiogenesis allows the tumour 
to rapidly proliferate, and this can lead to areas of ischemia within the rapidly growing 
tumour as proliferation quickly surpasses the new angiogenic growth. Furthermore, 
tumour vasculature is unlike normal vasculature found in the rest of the body, as it is 
poorly organised and leaky, this can lead to not all areas of the tumour being adequately 
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supplied.  This theory is supported by the fact that high levels of necrosis are associated 
with larger more vascular tumours.68 
Areas of inflammation and necrosis are also known to be conducive for increased 
genetic mutations which exacerbate genetic instability and promote the emergence of 
more aggressive tumours via the acquisition of additional mutations. In tumours low 
nutrient availability can lead to oxidative stress and the build-up of damaged proteins 
and organelles. This would normally stimulate p62 which would bind to the aggregates 
and target them for destruction via the autophagic pathway. However in cells with 
deficient autophagy this response is absent and both p62 and its damaged cargo build up 
until a cytotoxic response is stimulated. This can involve the stimulation of DNA 
damage responses, changes in gene expression and increased loss/gain of chromosomes. 
All this can work to increase the frequency of DNA mutations and hence stimulate 
further tumour progression and potentially the emergence of a more aggressive tumour. 
Ultimately whilst it has been observed that tumour necrosis is indicative of poor 
prognosis, the exact mechanisms behind this association are not yet understood. By 
examining the necrotic tissue itself and the cells which it is composed of, a better 
understanding could be formulated. Determining whether all tumour cells in areas of 
necrosis are indeed dead or whether some cells possess the necessary biochemical 
machinery to survive is an important first step in investigating the link between necrosis 
and tumour aggression.  
Investigating the biological mechanisms behind tumour necrosis will help to provide 
evidence towards the hypothesis that Tumour necrosis is associated with poor prognosis 
for patients as it provides a microenvironmental niche for the development of an 
increasingly aggressive, metastatic and treatment resistance population of cells. And 
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that the emergence of this population explains the association between tumour necrosis 
and patient prognosis. 
Before discussing the concept further it would be pertinent to first of all review the 
origins of tumour necrosis and the cellular responses to severe microenvironmental 
conditions. 
3 The Tumour Microenvironment 
3.1 Heterogeneous nature of tumours 
As mentioned previously one of the emerging hallmarks of cancer is deregulated 
cellular energetics which involves the capacity of the cell to reprogram its metabolism 
in order to survive and proliferate in changing tumour microenvironments. The tumour 
microenvironment has been gaining interest in the role it plays in tumour biology. The 
tumour microenvironment can be broadly described separately in terms of its two 
compartments, the stromal microenvironment and the hypoxic microenvironment. 
Normally the stroma acts as a barrier against tumour formation, however the presence of 
transformed cancer cells can cause changes in the stromal cells which leads to an 
increasingly tumour promoting environment.69 Cells which make up the stromal 
compartment include those which associated with the tumour vasculature namely 
endothelial cells, fibroblasts, macrophages, and immune cells including lymphocytes. 
The extracellular matrix is also a crucial part of the tumour microenvironment. Pericytes 
which wrap around the endothelial cells making up the tumour vasculature are known to 
be involved in paracrine signalling to maintain endothelial cell homeostasis. 
Pharmacological targeting of these cells causes loss of coverage leading to vascular 
instability, loss of integrity and function, importantly normal non tumour associated 
pericytes are not sensitive to pharmacological targeting, making this selective to tumour 
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vasculature.70, 71 Tumour promoting immune cells include, macrophages, mast cells, 
neutrophils, and B and T lymphocytes. Research has discovered that these cells can 
express and release various signalling molecules into the stroma which carry out their 
tumour promoting actions.72, 73 Fibroblasts are also found in solid tumours, they are 
often the preponderant cell population making up the stroma. Cancer associated 
fibroblasts (CAFs) have been found to support the surrounding tumour cells through 
paracrine signalling and a parasitic-host metabolic interaction whereby the tumour cells 
stimulate the CAFs to undergo autophagy in order to provide recycled nutrients for the 
tumour cells.74  
The hypoxic tumour microenvironment is another important consideration as the 
majority of tumours contain regions of low oxygen concentration also known as 
hypoxia. The pathogenesis behind this physiological microenvironment can be 
explained in part by the tumour vasculature. 
In order for a tumour to grow past a certain size, it needs to develop a vascular supply. 
The type of vessels formed and their structure leads to the generation of a tumour 
microenvironment which serves to help the tumour resist treatment.75 Tumour 
vasculature tends to be disorganised and leaky with blind ends, and arterio-venous 
shunts, which fails to supply all cells within the tumour consistently. This coupled with 
a poor lymphatic drainage system, changes in extracellular matrix (ECM) composition 
and contraction of the interstitial space mediated by fibroblasts, causes high interstitial 
fluid pressure (IFP).76 High IFP directs blood to the periphery of the tumour and away 
from the centre. Also another contributing factor is the high metabolic activity of the 
tumour cells meaning oxygen consumption within the tumour is high.77 All this leads to 
a tumour microenvironment where nutrient and oxygen availability is reduced, and cells 
become starved of nutrients and oxygen, often leading to the formation of necrosis. The 
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presence of tumour necrosis has been found to be correlated with tumour aggression, 
with the more aggressive tumours showing higher levels of necrosis. The reason for this 
association is yet to be elucidated but various theories will be discussed in detail later.  
Hypoxia can have many effects upon a tumour’s biology; it can lead to the selection of 
cells with genotypes more suited for the low oxygen conditions78 and changes in cell 
signalling in processes governing apoptosis79 and autophagy80 and cell metabolism.81 
Hypoxia can also promote certain physiological processes such as angiogenesis,82 
epithelial mesenchymal transition,83 invasion and metastases84 and as such can play a 
role in drug resistance through a variety of different mechanisms.85  
In order to take advantage of this characteristic of the tumour microenvironment 
hypoxia related signalling pathways, and in particular hypoxia-inducible factor (HIF) 
which controls the transcription of a number of hypoxia related genes, have been 
investigated as targets.86 As well as the physiological reduction in oxygen levels which 
has led to the development of hypoxia activated pro drugs. These bio reductive pro 
drugs are inactive until they reach the hypoxic environment of the tumour where they 
are reduced to their active form and can then exert they effect upon the cancer cells. 
Two examples of hypoxia activated pro drugs are tirapamazine which induces single 
and double strand breaks87 and AQ4N a topoisomerase II inhibitor88 which are both 
selectively activated in the hypoxic tumour environment. The advantage of this type of 
drug is that they are less toxic to normal tissues due to the added selectively.89 Hypoxic 
cells are known to be more resistant to certain chemotherapeutics and radiotherapy90 
making this microenvironment problematic when treating cancer, while at the same time 
giving rise to new targets. 
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The acquisition of chemotherapeutic resistance is a sign of active tumour evolution and 
the influence of environment pressures. The interactions between the tumours cells and 
the tumour microenvironment, and how this affects resistance needs to be more fully 
understood in order to discover new therapeutic targets, and explain the failure of 
previously investigated targets. The targeting of numerous cellular compartments may 
lead the way to overcoming therapeutic resistance and achieving improved patient 
responses.  
3.2 The metastatic microenvironment 
Tumour hypoxia has long been linked with increased tumour aggression and metastatic 
spread.91, 92 In order for cells to successfully metastasise they must first be able to 
penetrate through the basement membrane and then undergo the process of intravasation 
to gain access to the circulatory system. Once in the circulation, if the cells can survive, 
they are transported to a distant site where they must then go through extravasation. 
Whilst studies have shown that the frequency of arrival of metastatic cells at new sites is 
quite high, only a small number manage to thrive in their new environment.93 In order 
for a new cell to grow in its new environment it must receive the correct signals from 
the ECM, if the new microenvironment is more conducive to quiescence then the cell 
may not be able to proliferate and form micro metastases. 94 The biology of this can be 
explained by the before mentioned 'seed and soil' theory which explains why certain 
cancers tend to metastasise to certain organs such as prostate to bone, colorectal to liver 
and breast to brain. In order for tumour cells to grow in a new environment the new 
environment must be conducive to growth of that particular cell. Which means that 
microenvironments in different tissue are more appropriate for the growth of different 
cancer cells. Evidence behind this theory shows that circulating cancer cells with certain 
complements of cell surface receptors tend to implant in new microenvironments which 
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have reciprocal receptors/ligands. Chemokines in particular have been shown to be 
involved in the process. Cancer cells express specific chemokine receptors and they 
have been found to metastasise to sites which express the corresponding ligand. This 
was seen in breast cancer where metastasising cells were found to express the two 
chemokine receptors CXCR4 and CCR7, the corresponding ligands CXCL12 and 
CCL21 were found to be produced in the lung and lymph nodes, two common sites for 
breast cancer metastasis. Furthermore blocking the receptors with antibodies was shown 
to reduce the frequency of metastasis.95 This highlights the idea that to help prevent 
metastasis the molecular microenvironment of the organs where metastasis often occurs 
needs to be investigated carefully for new targets which could prevent the survival or 
growth of new cancer cells there. 
3.3 Therapeutic implications of the tumour microenvironment 
Cancer cells from different tumour types vary highly in their genetic complement of 
mutations; however changes in biology caused by the tumour microenvironment are 
hopefully more common to a wider variety of tumour types with similar 
microenvironments. This would suggest that approaches to target the microenvironment 
could be more transferable between different cancers. The first step in doing so would 
be to identify the individual molecular targets in the microenvironments of different 
tumour types. This been done for a number of different tumour types so far.96, 97  
Over time the understanding of the biological and therapeutic implications of the 
tumour microenvironment has increased greatly and the full impact of its contributions 
to not only primary tumour formation but tumour progression and invasion and 
metastasis, are finally being appreciated. This increased understanding of the 
differential pathophysiology in tumour tissue compared to normal tissue has lead and 
continues to lead to the discovery of new molecular targets.  
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4 Multicellular Tumour Spheroids (MCTS) as a model of the Tumour 
Microenvironment. 
Cancer's heterogenesis nature makes it important to choose the right model in which to 
study in vitro. Specifically the heterogeneity of the physical environments found within 
solid tumours. Regional differences in pH, oxygen concentrations and nutrient 
availability impose differing selective pressures upon tumour cells in different areas of 
the tumour. Two dimensional monolayers are the standard model for studying both the 
biology of cancer and the effects of chemotherapeutics in vitro. While they have 
undeniable benefits such as their reproducibility, simplicity to set up, and viability of 
cells in culture, the use of 3D models has recently undergone a resurgence in interest. 
One of the reasons for this is that solid tumours like breast cancer and colorectal cancer 
are not two dimensional but three and as such are physically different to cancer cells 
grown as a monolayer. Whilst every cell in a monolayer has equal access to nutrients 
and oxygen, in solid tumours only the cells in the viable rim have unobstructed access. 
Once inside the tumour the cells are at the mercy of diffusion gradients and a constantly 
changing and unreliable vasculature. Therefore there are distinct populations of cells 
which have adapted to living in different microenvironments depending on their 
proximity to tumour or host vasculature and as such are both phenotypically 
heterogeneous and can respond differently to chemotherapeutics. 
Multicellular tumour spheroids (MCTS) have been around since the 1970s where they 
were mostly used as an in vitro three dimensional model for studying radiotherapy and 
chemotherapy in solid tumours.98, 99Since then their value as a model for studying the 
tumour microenvironment has been realised, and they have been used to study a variety 
of different phenomenon such as hypoxia100 and tumour cell  metabolism101 in a less 
artificial way compared to work done in monolayers.  MCTS are one of the most 
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common forms of 3D culture and are particularly popular as they can be grown in large 
numbers. They are physically symmetrical, and this symmetry extends to the 
physiological characteristics like cell-cell adhesion, nutrient gradients, and areas of 
hypoxia and necrosis. They most represent avascular tumours and early 
micrometastasis. 
4.1 Advantages of MCTS as an in vitro model for studying the physiological 
microenvironment of tumours 
One of the main benefits of MCTS is that they are three dimensional and are more 
representative of an actual tumour than a monolayer of human cancer cells grown in a 
flask. This is due to the fact that the cells within a MCTS, unlike monolayers, are 
subject to diffusion gradients of oxygen and nutrients leading to the formation of a 
necrotic core similar to solid tumours (see Figure 3). In a MCTS the outer cells are able 
to proliferate due to the close proximity of the source of nutrients and oxygen, whilst 
the innermost cells cannot. This selective pressure can lead to different populations of 
cells within the same spheroid (Figure 4). Cells which have different phenotypes 
respond differently to chemotherapy, specifically chemotherapeutics which target 
proliferating cells. 
As the distance from the surface of the MCTS hence from the source of oxygen and 
nutrients increases the concentrations of both decrease whilst concentrations of waste 
productions increase (see Figure 3). At a critical distance often ~500µM for many 
cancer cell lines102, 103 the cells can no longer survive the conditions. Similarly MCTS 
will only grow to a certain size (~1000µm in diameter for many cell lines) before their 
growth stalls.104 Originally it was believed that oxygen concentrations dictated the 
thickness of the viable rim and once oxygen levels dropped below a critical point the 
cells became necrotic. It was discovered however that oxygen is not the sole contributor 
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to this process, cells can become necrotic within MCTSs at a variety of different oxygen 
concentrations, with other factors such as glucose levels being implicated.105 
 
Figure 3. Diagrammatic representation of the different gradients which exist within 
MCTSs.106 
The cells which reside at the innermost part of the spheroid become quiescent due to 
nutrient and oxygen deprivation and eventually die, mostly through necrosis. These 
differential growth kinetics resemble those of tumours grown in vivo, particularly micro 
metastases prior to angiogenesis. As the mass of cells increases in size the proportion of 
cells actively proliferating is reduced, while the proportion of quiescent cells is 
increased.107 Similarly in patients the tumour cells which are located near a blood vessel 
are actively proliferating but cells which are not located near a blood vessel exist in a 
non-proliferative dormant stage. Whilst much effort has been put into targeting and 
killing the proliferating tumour cells, the dormant cells by their very nature are resistant 
to many chemotherapeutic drugs as they target actively proliferating cells.108 These 
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dormant cells could contribute to relapse once the proliferating cells have been depleted 
through chemotherapy yet there has been little progress in targeting them.109, 110 One 
reason for the lack of progress could be the difficulty in finding an appropriate in vitro 
model to study this phenomenon in. 
 
Figure 4. Hypoxia and Necrosis in DLD-1 MCTS. Panel A hypoxia in a DLD-1 MCTS. 
Green represents Ki67 positive proliferating cells, red represents pimidozole staining 
representing the hypoxic population of cells.111 Panel B Shows a HT-29 MCTS (for further HT-
29 spheroid H&E staining see Chapter 2 results) stained with haematoxylin to detect the nucleus 
and eosin to highlight the cytoplasm, showing the thick viable rim (VR) and central necrotic 
core (NC). 
B 
A 
NC 
VR 
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4.2 Co-culture MCTS 
MCTS can also support the co-culture of different cells types, enabling stromal cells 
types such as fibroblasts to be grown with cancer cells. This model, which more closely 
resembles the cellular heterogeneity that is seen in in vivo tumours can be used to look 
at tumour-stromal interactions, which given recent findings appear to be increasingly 
important when looking at the consequences of the tumour microenvironment.112 
4.3 Culturing Spheroids 
There are a variety of techniques that can be used to culture spheroids. One of the most 
widely used involves spinner flasks which allow the cultivation of large numbers of 
spheroids at the same time. The theory behind growing spheroids involves preventing 
the attachment of the cells to any surface. Spinner flasks prevent cells from attaching to 
the surface of the flask by keeping the media constantly moving using a stirrer rod. In 
order to grow, the cells then have to attach to each other, and it is the process of 
inducing cells to attach to each other and grow that is fundamental for the formation of 
spheroids. 
4.4 MCTS as an in vitro model for solid tumours. 
Whilst spheroids were initially used for testing the response of different cell populations 
to radiotherapy, since then they have been used as a model for studying the effects of 
chemotherapeutics, in particular the penetration of chemotherapeutics into the 
spheroids. Similar to quantifying the effects of radiotherapy, spheroid diameter is taken 
to establish spheroid growth delay as a measure of drug efficacy. Proliferation can also 
be measured using autoradiography on spheroids treated with H-thymidine, 
histologically using BrdU antibodies or antibodies against proliferation markers such as 
Ki-67, or on single cell populations via flow cytometry. Though the three dimensional 
structure of spheroids makes it innately impossible to study single cells from the 
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spheroid in situ, by freezing or fixing and then sectioning spheroids different cell 
populations can be characterised. Multicellular mediated resistance has been seen in 
spheroids in response to certain drugs including alkylating agents like 
cyclosphosphamide113 and cisplatin.114 This is similar to the ‘contact effect’ seen in 
spheroids in response to radiotherapy whereby cells in a spheroid are more resistant 
than those grown in a monolayer. Although the reason behind this has not been fully 
established it is believed to be due to a combination of factors. Gap junction 
‘reciprocity’ which is essentially the ability of cells to provide nutritional support  to 
neighbouring sick or starving cells, is thought to be involved,115 along with changes in 
repair-related gene expression as a result of cell shape and modifications in chromatin 
packaging which affects DNA repair.116 Multicellular mediated resistance is believed to 
be caused by the same factors involved in the ‘contact effect.’117 The fact that there are 
such differences in the response of cells grown in monolayers compared to spheroids 
only highlights the importance of three dimensional cell culture as an intermediate step 
between classical in vitro monolayers and in vivo testing. 
4.5 Cell Sorting 
The ability to sort the different cellular populations within a MCTS allows for the 
individual characterisation of these cells, and can highlight the effects of known 
microenvironmental changes on the cells. Cells from MCTS can be sorted using 
different methods including serial trypsinisation where the enzyme tryspin is used to 
digest cells from the outside of the MCTS one layer at a time. Another method involves 
using non-lethal nucleic dyes such as Hoechst 33342 to stain the intact spheroids. Once 
stained it is possible to use FACS to separate the cells into different populations based 
on their level of fluorescence. Cells located on the outer edges of the spheroid would be 
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most strongly stained as the dye takes time to diffuse through the cells and penetrate the 
very centre of the spheroid.118, 119 
By using fluorescent associated cell sorting (FACS) it is possible to sort the cells in the 
spheroids into many different populations, based on their distance from the viable rim. 
These different populations can then be individually examined for relative numbers of 
necrotic, apoptotic autophagic and quiescent cells. The populations can also be assayed 
to compare the cells’ viability and aggressive characteristics such as the ability to 
invade and metastasise. The response of the different cellular populations within the 
MCTS to chemotherapeutics and a measure of drug penetration can also be achieved by 
examining the sorted populations.120 
5 Cellular responses to the hypoxic tumour microenvironment 
All cells not only cancer cells are able to adapt up to a point to changes in their local 
environment. Such mechanisms that can be used by the cells; particularly cancer cells in 
response to stress, nutrient deprivation and hypoxia, include autophagy, tumour 
dormancy, senescence, apoptosis, epithelial mesenchymal transition and many more. 
The tumour specific responses to the tumour microenvironment which can increase the 
survival and progression of the cancer are discussed in the following section. 
5.1 Autophagy 
Cells can adapt biochemically to different micro-environmental conditions and 
knowledge of these changes has potential implications for the development of novel 
therapeutics. The selective pressure leads to the development of a subpopulation of cells 
more adapted to their environment. Adaptations can include processes such as 
autophagy. The word autophagy in Greek literally translates to ‘self eating’ and is a 
biological process which has been known for decades but has only recently come to the 
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forefront of several areas of disease research. There are three types of autophagy, 
macroautophagy, microautophagy and chaperone mediated autophagy (CMA).121 Both 
micro and macroautophagy involve sequestering portions of the cytoplasm, via the 
formation of an autophagosome de novo, in microphagy the substrates in the form of 
individual proteins, are taken up straight into the lysosome by invagination of the 
membrane. CMA requires no membrane rearrangements but instead relies on a 
molecular chaperone Hsp90 and a lysosome-associated membrane protein LAMP-2a to 
transport proteins across the membrane of the lysosome.122  
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved 
process of protein degradation which occurs in all eukaryotic cells.123, 124 It is a highly 
regulated process that works to maintain cellular homeostasis under conditions of intra 
or extra-cellular stress such as nutrient deprivation by recycling long lived proteins and 
damaged organelles back to single amino acids to aid cell survival. Autophagy can also 
be stimulated under conditions such as oxidative stress, accumulation of damaged 
organelles and pathogen infection. Its stimulation can lead to either adaption to 
conditions and survival or death via a process known as programmed cell death II 
(autophagic cell death).125, 126 In the case of bacterial infection, bacteria can be 
selectively targeted for degradation within the autophagolysosomes,127 or alternatively 
the bacteria can trigger autophagic cell death.128  Autophagy occurs under many 
different pathological conditions, including cancer and neurodegenerative diseases such 
as Parkinson’s, Huntington’s and Alzheimer's. However whether autophagy acts in a 
protective or detrimental manner under these conditions is unclear.  The following 
sections examine the process of autophagy in more depth with a particular focus on the 
different steps involved in the process, it's role in cancer and different stimuli for 
induction. 
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5.2 Autophagy Signalling 
In response to stimuli, a double membrane structure named the isolation membrane, 
forms in the cytoplasm. The origin of which is currently unknown. The membrane 
elongates as it sequesters portions of the cytosol, where upon the edges of the isolation 
membrane fuse together to form a complete autophagosome. The autophagosome then 
traffics its cargo to a lysosome, and fuses with it to create an autophagolysosomes. Once 
fusion has occurred the lysosomal hydrolases degrade the sequestered contents which 
are then released back into the cytosol and recycled to provide fuel for protein synthesis 
(Figure 5). 129 
 
Figure 5. Diagram representing the molecular mechanism of autophagy and the genes 
involved in each of the steps as found through studies in yeast. The autophagic process is 
split into several steps; induction, vesicle nucleation, cargo recognition, vesicle completion, 
fusion with the lysosome, vesicle breakdown, and nutrient recycling. The Atg proteins involved 
in each of the steps are shown. The phagophore assembly site (PAS) which is believed to be  the 
location for the assembly of the phagophore is shown.130  
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Autophagy is essentially a process for recycling old or misfolded proteins and damaged 
organelles in order to provide a source of energy for starving cells, and also to provide a 
measure of quality control by ridding the cells of damaged components. This is 
particularly useful in post mitotic cells where there is no option to dilute these damaged 
proteins via cell division.131 The digested proteins and organelles provide both starting 
material for the production of new cellular structures as well as energy when the new 
amino acids are fed into the tricarboxylic acid (TCA) cycle to produce ATP.132  
Over the past years the machinery involved in autophagy has been determined using 
yeast as a model organism. More than 30 autophagy-related genes (ATGs) have been 
discovered so far in yeast, many with mammalian equivalents. 133  The autophagy 
pathway has been characterised into a series of separate steps including induction, cargo 
recognition and selection, vesicle nucleation, vesicle expansion and completion, 
autophagosome-vacuole fusion and breakdown of cargo (see Figure 5), of which similar 
processes have been identified in mammalian cells. So far, the function of many Atgs is 
now understood.   
There are different subtypes of autophagy, which differ depending on the stimulus for 
autophagy induction. Lack of nutrients tends to stimulate a type of autophagy where 
inhibition of mTOR leads to a reduction in the association of p62 with the 
autophagosome membrane, and the autophagosomes are more likely to contain large 
elements of free cytosol. The autophagosomes themselves, in starvation-induced 
autophagy are thought to be derived from mitochondria.134, 135 In contrast, a separate 
subtype of autophagy is thought to be stimulated by stress (e.g. oxidative) or the build-
up of ubiquitinated aggregates, and differs in that p62 is associated with the 
autophagosome membrane in the initiation stage.  Autophagosomes stimulated by such 
conditions are more likely to contain ubiquitinated cargo.136 
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5.3 Stimuli for Autophagy Induction  
In most cells basal levels of autophagy are quite low under normal conditions.137 
Autophagy can be induced by several stimuli, of which the most common and well 
known is lack of nutrient availability. This is detected via AMPK (adenosine 
monophosphate-activated protein kinase) which senses the low AMP-ATP ratio and 
becomes activated through the action of LKB1 kinase (Serine/Threonine Kinase 1).138 
Activated AMPK then goes on to phosphorylate Raptor, one of the subunits of 
mTORC1 (mammalian target of rapamycin complex 1, a regulator of protein synthesis 
and cellular growth and proliferation pathways) to cause induction of autophagy. 
AMPK also acts to activate TSC (tuberous sclerosis complex) which leads to the 
inhibition of Rheb and subsequent inhibition of the mTORC1 complex, which prevents 
the mTORC1 mediated phosphorylation of Ser757 on Ulk1. This allows activated 
AMPK to phosphorylate Ulk1 on Ser 777 and 317 which then renders the complex 
active and induces autophagy (Figure 6). 139 
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Figure 6. Pathway for autophagy regulation via AMPK under conditions of high and low 
glucose availability.140 
5.4 Hypoxia, oxidative stress and autophagy 
Autophagy can also be induced under conditions of mitochondrial stress such as a build 
up of reactive oxygen species (ROS).141  Under starvation conditions ROS produced 
from the mitochondria  have been reported to alter the activity of Atg4 a cysteine 
protease autophagy protein. In this state Atg4 still ‘primed’ LC3 by removing amino 
acids from the C terminal end of the protein but no longer carried out its delipidating 
actions further downstream by removing phosphatidylethanolamine from LC3 (known 
as LC3-II). This prevents LC3-II from being recycled back to LC3-I, which ensures the 
maintenance of high levels of LC3-II ready to fuse with the membranes of the 
phagophore and autophagosome.142 This method of induction links autophagy to 
another process characteristic of the tumour microenvironment, hypoxia. Autophagy has 
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been shown to be induced in hypoxic cells that characterise solid tumours., 143 This 
process has been found in some cases to be dependent upon HIF-1 , specifically HIF-1 
dependant expression of BNIP3. 144 This induction acts to protect the cell under 
unfavourable conditions by allowing them to adapt to the hypoxic environment and also 
by reducing the cell's apoptotic potential.145 In other cases however induction of 
autophagy in response to hypoxia has been found to be HIF-1 independent. This has 
been found in cases of severe hypoxia (<0.1% oxygen) often in the presence of nutrient 
deprivation. Implicated in this induction is AMPK. The induction of autophagy under 
these conditions has been found to be associated with autophagic cell death and is 
considered a failed attempt at adaptation. 146 In cells being treated with certain 
chemotherapeutics autophagy has been shown to have a protective effect on the cells, 
not just allowing them to survive low oxygen conditions but also in response to 
chemotherapeutics by reducing their apoptotic potential. For instance in one study 
hepatocellular carcinoma cells were shown to be more resistant to chemotherapeutics 
under hypoxia compared to normoxia; however this difference was abolished by the 
addition of autophagy inhibitors to the hypoxic cells.147 
Hence hypoxia induced autophagy and the mechanisms governing this can have both 
pro survival and pro death effects depending on the nature of the stimulus.148, 149 
5.5 Autophagy and Cancer: The Autophagy Paradox 
Autophagy has been linked to both tumour suppression and tumourigenesis as many 
proteins involved in autophagy are also known oncogenes and tumour suppressors. The 
process and function of autophagy within cancer is however a complicated matter. In 
some instances cancer cells undergo autophagy as a defence mechanism against nutrient 
shortages, and in tumours with limited blood supply autophagy works to help those cells 
not sufficiently fed by diffusion from blood vessel to survive (Figure 7). In these 
30 
 
circumstances if autophagy is inhibited this can then lead to relatively selective tumour 
cell death.150 Furthermore autophagy has also been found to correlate with poor 
outcome in pancreatic ductal adenocarcinoma,151 which is thought to be due to 
dependence of pancreatic ductal adenocarcinoma  cells on autophagy for growth.152 
Recently several trials have started which are looking into the effects of an autophagy 
inhibitor (hydrochloroquine) in combination with the standard treatment regime for a 
variety of solid tumours (breast, prostate, lung) plus multiple myeloma.153 
 
Figure 7. The differing roles of autophagy in tumour formation and growth. Autophagy 
can be both induced and inhibited in order to help tumours form, grow or evade type II cell 
death. These conflicting roles make it difficult to determine how autophagy should be targeted 
therapeutically.154 
At other times a different situation arises where the stimulation of autophagy by certain 
anti-cancer drugs leads instead to autophagy-based type II cell death (see Figure 7).  
This has been reported in various different cancer cell types. It is most clearly seen in 
cells where apoptosis has been inhibited, for instance in bax-/-bak-/- mouse embryonic 
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cells apoptosis inducers actually stimulate autophagic cell death, which is known to be 
autophagic as it is Beclin-1 and ATG-5 dependant. 155 This occurs as autophagy like 
other cellular processes must be tightly regulated, and while it can be beneficial to cells 
in a controlled way, if autophagy is up-regulated too much, the levels of catabolism 
surpass the levels of cellular anabolism, the result of which is cell death. Another 
possible reason for autophagic cell death under conditions of apoptotic 
inactivation/deficiency could be as a backup mechanism of cell death for the cell. 
Autophagy has also been seen to have tumour suppressive effects (Figure 7), as it has 
been reported that loss of autophagy can lead to increased incidence of cancer. Various 
tumour suppressors such as p53, DAPK, PTEN and TSC1-TSC2 are known to induce 
autophagy, similarly some oncogenes like Ras and Akt suppress autophagy.156 Certain 
types of cancer including breast, ovarian and prostate commonly have deletions of one 
allele coding for Beclin-1, a coiled-coil protein which interacts with Bcl-2, and 
stimulates autophagy by silencing the inhibitory actions of mTOR.  The effects of this 
deletion have been studied in mice where it was seen to cause increased incidence of a 
range of cancers including lymphoma and lung cancer.157  The reason behind this is 
thought to be due to the hypothesised protective effect of autophagy on genomic 
stability. It is thought that in cells lacking autophagic function, damaged organelles and 
misfolded proteins are allowed to build up. These damaged organelles, in particular 
peroxisomes and mitochondria become a source of reactive oxygen species that can lead 
to genotoxic stress. Essentially the cells become unable to buffer the metabolic stress 
and this can leave the cell susceptible to tumourigenesis. This theory is supported by 
work which reported that in mice allelic loss of Beclin-1 has been shown to increase the 
sporadic formation of tumours.158 In vitro research has also shown that the loss of 
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Beclin in iBMK cells was associated with chromosomal losses and gains and gene 
amplification.159  
Alternatively another mechanism to consider is that autophagy enables damaged cells to 
survive under conditions of metabolic stress, which may be another mechanism of 
promoting tumourigenesis by allowing these damaged cells to endure. 160 This has been 
examined in vitro where beclin1+/- cells were shown to be unusually large with 
abnormally shaped nuclei, when this was further examined it was seen that in cells 
containing only one beclin1 gene there was an increased incidence of chromosomal 
abnormalities including increased centromere number.161 
Furthermore there is another proposed mechanism involving loss of autophagy and 
increased tumourigenesis. In cells where apoptosis is down-regulated, if autophagy is 
also restricted in some way and the cells are under conditions of metabolic stress (i.e. in 
the hypoxic area of a solid tumour), the cells can undergo necrosis. This necrosis can 
lead to inflammation due to the release of pro-inflammatory molecules like HMGB1 
(High-mobility group protein B1) which attracts macrophages to the site. As the 
macrophages release chemokines and cytokines into the area this acts to increase 
proliferation and angiogenesis at the site (similar to wound healing) increasing the 
growth of the tumour.162  Therefore in cancers where apoptosis is known to be down 
regulated the induction of autophagy could prevent wide spread necrosis and 
inflammation which would be conducive to tumour growth, and hence act to suppress 
the tumour. 
The 'Autophagy Paradox' where both induction and inhibition of autophagy are found to 
have tumourigenic effects makes it difficult to conclusively say how autophagy should 
be targeted to treat cancer. However paradigms have been proposed to explain the 
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paradox. For instance, studies have shown that epithelial cancer cells can use oxidative 
stress to stimulate autophagy in the surrounding cancer associated fibroblasts. As 
oxidative stress induces autophagy this leads to the production of recycled nutrients 
within the fibroblasts. The fibroblast then excrete the recycled nutrients which can then 
be used by the tumour cells to stimulate growth even in the presence of low oxygen and 
other nutrient shortages.163 This can be thought of as the tumour using the stroma as a 
sort of autophagic battery to provide energy to the tumour cells. If we are to accept this 
paradigm then it is clear how both the induction and inhibition of autophagy can both 
have anti-cancer effects. If autophagy was to be induced systemically then the 
stimulation of autophagy within the cancer cells would inhibit tumour growth, whilst 
the inhibition of autophagy systemically would disrupt the parasitic relationship by 
preventing the flow of recycled nutrients from the stromal cells to the cancer cells, again 
inhibiting growth. One of the benefits of this theory is that if autophagy inhibitors were 
being used to treat the cancer and resistance developed, treatment could switch to 
autophagy induction and vice versa. A combination treatment regime which alternated 
between the two could possibly prevent the development of drug resistance.164 The 
reality is that autophagy may need to be treated differently depending on the type and 
stage of cancer, because if all theories are to be believed autophagy has multiple 
contradictory roles in both cancer growth and progression. 
5.6 Autophagy and Apoptosis 
To further complicate the matter it is now known that there is a certain amount of cross 
talk between autophagy and apoptosis, however, as before, this is not straight forward 
as the cross talk can involve both positive and negative feedback depending on the 
situation. In some cases autophagy can work with the apoptotic machinery to cause cell 
death. In cells where beclin1 and atg7 have been knocked down there is a reduction in 
34 
 
apoptosis seen.165 However in other cases it appears that autophagy is only activated 
when apoptosis has been inhibited, an example of negative feedback between the two 
pathways. In this way autophagy acts as a ‘back up’ for when apoptosis fails. For 
example, this use of autophagy as a compensatory mechanism was seen under caspase-8 
inhibition where stimulation of receptor-interacting protein and jun amino-terminal 
kinase, two molecules involved in sensing intra- and extracellular stress caused 
autophagic cell death.166 
Another link between autophagy and apoptosis lies with p53. This ‘genome guardian’ is 
involved in both apoptosis and autophagy. p53 acts to stimulate apoptosis after sensing 
DNA damage, and therefore it is not surprising that nearly 50% of all cancers have 
some kind of mutation or deletion in the gene. Its role in autophagy is not so 
straightforward and p53 can be a positive regulator of autophagy when stimulated by 
genotoxic stress. For instance treatment of cells with a DNA damaging agent 
(etoposide) stimulates p53 which activates AMPK, which in turn inhibits mTOR 
leading to autophagy induction.167 Furthermore under genomic stress p53 has also been 
reported to stimulate the transcription of DRAM (Damage-regulated modulator of 
autophagy) a highly conserved protein found on the lysosomal membrane which is 
essential for genomic stress-induced p53 activated autophagy and cell death. This effect 
was negated by knockdown of ATG5 thereby proving this effect to be dependent on the 
autophagic machinery.168  However the relationship between p53 and autophagy is not 
always this simple. In other cases loss of p53 function either by pharmacological 
inhibition, knock out or knock down can in fact stimulate autophagy as well. This loss 
of p53 signalling leads to an increased rate of basal autophagy, interestingly this 
stimulation was seen to be almost maximal, meaning that autophagy could not be 
further enhanced by starvation.169 
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Figure 8. The consequences of autophagic inhibition in cancer. Many tumour types down 
regulate both autophagy and apoptosis. By inhibiting autophagy cells are unable to survive the 
low nutrient microenvironment often found in solid tumours, this would normally lead to 
apoptosis, however in some cancer cells which have down regulated the apoptotic pathway in 
order to prevent cell death, this can push the cells into undergoing necrosis which can then lead 
to further tumour progression. Furthermore by inhibiting autophagy this can also lead to an 
accumulation of damaged proteins and organelles within the cell resulting in creased oxidative 
stress and increasing the acquisition of mutations within the cell, some of which may be 
advantageous for cell growth and survival. 170 
While sometimes it seems that cancer cells undergo autophagy as a protective 
mechanism in order to survive nutrient shortages, other times certain anti-cancer drugs 
are able to promote cancer cell death via the autophagic pathways (autophagic cell 
death) (Figure 8). Therefore the challenge is to be able to characterise different cancers 
and the different stages of cancer to see where and when autophagy acts as a tumour 
suppressor and when it acts as a protective mechanism for cancer cells. 
5.7 Measuring Autophagy   
There are many methods that can be used to measure autophagy, each working to 
measure a different aspect of autophagy in a different model. Methods such as using the 
electron microscope to visualise the cell are useful for measuring the number of the 
autophagosomes present at a given time. If a measure of autophagic flux (the rate of 
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degradation of autophagic substrates) is needed then monitoring the steady state levels 
of autophagosomes, or punctate GFP-LC3, or LC3 levels using a western blot may not 
be appropriate. Instead there are several methods that directly monitor autophagic flux 
such as measuring the co-localisation of the autophagosome and the lysosome, the 
levels of autophagic substrates, and using chemical modulators of the autophagic 
process when carrying out methods such as western blots. The problem however with 
many of these methods is the interpretation of the results generated. Increases in levels 
of LC3-II generally mean an increase in autophagic activity however it can also be due 
to a reduced lysosomal degradation of the molecule.171 Because of the complex nature 
of autophagy and the limitations of the above methods, it would seem prudent to use 
more than one method in order to look for corroboration between the two sets of results 
to avoid false positives and false negatives. All the methods have their disadvantages so 
it is best not to use them in isolation. The use of chemical modulators of autophagy and 
appropriate controls is key to understanding the results generated by many of the 
methods. By inhibiting a certain step in the autophagic process it is possible to validate 
the results, which enables conclusions to be made as to the exact cause of an increase or 
decrease in the target being monitored. For example, in protein degradation assays the 
degradation of long lived proteins may not be wholly due to autophagic degradation but 
also due to proteasomal degradation. Therefore by inhibiting autophagy it is possible to 
work out the extent to which it contributes and therefore work out the autophagic 
activity.172 
When looking at spheroids, and in particular when looking at certain regions within a 
spheroid the most straight forward method for detecting autophagy would be 
immunohistochemistry. By staining for a molecule such as LC3-II or Beclin-1 it would 
be possible to examine and compare the expression within the different regions of the 
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spheroid. Additionally western blotting for LC3 or Beclin-1 would also be an invaluable 
tool for quantifying the expression and by splitting the spheroid into its respective layers 
(viable rim, necrotic core etc) using FACS, this would also make it possible to compare 
the expression at different locations within the spheroid. The electron microscopy is 
seen as the gold standard of autophagy detection, as the double membrane 
autophagosomes and autophagolysosomes can be visualised. As it is possible to 
confidently identify the autophagic vesicles, the results derived from using an electron 
microscope are more reliable than many of the other techniques. Other methods instead 
measure different markers of autophagy, markers which can be increased or decreased 
in response to other cellular processes other than autophagic flux, making the choice of 
appropriate controls crucial. The ability of electron microscopy to generate quantitative 
results is however somewhat reduced compared to other techniques, hence the need for 
multiple methods to provide a definitive conclusion. 
6 Anoikis 
Anoikis, a Greek word meaning "homelessness", is the process of apoptosis induced 
upon a cell's detachment from its surroundings. Cells rely upon their attachment to the 
extracellular matrix (ECM) and neighbouring cells not only for physical support but for 
signalling for a variety of processes, including proliferation, differentiation, gene 
expression, migration and continued survival. This exchange of information is made 
possible through integrins and transmembrane receptors which bind to the ECM and 
provide a scaffold for signalling molecules (Figure 9).  
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Figure 9. Diagrammatic representation of pro survival signalling mediated through 
cellular attachment. Integrin attachment to the ECM activates pro-survival signalling through 
a number of pathways shown. It also inhibits certain pro-apoptotic proteins. Cell-cell contacts 
involving Cadherins contribute to cell survival through the PI3K-Akt pathway causing a down 
regulation in BH3 proteins. 
A cell's phenotype is highly dependent on the environment they exist in and is 
controlled by their interactions with the ECM.173 When a cell loses contact with the 
ECM, its cell cycle is arrested and the cell then undergoes caspase-dependent cell death 
(apoptosis) (Figure 10). This is to ensure that any inappropriately placed cells are 
rapidly eradicated in order to prevent dyplasia within the tissue. 174
 
Anoikis is also used 
in tissue development, where it plays a role in the hollowing out of glands and other 
such involution process.175 
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Figure 10. Diagrammatic representation of the mechanism underlying the cellular 
response to cellular detachment. Absence of ECM attachment fails to activate the pro-survival 
pathways. Lack of Cadherin mediated attachment to neighbours cells means a further lack of 
stimulation of the PI3K-Akt pathway. An increase in expression of Fas receptors on the cell 
surface further activates the extrinsic apoptotic pathway. 
A cell's sensitivity to anoikis can be regulated. Not all cells react to a lack of anchorage 
by undergoing anoikis, fibroblasts for example do not. Tumour cells manage to resist 
anoikis through a number of different mechanisms (Figure 11). The resulting anchorage 
independent growth is necessary in order for cancer cells to metastasise as cells which 
have become anchorage independent then have the ability to travel throughout the body 
and form distant metastatic colonies.176 Thus resistance to anoikis is emerging as a 
hallmark of metastatic cancer. Epithelial cells in particular are very sensitive to anoikis, 
though a reduction in this sensitivity has been documented in response to a number of 
different stimuli such as exposure to migratory factors, and transformation of the cell 
with certain oncogenes.177 Resistance to anoikis has been found to promote malignancy 
in a number of different types of cancer including colorectal.178, 179 
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Figure 11. Summation of the various signalling molecules involved in anoikis resistance. 
Anoikis resistance is mediated through a number of different mechanisms. Survival pathways 
such as PI3K-Akt, MEK/ERK and NF-κβ can become constitutively activated through autocrine 
or paracrine signalling. Integrin expression can be modulated. Constitutive ROS production can 
also contribute to pro-survival signalling. EMT is also involved in anoikis resistance, up-
regulation of several transcription factors involved in EMT, Snail and Twist, activate survival 
genes involved in the PICK-AKT signalling pathway. An induction in hypoxia may also survive 
to inhibit proapoptotic factors. 
Several proteins found to have a role in cellular resistance to anoikis are involved in 
carcinogenesis.180 Several of the proteins involved in the EMT are involved, including 
E-Cadherin, the down-regulation of which is known to circumvent anoikis through its 
relationship with the protein NRAGE.181 Snail and Twist, two other proteins involved in 
the EMT, are also implicated in anoikis resistance both through their ability to regulate 
certain apoptosis control genes and to repress the expression of E-Cadherin.182  
Another tactic cells employ to resist anoikis when metastasizing involves altering their 
expression of integrins. The expression of a differential complement of integrins can be 
induced through oncogenic signalling or in response to the local microenvironment the 
cell is currently residing in.183, 184 By changing the expression of integrins to ones 
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appropriate for the new environment the cell can finally transduce ECM stimuli 
appropriately and hence suppress anoikis.185 Conversely if a cell was not expressing the 
correct integrins for its current environment it could resist the induction of anoikis by 
'ignoring' the signals which would usually lead to cell cycle arrest and cell death. By 
constitutively activating pro survival molecule such as PI3K,Rho-GTPase, Ras-Erk and 
NF-κβ the cells continue to survive and proliferate in the absence of integrin 
signalling.186 To activate these pro survival factors the cells can employ autocrine 
secretion of a number of growth factors such as, HGF, bFGF, IL-8 and PDGF or over 
express certain receptors like EGFR and HGFR.187, 188  Pro survival signalling can also 
be maintained in the absence of attachment by preventing the internalisation of 
signalling platforms located on the cell's surface. Under normal conditions these lipid 
rafts act to host the assembly and initiation of signalling pathways in response to the 
interaction between the ECM and the cell's integrins. When cells become unattached to 
the ECM the cell surface integrins are in an inactive state which causes the 
internalisation of the platforms and hence disrupts the pro survival signalling pathways. 
Caveolin-1 is required for the trafficking of the membrane platforms, loss of caveolin-1 
leads to an inhibition of this process and hence prevents the disruption to cellular 
survival pathways. 189 
Autophagy has also been implicated in anoikis resistance in cancer cells. When the cell 
become detached from the ECM the reduction in integrin signalling stimulates 
autophagic signalling. Autophagy can then delay the onset of apoptosis in order to give 
the cell a chance to reach a new location and resume attachment to the ECM. Inhibition 
of autophagy results in reduced survival of detached cells and reduced viability in cells 
upon reattachment.190, 191 
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7 Senescence 
Once a cell has reached the Hayflick Limit (maximum number of cell replications) it 
enters replicative senescence where the cell ceases cell division. Senescence was first 
described 5 decades ago when it was observed that normal cells have a limited 
replicative capacity in culture. A culture of cells was shown to gradually lose the ability 
to proliferate over time until ultimately all cells were growth arrested even in the 
presence of sufficient space, nutrients and growth factors. These non-dividing cells were 
however shown to remain viable for a substantial period of time following this arrest. In 
normal diploid cells the Hayflick Limit is determined by the shortening of the 
telomeres.192 Other phenomenon can also induce cellular senescence such as toxins, 
oxidative stress, irradiation, DNA damage and certain oncogenes. This type of telomere 
independent senescence is termed premature senescence (PS). Senescent cells while 
they no longer replicate are still viable and do retain metabolic activity. The growth 
arrest seen in senescent cells is maintained in either the G1 or G2/M phase of the cell 
cycle with the help of increased expression of certain cyclin dependant kinase inhibitors 
(CDKIs).193 The senescent phenotype includes a characteristic large, flattened cell 
morphology with a prominent nucleus and increased granularity of the cytoplasm 
(Figure 12). Alterations in the cell's gene expression profile and changes in the cell's 
secretion profile are also seen, termed the senescence-associated secretary phenotype.194 
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Figure 12. Senescent cell morphology. Panel A represents a normal proliferating PC3 cell. 
Panel B shows the flattened and round morphology of a senescent PC3 cell. Scale bar represents 
100µm.195 
Cellular senescence has now been recognised as a potent tumour suppressor mechanism 
similar to that of apoptosis. 196 As senescence prevents cells from proliferating 
indefinitely, cancer cells must be capable of evading the process in order to proliferate.  
Benign melanocytic nevi are one example of where senescence prevents the expansion 
of the cell population. The moles initially form due to increased activity of the mutant 
oncogene  BRAF (v-raf murine sarcoma viral oncogene homolog B1) which causes  an 
increase in proliferation, the melanocytes then undergo growth arrest accompanied by 
the p16Ink4a expression and stain positive for senescence markers.197 Senescence has also 
been detected in lung adenomas but is absent in adenocarcinomas, indicating that 
senescence could function as a mechanism for preventing malignant transformation.198 
Most cancer cells are immortal, the majority of which evade senescence through a 
mechanism involving the re-activation of the telomerase genes.199 Lack of senescence 
associated tumour suppressors such as p53 and retinoblastoma protein is not however 
enough to suppress senescence under certain conditions such as ionizing radiation or 
exposure to chemotherapeutic drugs.200, 201 Chemotherapy induced senescence is termed 
Therapy Induced Senescence (TIS) and has been recognized in a subset of cells in many 
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different tumour types after chemotherapy or radiation treatment.202 TIS may represent a 
back up mechanism for growth arrest in tumours which are apoptosis resistant. In an in 
vivo setting induction of TIS has been linked to a better post treatment prognosis. 203 
7.1 Detecting Senescence 
Senescence can be induced in cells through a variety of different stimuli, but regardless 
of the stimulus, senescence can be detected in vitro and in vivo using several methods. 
The ‘gold standard’ for detecting senescence in cells is the SA-β-Gal assay which 
involves staining for the presence of senescence associated β-galactosidase activity. 
This assay requires active lysosomal activity and hence necessitates the use of fresh or 
frozen tissue making it incompatible with IHC detection methods in archived paraffin 
embedded samples. Other detection methods can be used when the SA-β-Gal assay is 
inappropriate, these tend to rely on the characteristic changes in a cell when it becomes 
senescent.  A long term exit from the cell cycle is also a hallmark of cellular senescence 
along with changes in the cell's morphology. Morphological changes are more easily 
seen in cells in vitro as opposed to in tissues.204 
To detect senescence in tissue samples particularly those that have been paraffin 
embedded, several senescence-associated markers can be used. In fibroblasts, 
senescence-associated heterochromatic foci  (SAHF) areas of highly condensed 
chromatin can be stained for. Under senescence, SAHF form and can be detected using 
DNA binding dyes such as DAPI and Haematoxylin.205 Furthermore certain chromatin 
associated proteins localise to these SAHF and can be stained for to detect the 
regions.206 Markers of DNA damage can also be used to identify senescent cells 
specifically double strand breaks.  DNA damage can result in the presence of DNA 
damage foci which have been found to be characterised by an ATM/ATR activation 
which leads to the phosphorylation of Ser139 on histone H2AX molecules which 
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localises to the site of damage.207, 208 Staining procedures for the expression of 
phosphorylated H2AX have been used to detect senescence. In conjugation with 
negative Ki-67 staining, γ-H2AX staining has been shown to detect senescent cells in 
vitro in fibroblasts and in vivo in hepatocytes209 and intestinal sections.210  
7.2 How cancer might use senescence to survive 
The role of senescence in cancer is a complicated one but recently it has been suggested 
that senescence might not just represent a tumour suppressive mechanism but may also 
have tumour promoting effects. Premature senescence is considered a DNA damage 
response for cancer cells subjected to chemotherapy.211 While exit from the cell cycle 
and growth arrest has a cytostatic effect on tumour cells, evidence has shown that 
senescent tumour cells are not as benign as originally thought. Senescent cells can 
promote the growth of their neighbouring cancer cells by the cytokines they secrete.212, 
213
 Moreover senescent cells by their very nature are resistant to many forms of 
cytotoxic chemotherapeutic drug which target actively proliferating cells. Most 
importantly cancer cells have been shown to be capable of re-entering the cell cycle 
following acquisition of a senescent phenotype.214 These cells' escape mechanism has 
been found to involve various proteins. Survivin has been linked to the process through 
its relationship with the Cdc2/Cdk1 complex, the complex is responsible for 
phosphorylating Survivin enabling its senescence escaping capabilities. Cells which 
escape senescence are known to over express Cdc2/Cdk1, and this expression directly 
effects their viability.215 Twist a protein involved in the EMT has also been revealed to 
be involved. It was found to be able to override senescence through the abrogation of 
the inhibition of the cell cycle via p21 and p16. The effects of this are twofold; the cell 
escapes senescence and also undergoes EMT producing a viable, proliferative and 
invasive cancer cell.216 The survival of senescent cancer cells and their return to a 
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proliferative cell state is clearly a cancer promoting mechanism and could affect the 
efficacy of anti-cancer treatments, thereby making it a possible target for the future. 
7.3 Autophagy and Senescence 
Studies have shown a link between autophagy and senescence. As both autophagy and 
senescence can be induced by the same stimuli, a link between the two processes was 
not unexpected. Autophagy has been found to contribute to the cellular state of 
senescence and up regulation of autophagy and autophagy related genes has been seen 
to occur during senescence. Furthermore inhibition of autophagy using autophagy 
inhibitors has been found to have an inhibitory effect upon the induction of a senescent 
state.217 It has been suggested however than autophagy can switch between its cell 
survival function and its cell death function (autophagic cell death) by switching 
between senescence and apoptosis. 218 
8 Tumour Dormancy 
The vast majority of cancer deaths are the result of a metastatic form of the disease.219 
Metastatic deposits form from disseminated tumour cells which often remain dormant 
for a substantial period of time. The term 'dormancy' was first used to describe the 
prolonged latent phase in the development of disease progression from primary tumour 
to secondary metastatic deposits in the mid 20th century by pathologist Rupert A. 
Willis.220 Tumour dormancy is quite common, for instance in breast and prostate cancer 
20-45% of patients will relapse years or decades later.221, 222 In fact many different 
cancer types are associated with persisting disseminated cells which can result in 
residual disease post treatment.223 How these disseminated cells remain dormant and 
why is not fully understood though there has been research into the area in recent years.  
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Tumour dormancy can be divided into two main categories. First, tumour mass 
dormancy whereby the expansion of the tumour cells as a population is inhibited for 
example by restrictions in the blood supply. Second, tumour cell dormancy where the 
tumour cells are in a state of growth arrest or quiescence.224 In the following section 
tumour cell dormancy will be discussed. 
8.1 Dormancy: Senescence or Quiescence? 
The mechanisms underpinning tumour cell dormancy have not been fully elucidated, 
yet those which are often attributed to the phenomenon include quiescence and 
senescence.  Senescence which tends to function as a tumour suppressive mechanism 
has been detected through positive S-β-Gal staining in patient tumour samples following 
chemotherapy.225 However for a tumour to perpetuate it needs to have acquired the 
ability to bypass senescence, though it is possible that some parts of the senescent 
machinery can still be induced in the tumour cells. Whether or not it is the senescent 
cells detected in tumours which are responsible for the tumours relapse is unknown. 
Conversely quiescence might be a better suited226. Quiescence has been seen in cancer 
stem cells and in cells which have entered G0 growth arrest due to insufficient growth 
stimulatory signals, and more so than senescence it is easily reversible.227 
8.2 Tumour Cell Dormancy Manifestations 
It is a commonly held view that some cancer cells within a primary tumour will have 
metastatic capabilities, and that these traits are acquired over the period of time that it 
took the tumour mass to develop from a mass of proliferating cells (hyperplasia) into an 
established tumour.228 However more recent research has suggested that dissemination 
of tumour cells may occur far earlier than previously thought, preceding the acquisition 
of a full complement of metastatic abilities. 229 These disseminated cells then progress 
through the acquisition of the metastatic phenotype whilst separate from the tumour 
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mass. If these disseminated cells, which managed to survive chemotherapeutic 
intervention, were to continue to proliferate continuously then the time before relapse 
would be much shorter than often observed. The best explanation for why this does not 
occur is tumour cell dormancy. The explanations for the lag time in return to cellular 
proliferation could be due to a number of different possible reasons. The niche in which 
the cancer cell has lodged itself could be conducive for a quiescent state, or the stress of 
a new microenvironment could induce growth arrest. The cell might then be able to 
remodel the new niche in order to produce an environment more conducive to 
growth.230, 231 Another possible explanation for the lag time in the development of 
metastases is the initial lack of sufficient vasculature. Prior to the development of a 
tumour vasculature the cells within a metastatic deposit can only proliferate so much 
before outgrowing the current vasculature, after this areas of necrosis can form as the 
rate of growth/proliferation balances the rate of cell death. This is termed angiogenic 
dormancy.232 
8.3 Clinical Implications of Tumour Dormancy 
Disseminated tumour cells are hard to detect owing to their low numbers. Whilst they 
are commonly found in the circulation and bone marrow they can also lodge themselves 
in other organs not routinely checked. Furthermore due to their non-proliferative state, 
dormant cancer cells are intrinsically resistant to many common chemotherapeutics 
which target actively dividing cells. For example studies carried out in vivo found that 
disseminated breast cancer cells which were tagged with GFP (green fluorescent 
protein) were both growth arrested and resistant to the commonly used 
chemotherapeutic Doxorubicin.233 In order to better detect and treat dormant 
disseminated cells better biomarkers need to be found that will help detect the low 
abundance cells throughout the body. Treatments which are either effective on non 
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proliferative cells or cause the cells to exit their dormant phase and become active once 
more, are needed. 
In order for an epithelial tumour cell to disseminate it must first acquire mesenchymal 
properties. Furthermore when activated a once dormant epithelial tumour cell will only 
be successful in forming a metastatic deposit if it has undergone the Epithelial 
Mesenchymal Transition (EMT). Both the EMT and its role in cancer will be discussed 
in the next section. 
9 Epithelial Mesenchymal Transition 
The EMT is a morphogenetic process that was first discovered following studies on the 
development of complex structures in embryonic development.234 The beginnings of a 
metazoan organism starts with epithelial cells organised in a single layer. Polarized 
epithelial cells form continuous sheets that are interconnected by specific structures, 
tight junctions, gap junctions, desmosomes, hemidesmosomes and adherens junctions. 
The basal-apical polarity is perpendicular to the plane of the epithelium and influenced 
by the cells' association with the basement membrane, allowing the exchange of nutrient 
and waste products between external and internal compartments.  At some point in the 
early stages of embryonic development mesenchymal cells develop from the epithelium. 
Mesenchymal cells in contrast to epithelial cell display front-rear polarity (see Figure 
13) and rarely have any point of physical contact with other mesenchymal cells. 235 
Unlike epithelial cells mesenchymal cells have the ability to migrate and invade through 
both epithelial cells and other mesenchymal cells, with the front-rear polarity enabling 
their locomotive capabilities. The conversion of an epithelial cell into a mesenchymal 
cell is termed the epithelial mesenchymal transition and was first defined in the 
1980s.236 
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Figure 13. Cellular Polarity and Epithelial Mesenchymal Cell Phenotype. Panel A Apical-
basal Polarity, polarized epithelial cells have an distinct apical basal polarity in an orientation 
perpendicular to their attachment to the basement membrane (ECM). Organelles and various 
internal structures are organised in response to this polarity. Panel B Front-rear polarity, 
mesenchymal cells are organised based upon polarity between the front end (leading edge) and 
rear (uropod) of the cell. Certain organelles are orientated to the front of the cell, including 
centrosome, microtubules and golgi body, while the endocytic and exocytic pathways are 
orientated to the rear.237 
EMT is required for many different processes, through embryonic development into 
normal adult physiological process, including mesoderm formation, neural crest and 
heart valve development during embryogenesis and the formation of fibroblasts during 
adulthood.238 Passage through the EMT is not irreversible, once the cells has gone 
through the change there is the process of Mesenchymal-Epithelial Transition (MET) 
which reverses the transformation. This just serves to highlight the plasticity of cells in 
terms of their phenotype and functional capabilities.239 
The process of EMT requires three profound changes to the phenotype of the epithelial 
cells. They must first un-attach themselves from their neighbouring epithelial cells by 
severing the various connections that anchor them to their neighbours. In order to do 
A B 
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this they must change their expression of differentiation markers, from the epithelial 
type cell-cell adhesion junction proteins and cytokeratin intermediate filaments to 
mesenchymal type fibronectin, vimentin filaments and  certain integrins,240 and different 
spicing variants of certain cell surface receptors like FGFR2.241 Loss of the molecule E-
Cadherin and other components from tight junctions, is sufficient to reduce the 
attachment and change the polarity of the cell.242 The cell must then undergo a change 
in morphology from the typical polygonal cobblestone shape to the mesenchymal 
spindle shape. Lastly the cell must undergo certain changes in it's functional 
characteristics in order to enable it to invade through ECM.243 While not all changes are 
present in all cases of EMT, the one functional hallmark of EMT is the ability to 
migrate through the ECM. 
9.1 The role of the EMT in Cancer 
The detection of EMT in cancer cells is usually carried out by measuring the expression 
of proteins known to be involved in the process. Loss of E-Cadherin and gain of N-
Cadherin is characteristic of cells having gone through the EMT, along with expression 
of other molecules including vimentin, snail, slug, twist, various integrins and matrix 
metalloproteinases (MMPs). The transcriptional regulator Snail is central to the 
repression of E-Cadherin and its protein levels are also measured to determine EMT. 
Loss of E-Cadherin has been widely documented in epithelial tumours, furthermore the 
blocking of E-Cadherin has been shown in in vitro cell systems to be enough to trigger 
EMT in epithelial cell types.244 The loss of E-Cadherin in epithelial tumours has also 
been shown to trigger the swift conversion from a benign adenoma to an invasive 
carcinoma. Inherited mutations in the E-Cadherin gene are known to predispose to 
gastric cancer, loss of expression of the protein in sporadic tumours is linked with poor 
prognosis. 245 As Snail acts to repress E-Cadherin it is understandable that the 
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expression of the two proteins is inversely correlated at the invasive edge of tumours.246 
Snail along with Twist, another transcriptional regulator, also have roles in promoting 
expression of mesenchymal markers such as N-Cadherin.247 
10 Cancer Stem Cells 
Stem cells are defined as undifferentiated cells with limitless replicative potential which 
have the ability to give rise to differentiated daughter cells. Cancer stem cells are 
therefore defined are tumourigenic (capable of forming a tumour) and have been proven 
to be capable of forming a completely heterogeneous tumour.248 Types of tumour cells 
which are known to have undergone the EMT include cancer stem cells. Cancer stem 
cells are strongly implicated in metastasis as they are able to disseminate and survive 
the journey to a new target tissue and then have the ability to form a new heterogeneous 
tumour mass.249, 250 The links between EMT and stem cells in the context of cancer will 
be discussed further in subsequent sections. 
10.1 Stochastic vs. Hierarchical Growth 
Originally it was believed that tumours grew through a stochastic model where all cells 
within the tumour had equal tumour forming abilities. The theory hypothesises that 
tumours arise due to the accumulation of mutations, specifically activation mutations in 
oncogenes and inactivation mutations within tumours suppressor genes. In colorectal 
cancer this model is called the Vogelstein model. The model states that it is the normal 
epithelial cells lining the gut that are the origin of colorectal cancer after undergoing a 
sequential series of genetic mutations which change their proliferation and self renewal 
capabilities.251  
More recently evidence has been found that suggests that the stochastic theory is less 
likely and instead a hierarchical theory based on cancer stem cells has been proposed.  
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The cancer stem cell hypothesis is a contentious issue, it hypothesises that there is a 
population of quiescent cells which upon depletion of the majority of the tumour mass, 
via chemotherapy, are able to repopulate the tumour. It is only these so called cancer 
stem cells which are believed to have the ability to initiate and maintain a tumour and 
then metastasise.252 These tumour initiating cells are believed to be stem cells or stem-
like cells due to their ability to differentiate into phenotypically heterogeneous progeny. 
Differentiated daughter cells with a limited replicative lifetime are produced from 
undifferentiated highly clonogenic parent stem cells which have a limitless replicative 
potential. Therefore indicating that growth and propagation of the tumour is determined 
by a small sub-population of cells. This hierarchical model is similar to the growth of 
normal tissues, for instance colon crypts are known to undergo continuous regeneration 
driven by the population of crypt intestinal stem cells (ISC). 
This model suggests that a tumour is made of two main populations of tumour cells, 
those that have through differentiation lost their ability to propagate a new tumour and 
those that remain undifferentiated and retain this clonogenic ability.253 Furthermore 
pathways known to be involved in self renewal of non cancerous stem cells such as Wnt 
signalling in colon derived stem cells, are also found to be involved in colorectal cancer 
suggesting that tumours are indeed derived from the stem cell compartment.254  
10.2 Evidence for Cancer Stem Cells in Solid Tumours 
Until recently there was little known about cancer stem cells in solid tumours. While 
haematopoietic stem cells found in the blood were relatively easy to access, accessing 
stem cells within solid tumours is more difficult.  The need for markers to identify them 
is crucial. Breast cancer was the first solid tumour from which cancer stem cells were 
identified. Using CD44high/CD24low as markers, cells were isolated which were then 
capable of initiating a tumour in vivo with implantation numbers as low as 200. The 
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cells were found to be capable of regenerating the heterogeneity of the original tumour. 
This demonstrated that the cells had a stem cell's capacity for self renewal, proliferation 
and differentiation.255 
Figure 14. Structure of the Cypts of 
Lieberkϋhn in the colon. Showing the 
location of stem cells at the base of the 
crypt and the cycle of proliferation and 
differentiation upwards through the 
crypt.256 
Cancer Stem cells have also been 
found in colorectal cancer, identified 
using a downstream target of Wnt, 
Lgr5.257 Using lineage tracing it was 
discovered that these Lgr5 
expressing cells were capable of 
differentiating into all cell types found in the intestinal crypt.258  
It is known that normal stem cells exist in the intestinal crypts. The colon is organised 
into 4 layers, the outermost epithelial layer is one cell thick and organised into finger 
like projections called the crypts of Lieberkϋhn. The function of the crypts is to increase 
surface area. This entire layer is replenished once every 5 days.259 The upper parts of the 
crypt are composed of terminally differentiated cells which gradually migrate up the 
crypt until they are shed into the intestinal lumen. These differentiated cells are derived 
from multi-potent stem cells which reside at the base of the crypt (Figure 14). The stem 
cells divide asymmetrically to produce two daughter cells, one remains undifferentiated 
to retain the stem cell phenotype and the other differentiates into one of the three types 
of epithelial cell found in the crypt. The three epithelial lineages found in the crypt are 
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the goblet cell which is involved in producing mucus, enterendocrine cells and 
absorptive enterocytes. This cycle of cellular proliferation and differentiation is tightly 
controlled through the Wnt signalling pathway.260 
10.3 The colorectal cancer stem cell model 
 
Figure 15. Proposed models for the colorectal cancer stem cell. Panel A Bottom-up model 
where the cell of origin is an intestinal stem cell located in the base of the crypt. Panel B Top-
down model where the cell of origin is located at the top of the crypt.261 
There are two different hypotheses for the mechanism involving stem cells by which it 
is believed colorectal cancer develops (Figure 14). The 'Top-down' model hypothesises 
that the cell of origin is a progenitor or differentiated cell found in the upper levels of 
the crypt. It is this cell which acquires a number of mutations which give it a cancer 
stem cell-like phenotype. Histological evidence for this using small colorectal adenomas 
showed that while cells at the top of the crypt had APC (adenomatous polyposis coli) 
mutations, these same genetic alterations were not seen in the intestinal stem cells. 
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Furthermore these differentiated cells were not found to be clonally related to the stem 
cells.262 
The 'Bottom-up' model suggests that the origin of tumourigenesis is the intestinal stem 
cell found at the bottom of the crypt. The stem cell is the first to acquire gain of function 
mutations which lead to anomalous proliferation producing more cancer stem cells and 
other progeny, which lead to further cancer cells devoid of any ability to self renew. 
Evidence supporting this theory includes studies which have shown that deletion of both 
APC alleles specifically in intestinal stem cells using BMi1-, CD133- and Lgr5-Cre 
recombinase mice leads to the formation of tumours. Yet when the same deletions were 
performed in differentiated cells tumours did not form.263  
Figure 16. Model of sporadic adenoma polyp formation. APC is 
inactivated in a single cell (see arrow) at the base of the crypt (Top). 
The transformed cell then begins to proliferate and passively 
migrates upwards to the top of the crypt as part of the routine process 
of epithelial cell turnover (Middle). When the transformed cells reach 
the top of the crypt they continue to spread into the normal 
epithelium and surrounding crypts pushing the normal cells down 
and gradually replacing them in the crypts in a top-down mechanism 
(Bottom).264 
While neither hypothesis has been disproved there are theories 
which explain how both may in fact occur. Evidence has shown 
that transformed cells are present at the top of the crypt in small 
adenomas while the bottom of the crypt remains unchanged yet 
it has been suggested that the cell origin may still be the 
intestinal stem cell. Once transformed in the base of the crypt this malignant stem cell 
could have migrated to the top and then spread throughout the intestinal epithelial layer 
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to surrounding crypts where it then invaded the crypts in a top-down movement (Figure 
16). 
10.4 Cancer Stem Cell Properties 
Cancer stem cells are believed to be defined by three particular properties; the ability to 
self renew indefinitely, the ability to independently give rise to a heterogeneously 
diverse tumour, and the expression of a number of stem cell markers.  Cancer stem cells 
are known to be extremely tumourigenic with the ability to form serially transplantable 
tumours from primary tumours in immunocompromised mice.265  While cancer stem 
cells are known to be able to form a tumour in vivo most of the cells making up the bulk 
of the tumour are not.266 One of the most clinically important characteristics of cancer 
stem cells is their resistance to chemotherapeutics, a characteristic which makes them 
critically important in the role of tumour recurrence. Stem cells have several key 
features which are involved in their chemoresistance. They are not highly proliferative, 
in fact they tend to exist in a quiescent state until needed, as shown by their retention of 
BrdU labelling.267, 268 As many anti cancer  drugs are targeted against proliferating 
cancer cells this makes them inherently resistant to them. Also stem cells are known to 
differentially express a number of signalling molecules which are involved in 
chemoresistance. Cancer stem cells are also thought to evade chemotherapeutic induced 
cell death by the expression of multiple drug efflux pumps in their cell membranes such 
as Multidrug Resistance Transporter 1 (MDR1) and Adenosine triphosphate-binding 
cassette (ABCB1).269 An increased DNA damage repair response has been discovered to 
be the cause for increased resistance in the response to radiotherapy. Cancer Stem Cells 
are able to activate DNA damage checkpoints more easily than normal cells and in fact 
have been found to have a higher basal level of activation of the DNA damage 
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checkpoint.270, 271 The Wnt/β-Catenin pathway is also believed to be involved in cancer 
stem cells increased radioresistance.272 
Colon cancer stem cells are known to express Bcl-2 at higher levels and this results in 
an increased resistance to apoptosis.273 Increased expression of IL-4 has also been 
shown to provide protection against drug induced apoptosis in colon cancer stem cells 
via its modulation of cell death pathways. In particular it has been shown to increase 
resistance of cancer stem cells against 5-Fluorouracil, a resistance which can be 
diminished with the use of IL-4 blocking antibodies.274, 275 Aldehyde dehydrogenase 
(ALDH1) is also known to be up regulated in cancer stem cells, so much so that it is a 
marker for cancer stem cells.276 ALDH is an enzyme which oxidises aldehydes and 
therefore protects cells against alkylating agents. The increased expression seen in 
cancer stem cells has been shown to confer resistance to anti cancer drugs such as 
cyclophosphamide.277, 278 Altered metabolism within CSCs is also thought to be 
involved in their increased survival.279 
This chemoresistance is partly why cancer stem cells are implicated in the recurrence of 
tumours after chemotherapeutic intervention. Once the majority of the tumour has been 
eradicated using an anti-cancer drug the chemoresistant cancer stem cells are enriched 
within the population as they managed to survive and go on to repopulate the tumour. 
This expansion of the stem cell pool within the tumour would make it more likely that 
the resulting secondary tumour would be chemoresistant as it is made up from daughter 
cells of chemotherapy resistant cancer stem cells.280  Therefore to stop tumour re-
growth and metastasis it is necessary to ensure that all cells within a tumour including 
the quiescent cancer stem cells have been targeted and killed. In order to do this a 
targeted therapy must be developed which takes advantage of the differences within 
cancer stem cells to selectively kill them. One of the ways to do this is by looking for 
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cancer stem cell markers as a means of targeting new or existing drugs specifically to 
the cancer stem cells. 
10.5 Stem Cell Markers 
As mentioned previously ALDH is known to be a marker of cancer stem cells, in 
particular ALDH1 is known to identify colorectal cancer stem cells.281 Other identified 
colorectal cancer stem markers include epithelial cell adhesion molecule EpCAM, 
CD44 and CD166. Research has shown colorectal cancer cells expressing these three 
markers to be capable of engrafting in vivo in immunocompromised mice to form 
heterogeneously differentiated tumour similar to the parent tumour. 282 CD44 is known 
to be not just a stem cell marker but is actively involved in the tumourigenic process, 
CD44 is a glycoprotein involved in cell adhesion, proliferation and differentiation.283 In 
hepatocellular carcinoma targeting CD44 has been shown to induce apoptosis 
specifically in the cancer stem cell population.284 Genetic knockout of CD44 in mice 
prone to intestinal tumours shows a reduction in tumour occurrence.285 Hence CD44 is 
an example of a stem cell marker which might be useful not only for identifying cancer 
stem cells but also as a way of selectively killing them.  
CD133 is also a stem cell marker in a number of different tumour types. In colorectal 
cancer CD133 has been shown to be important for identifying cells with tumour 
initiating capabilities. CD133 positive cells were shown to be able to establish tumours 
in vivo, as well as maintain an undifferentiated population while allowing some CD133 
cells to differentiate to establish tumour heterogeneity. On the other hand CD133 
negative cells were found to be unable to initiate tumour growth in vivo.286 CD24 is 
another cell surface antigen found to be expressed on colorectal cancer stem cells, it has 
been found to be correlated with increased invasiveness287 drug resistance288 and the 
ability to form heterogeneous tumours in vivo.289 Even when working with defined 
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stably expressed stem cell markers it is difficult to identify cancer stem cells due to their 
low number within tumours. This means that very large numbers of tumour cells must 
be assayed in order to find cancer stem cells.  
10.6 Stem cells and the microenvironment: the stem cell niche 
Stem cell niches were first discovered when it became clear that stem cells exist in 
specific stable microenvironments.290 Normal stem cells reside in this stem cell niche 
where their undifferentiated state is maintained with help from the microenvironment.291 
Stem cells niches are groups of cells residing in a special location that functions to 
maintain a population of stem cells. A niche in particular acts to anchor the stem cells in 
a specific location using various adhesion molecules to tether the stem cells to the 
extracellular matrix (see Figure 17). The niche also has a role in maintaining a certain 
number of stem cells by the use of extracellular factors to control their proliferation and 
lineage fate. Numerous different signalling molecules have been implicated in this 
process including Wnt, Notch, FGF and BMP.292  
While normally a niche would restrain stem cell division by supplying anti proliferative 
signalling, if a mutation were to arise which made the stem cells resistant to anti 
proliferative signalling or self sufficient in growth signals this could then lead to 
uncontrolled cell proliferation and possibly tumourigenesis.  
The stem cell niche has also been implicated in the process of tumourigenesis.  This is 
due the niche's role in maintaining stem cell populations. The niche anchors the stem 
cells in the specific microenvironment, this anchorage is composed of cadherin and β-
catenin  adhesion molecules which form complexes to hold the cells in place.293 There is 
a large amount of commonality between the mechanisms and signalling molecules 
involved in regulating this anchorage process and those involved in cancer cell invasion 
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and metastases.  For instance matrix metalloproteinases such as MMP-9 are involved in 
activation and translocation of stem cells in the bone marrow.294 MMPs are also known 
to be involved in the invasion and metastases of cancer cells through their roles in 
extracellular matrix degradation.295 Integrin signalling is also involved in the migration 
of stem cells in both haematopoietic and neural stem cell niches,296, 297 as well as being 
involved in the metastasis of cancer cells.298 
 
Figure 17. The Stem Cell Niche, depicts stem cell anchored to the basement membrane via 
adhesion molecules which relay signals to the stem cells controlling their division and 
blocking differentiation. As seen at the bottom when a lineage specific signal is received the 
stem cell divides so that one daughter cell maintains its connection with the basement and hence 
maintains its undifferentiated status. Above is shown a stem cell undergoing cell division to 
produce two new stem cells. 299 
10.7 Stem Cells: EMT and Metastasis 
The majority of patients do not die from their primary tumour but as a consequence of 
metastasis.300 Cancer stem cells are also known as cancer initiating cells due to their 
ability to initiate a primary tumour, also due to their abilities to repopulate a 
heterogeneous tumour after chemotherapeutic assault. They are also able to avoid 
62 
 
anoikis when detached from surrounding cells, therefore it is straightforward to 
extrapolate that cancer stem cells are the cells which first form metastatic deposits. In 
order for this to be possible the cancer stem cells must be able to detach from their 
surroundings, migrate and invade into blood vessels, survive within the circulation and 
then disseminate into new tissues to form a secondary tumour. This cellular behaviour is 
indicative of a cell undergoing the epithelial mesenchymal transition, a process 
undergone by cells before they are capable of metastasising.301 Mesenchymal cells have 
a scaffolding/anchoring function and have multiple roles in wound healing and 
embryonic development and unlike epithelial cells are resistant to anoikis.302  
Evidence has suggested that metastatic cancer cells that have undergone EMT  may 
express a cancer stem-like phenotype. Pleural effusions were found to contain 
disseminated breast cancer cells which expressed a breast cancer stem cell phenotype 
(CD44high/CD24low).303 In fact CD44 happens to be a β-catenin/TCF target gene further 
supporting the link between EMT and cancer stem cell phenotype. Induction of EMT in 
immortalised mammary epithelial cells caused expression of a number of stem cell 
markers as seen previously, and in addition showed increased mammosphere formation, 
an ability consistent with breast cancer stem cells. This phenomenon was also 
investigated from the opposite angle, stem-like cells which were isolated from 
mammary carcinomas were investigated for EMT markers which were found to be 
expressed.304 Further evidence has been seen in pancreatic cancer where CD133 
expressing cells with a mesenchymal phenotype were found on the invasive edge of 
tumours, these cells were also found to express the chemokine receptor CXCR4 known 
to be involved in the  metastatic spread of cancer.305 
This link between EMT and stem cell properties help to explain how the process of 
metastasis is possible in light of the cancer stem cell hypothesis. It is understood that 
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before a cell can metastasise it must first undergo the EMT to give it the required 
migratory phenotype in order to detach from its surrounding, avoid anoikis and travel to 
a distant site. However what isn't clear is how it is able to complete the last step of 
metastasis, formation and growth of the new tumour, especially since most metastases 
manage to recapitulate the structure and organisation of the primary tumour.306 While 
the EMT gives the cell the required capabilities to migrate to the new site, self renewal 
which the majority of the cells making up the bulk of the tumour lack makes it difficult 
to understand how a metastatic deposit would be formed.  However the discovery that 
the EMT induces many of the properties of stem cells including self renewal, provides 
an answer. Patients which were found to have stem cell markers such as ALDH1 on 
circulating tumour cells in the blood have a worse prognosis than those who do not.307  
10.8 The Migrating Cancer Stem Cell Model 
All this evidence lead to the Migrating Cancer Stem Cell Model. It is proposed that 
there are two different types of stem cell, the stationary cancer stem cell and the 
migratory cancer stem cell. Whilst the stationary cancer stem cells is thought to be 
located within the mass of tumour embedded in epithelial tissue, the migratory cancer 
stem cell is believed to be located on the periphery of the tumour on the boundary 
between tumour and host tissue. The migratory cancer stem cells are derived from their 
counterparts the stationary cancer stem cells, but have acquired EMT-like 
characteristics. In colorectal cancer the migratory stem cells have been characterised as 
having high levels of nuclear β-catenin (consistent with having undergone the EMT). 
Levels of these cells at the tumour-host boundary have been found to be correlated with 
metastasis and poor survival.308,309 These cells then have all the necessary traits for 
metastasis; the EMT enables them to disseminate from the original tumour and survive 
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the journey to a new metastatic site, and the stem cell functionality allows them to form 
metastatic deposits at the new site (Figure 18).  
 
Figure 18. The Migrating Cancer Stem Cell Model. Panel A Normal intestinal stem cells are 
located at the base of the crypts in normal colon. Stationary stem cells are found in benign 
adenomas though remain detectable in more differentiated tumours and metastatic deposits. The 
step from benign to malignant occurs as the EMT is induced in tumour cells specifically the 
stationary stem cells to produce migrating cancer stem cells. Panel B Migrating cancer stem 
cells divide asymmetrically to produce to daughter cells, one of which is set on a path of 
differentiation and proliferation (a), the other either migrated a small distance before beginning 
another asymmetric division (b) thereby contributing the mass of the original tumour or 
migrates a greater distance to begin the formation of a metastatic deposit (c).310 
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10.9 Stem Cells and Autophagy 
Stem cells have be found to be more reliant on autophagy under conditions of low 
oxygen and nutrient availability than their counterpart normal cancer cells. In pancreatic 
cancer, in vitro starved cancer stem cells were shown to have increased survival under 
hypoxic conditions compared to non stem cell starved cancer cells. Furthermore after 
survival under hypoxic conditions the cancer stem cells went on to change morphology 
to a fibroblast phenotype and this was accompanied by an increase in their migratory 
potential as measured by the wound healing assay. This behaviour is consistent with the 
cells having undergone the EMT stimulated by the harsh microenvironment. It was 
found that in response to hypoxia and starvation the cancer cells up-regulated their 
levels of autophagy, this process was found to be critical for their survival under these 
conditions. When autophagy was inhibited the cancer stem cells underwent apoptosis. 
Inhibition of autophagy has also been shown to inhibit the self renewal capabilities of 
stem cells as shown by reduced sphere formation in vitro and tumour formation in vivo, 
suggesting that the hypoxic tumour microenvironment is an inducer of an increased 
migratory cancer stem cell.311 Similar evidence has also been found in liver cancer stem 
cells where higher levels of autophagy in response to hypoxia and nutrient deprivation 
were seen in CD133 positive cells compared to CD133 negative cells. And as with the 
pancreatic cells the liver cancer stem cells were shown to have increased survival 
capabilities in the hostile environment compared to the normal cancer cells, a survival 
ability which was also impaired by the inhibition of autophagy.312, 313  
Autophagy also has a role in the maintenance of quiescence and senescence within stem 
cells, by removing damaged macromolecules which would otherwise cause a loss of 
quiescence within the cell and suppressing mitochondrial biogenesis and ROS 
production.314 
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Autophagy has also been implicated in the survival of colorectal cancer stem cells. Stem 
cells isolated using cell surface markers CD44 and CD24 were found to have higher 
colony forming abilities, these same cells showed an increased resistance when exposed 
to paclitaxel. This resistance was related to the autophagic flux within the cell. Resistant 
cells were shown to have a higher level of autophagy and when autophagy was inhibited 
the cytotoxicity of paclitaxel was increased.315 The discovery that autophagy may be 
involved in cancer stem cells increased survival ability in a toxic tumour 
microenvironment may lead to new ways in which to selectively target them. 
10.10  Stem Cell Assays 
The use of stem cell markers for identifying cancer stem cells is not straightforward. As 
with normal stem cells in different organs, cancer stem cells from different tumour types 
express different combinations of  markers. The stem cell markers which characterise a 
glioma cancer stem cell would not be the same as those which characterise a colorectal 
cancer stem cell, though there is some cross over. To further complicate the issue, 
cancer stem cells do not stably express the same markers all the time and marker 
expression can be varied depending on the microenvironment in which the stem cell is 
currently growing. To make the use of markers more robust a combination of different 
marker expression is often used, along with experimental evidence from various 
functional in vivo and in vitro assays which measure the stem-like characteristics 
displayed by the cells. 316  
The gold standard for stem cell assays is the serial transplantation assay, which is used 
to show the self renewal and multi-lineage differentiation capacity of the cells (Figure 
19). The assay involves transplanting cells into orthotopic sites of immunocompromised 
mice to determine xenograft formation. To assay self renewal cells from the xenograft 
are then transplanted into a second animal and so on with the resulting tumours sharing 
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similar histological phenotypes. 317 While this assay remains the best option for 
determining stem cell like behaviour of cells it is both time consuming and expensive. 
In vitro assays therefore have been developed to try and measure the same stem cell 
characteristics in a more rapid and quantitative way. 
In 1996 a significant breakthrough in stem cell research resulted in the discovery that 
undifferentiated multipotent neural cells could be grown and maintained in suspension 
without loss of proliferation of multilineage potential. This discovery led to the 
introduction of the neurosphere assay.318 Since then this sphere formation assay has 
been used to measure the 'stemness' of stem cells in many different tissue319, 320, 321 and 
cancer types.322, 323, 324 The sphere formation assay, which measures the ability of single 
cells to form spheroid like structures in non adherent conditions, is dependent on the 
stem cells ability to avoid anoikis. Sphere formation assays are conducted under 
conditions for stem cells growth which normally involved serum free media and growth 
factors such as Epidermal Growth Factor. 325  
 
Figure 19. Diagram depicting the serial transplantation assay used to identify cancer stem 
cells. Using a marker such as CD133 the ability of these cells to initiate and repopulate a 
heterogeneous tumour can be measured.326 
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10.11  How to target cancer stem cells 
The discovery and characterisation of cancer stem cells has major implications for the 
treatment of cancer. Treatment of colorectal cancer is difficult and various regimens 
exist including surgery, radiotherapy, cytotoxic drugs and monoclonal antibodies 
against VEGF and EGFR. However in advanced cases of the disease most treatments 
are not curative. The reason behind this is that most conventional therapies are targeted 
against actively proliferating or cycling cancer cells which compose the bulk of the 
tumour, but which excluded the cancer stem cells. Cancer stem cells are also known to 
be more resistant to chemotherapeutics through other mechanisms including increased 
drug efflux pumps and increased DNA repair. Treatments which decrease the proportion 
of normal cancer cells whilst sparing the cancer stem cell population only serve to 
enrich the stem cell population in tumours.327 Therefore in order to successfully treat 
colorectal cancer a method must be developed to target the cancer stem cells. 
There are various different ways to target cancer stem cells. One method is to force 
them to terminally differentiate thereby resulting in their loss of tumourigenic 
potential.328 The effect of differentiation therapy would be to cause the cancer stem cells 
to develop into mature cancer cells which no longer have the ability to initiate further 
tumour growth. Compounds such as salinomycin have been found to induce terminal 
epithelial differentiation in breast cancer stem cells thereby reducing the percentage of 
stem cells within the breast cancer population; this has been shown to inhibit tumour 
growth in vivo.329 
The use of stem cell markers to target the cancer stem cells is not as straight forward as 
it seems. While the markers are specific to cancer stem cells and therefore absent in 
normal cancer cells they are often found to be expressed by a wide variety of cells in 
normal non-cancerous tissue. This would mean that any drug targeted against that 
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marker would have a very small therapeutic window as it would also target the healthy 
tissues, an effect which would limit its use. However success has been seen in vivo for 
the targeting of CD44.330 The choice of which stem cell marker to use through its 
distribution in healthy tissues and the cancer stem cells reliance upon it is crucial.  
Elucidating some of the mechanisms for multidrug resistance employed by cancer stem 
cells has lead to further ways to selectively target the cells. Cancer stem cells are known 
to over express certain drug effluxers such as the ABC transporters. Inhibition of the 
these transporters in combination with a classical chemotherapeutic agent would 
selectively target the stem cells. This method has shown to be successful in 
melanoma.331 Other drug resistance mechanisms such as the expression of IL-4 have 
also been exploited; in colorectal cancer pre-treatment of CD133 positive cells with an 
IL-4 neutralising antibody was shown to increase apoptosis in response to 
chemotherapeutics both in vitro and in vivo.332 
Another mechanism which could be used to target cancer stem cells is their ability for 
self renewal. By targeting the evolutionarily conserved pathways known to be involved 
in this process, such as Wnt and Notch signalling it is possible to induce cell death in 
these cancer stem cells.333 However these signalling pathways are also relied on by 
normal stem cells so there is an issue with selectivity. 
11 Synopsis 
In summation clinical data has established a link between tumour necrosis and poor 
prognosis, though the mechanisms surrounding the relationship are unknown. Recent 
evidence has found active enzyme activity, along with mRNA synthesis, to be occurring 
in the necrotic core of MCTS; therefore warranting further investigation.334  
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The topics discussed in this chapter include a number of different physiological 
processes that are implicated in cancer progression and metastasis that could help to 
explain the link between tumour necrosis and poor prognosis. Whilst the biological and 
therapeutic implications of the hypoxic tumour microenvironment have been deduced 
the necrotic microenvironment is still waiting to be investigated.  
How the cells manage to survive within the poor conditions found in necrotic tissue is 
an important question which when answered could highlight new therapeutic targets. 
The various different processes by which a cell could use to survive such a 
microenvironment need to be investigated. Such processes include the EMT which 
could be used to survive low attachment conditions; resistance to anoikis can be 
mediated through this process, and entering the cellular state of senescence or 
conversely becoming dormant for a time to survive the low oxygen and nutrient 
conditions. Metabolic adaptations such as the induction of autophagy can be used by the 
cell to survive the low nutrient conditions, the properties of cancer stem cells including 
both increased survival capabilities in response to poor conditions and the induction of 
EMT could also help explain the survival of cells with necrotic tissue. 
By investigating each of these cellular mechanisms and their role in the tumour 
microenvironment specifically in necrotic cells it may be possible to more fully 
elucidate their role. This thesis therefore will work towards proving or disproving the 
hypothesis that viable cells within areas of necrosis are more aggressive and treatment 
resistant. And that their existence explains why tumour necrosis is associated with poor 
prognosis and overall survival in cancer patients, hence suggesting that necrotic tissue 
must also be considered when treating cancer. 
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12 Aims 
It is currently understood that necrosis, which is characteristic of large solid tumours, 
involves the disruption of the cell membrane and release of cellular contents into the 
extracellular space. The result of which can be promotion of further cancer growth, 
invasion and progression.335 Necrosis has been shown to lead to the acquisition of a 
more aggressive phenotype and chemoresistance in a range of different tumour types, 
including breast and gastrointestinal.336, 337 Due to recent evidence that cells in areas of 
necrosis are actively expressing mRNA and proteins,338 the focus of this research is to 
understand how and why tumour necrosis is linked to poor progression and aggression 
in tumours. The primary objective of this research is to investigate the necrotic core of 
the MCTS. Particularly to try and determine whether or not it is simply a mass of dead 
cells or whether it harbours different populations of cells which have adapted to live in 
the harsh environment. These adaptations could possibly make the cells in some way 
more resilient and possibly aggressive than the cells found on the viable rim. By 
establishing whether there are any biological differences in these cells it may be 
possible to determine whether this has any therapeutic significance and may lead to a 
new biological target. Furthermore it would go towards explaining why high levels of 
necrosis have been linked to increased aggression in some solid tumours.  
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Chapter 1: Identification of viable cells within the Necrotic Core of 
multicellular tumour spheroids (MCTS).  
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1 Introduction 
The first experimental chapter in this thesis is concerned with whether there is any ‘life’ 
within the necrotic core of MCTS and if this can be characterised. As described 
previously tumour necrosis has long been associated with poor prognosis yet the 
mechanisms behind this association have yet to be understood. However active enzyme 
activity recently discovered in the necrotic core of MCTS
1
 has led to the formation of a 
new hypothesis to explain the link. If viable cells are able to survive within areas of 
tumour necrosis and return to proliferation when conditions improve then this could 
explain the association and lead to the discovery of new biology and targets for cancer 
therapy. The tumour microenvironment which is known to act as a niche for different 
populations of cells with different phenotypes is considered a valid target for 
chemotherapeutic intervention however most research involves the hypoxic or tumour 
stoma microenvironment. The necrotic tumour microenvironment has been largely 
ignored due to the assumption that it consists of only dead cells. Autophagy is an 
evolutionarily conserved cellular response to low nutrient and oxygen conditions, such 
as those seen in areas of necrosis in MCTS. The role of autophagy in tumour 
development and progression is a paradoxical one with roles being uncovered in both 
tumour promoting and tumour inhibiting mechanisms.  The discovery of full length 
proteins involved in autophagy in the necrotic core of MCTS
2
 prompts further 
investigation in autophagy within MCTS.  The specific aims of this chapter are to 
identify, characterise and isolate the living cells within the necrotic core of MCTS. 
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2 Materials and Methods 
2.1 Cell Lines 
DLD-1 cells were obtained from American Type Culture Collection (ATCC, Manassas, 
VA, USA) and maintained in RPMI 1640 medium (ATCC, Manassas, VA, USA) 
supplemented with heat inactivated Foetal Bovine Serum (FBS) (Invitrogen, Camarillo, 
CA, USA) to a final concentration of 10% (v/v). HT-29 cells were obtained from 
American Type Culture Collection and maintained in McCoy's 5A Medium Modified 
(ATCC, Manassas, VA, USA) supplemented with heat inactivated FBS to give a final 
concentration of 10% (v/v). MCF-7 cells were obtained from American Type Culture 
Collection and maintained in Eagle's Minimum Essential Medium (ATCC, Manassas, 
VA, USA) supplemented with 0.01 mg/ml Bovine Insulin (Sigma Aldrich, St Louis, 
MO, USA) and heat inactivated FBS to give a final concentration of 10% (v/v). HCT 
116 cells were obtained from American Type Culture Collection (ATCC, Manassas, 
VA, USA) and maintained in Dulbecco's Modified Eagle Medium (Life Technologies, 
ThermoFisherScientific, MA, USA) supplemented with heat inactivated FBS to give a 
final concentration of 10% (v/v). 
2.2 Routine Cell Culture 
All cells were incubated at 37
o
C in 95% air, 5% CO2 in T75 flasks until approximately 
90% confluence and then passaged. Monolayers were washed twice in 10ml of Hanks 
Balanced Salt Solution (Sigma Aldrich, St. Louis, MO, USA) before incubation at 37
o
C 
in 0.25% (w/v) trypsin (Sigma Aldrich, St. Louis, MO, USA) for 5-15 minutes until a 
single cell population was obtained. Trypsin was neutralised with 10ml complete 
medium before the cell suspension was centrifuged at 1000g for 5 minutes. The cell 
pellet was re-suspended in 10ml of medium and then split between different T75 flasks 
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using a typical split ratio of 1:10. Cells were then incubated as described above and 
medium was changed 2-3 times a week. 
2.3 HT-29 Multicell tumour spheroid (MCTS) Culture 
Cells (1x10
6
) were seeded into a spinner flask (F7690, Techne, Bibby Scientific 
Limited, Staffordshire, UK) containing 150ml of medium, and placed on a magnetic 
stirrer plate (MCS-104S, Techne, Bibby Scientific Limited, Staffordshire, UK) where 
the medium was stirred at a rate of 55rpm. Spheroids were left to grow for 4-5 days 
before the medium was first changed, thereafter medium was changed every 48 hours 
and then 24 hours as needed.  
2.4 DLD-1MCTS Culture 
Cells (5 x 10
5
) were plated into T75 flasks that had been base coated with 1% agar and 
incubated in 10-20ml medium for 24-72 hours. Once small spheroids had formed, they 
were transferred to spinner flask and medium volume increased to 150ml as described 
above. Spheroids were left to grow for 4-5 days before the medium was first changed, 
thereafter medium was changed when needed. 
2.5 HCT 116 MCTS Culture 
Cells (7.5 x10
3
) were plated into individual 1% agar coated wells in a 96 well plate. 
Cells were incubated for 4-5 days in 200µl of medium in the 96 well plate until the cells 
had formed a MCTS. MCTSs were then individually transferred to a spinner flask for 
continued culture. MCTS were initially incubated in 150ml medium which was 
increased to 250ml as the spheroids increased in size.  
2.6 MCTS Growth Curves 
MCTS growth curves were generated by measuring the average diameter of MCTS. The 
average spheroid diameter was determined by measuring 20 spheroids every 24-48hrs 
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using an inverted microscope fitted with a graduated eyepiece graticule. In order to 
visualise the morphology of MCTS at different stages of the growth curve, spheroids 
were removed from the spinner flask and fixed in Bouin's Solution (Sigma Aldrich, St. 
Louis, MO, USA) before being processed and embedded in paraffin wax, sectioned and 
stained using Haematoxylin and Eosin as described elsewhere (see section 2.10). 
2.7 Characterising Autophagy Inhibitors 
In order to determine which autophagy inhibitor was the best to use for assessing 
autophagic flux, Bafilomycin A1 (10nM, Enzo Life Sciences, New York, USA), 
chloroquine (50mM, Sigma Aldrich, St. Louis, MO, USA), and 3-methylalanine (5mM, 
Sigma Aldrich, St. Louis, MO, USA)  were all tested on starved and un-starved cells to 
see their effects. Briefly, 2x10
4
 cells were plated on coverslips in 6-well plates and 
grown under normal culture conditions for 24 hours, after which media was removed 
and replaced with starvation media (containing no serum or added amino acids such as 
L-glutamine). Autophagy inhibitors were then added to the media and the cells 
incubated for a further 24 hours. After this, cells were fixed in ice-cold methanol and 
LC3-II immunofluorescence carried out as described elsewhere (see section 2.12). 
2.8 Inhibition of Autophagy in Spheroids 
HT29 spheroids were grown for 15 days until they reached approximately 1mm in 
diameter. Spheroids were individually picked and placed in 6 well plates base coated 
with% (w/v) agar and incubated in 2ml of RPMI 1640 for 24 hours with Bafilomycin 
A1 at a concentration of 10nM. Spheroids were then collected, fixed, processed and 
embedded as described below. 
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2.9 Histology 
Fixation: Spheroids were collected from spinner flasks and transferred to a universal 
tube where any remaining media was removed and replaced with Bouin’s Solution 
(Sigma Aldrich, St. Louis, MO, USA). The spheroids were left in Bouin’s Solution for 
75 minutes before being washed in 70% ethanol to remove excess fixative and then left 
in 70% ethanol at room temperature until processing. 
Processing: The 70% ethanol was removed, replaced with 90% ethanol for 1 hour at 
room temperature, which was removed and replaced with 100% ethanol for 30 minutes. 
This was then replaced with fresh ethanol for another 30 minutes and then repeated once 
more. The ethanol was removed and replaced with xylene for 30 minutes before 
replacing with fresh xylene and repeated one final time. Spheroids were removed from 
the universal tube and placed in an embedding mould, any excess xylene removed and 
the mould filled with liquid wax. The spheroids were left for 30 minutes in a warming 
oven at 68
o
C in the wax before the waste wax was pipetted off and replaced with fresh 
and returned to the warming oven. This was repeated twice before the mould was placed 
on a cold stage to set. 
Sectioning: Blocks were chilled by storing at -20
o
C overnight. Using a microtome, 
5.0µm sections of paraffin embedded spheroid blocks were cut and mounted on 
Superfrost Plus slides (BDH, Poole, UK). Slides were incubated on a heated stage at 
37
o
C for two hours to dry to ensure sections were fully adhered to the slide and reduce 
the risk of the sections coming away from the slide during subsequent use. 
2.10 Haematoxylin and Eosin Staining 
Sections were de-paraffinised with xylene (3x5 minutes) and rehydrated using ethanol 
(3x2 minutes) before being washed in running tap water for 5 minutes. Sections were 
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then stained with Mayer’s haematoxylin (Sigma Aldrich, St. Louis, MO, USA) for 10 
minutes. Excess stain was removed from the section by soaking in acid alcohol for 60 
seconds before rinsing in running tap water for 5 minutes and then immersing in Scott’s 
Tap Water for 60 seconds to allow the colour to develop. Sections were counterstained 
in Eosin for 60 seconds before a final wash in running tap water. Finally the sections 
were dehydrated using sequential ethanol (1x2minutes, 2x1minute) and xylene 
(3x1minute) series and mounted using diphenylxylene (BDH, Pool, UK).   
2.11 Immunohistochemistry 
Sections were de-paraffinised with xylene (3x5 minutes) and rehydrated using ethanol 
(3x2 minutes) before being washed in running tap water for 5 minutes. If necessary, 
antigen retrieval was then carried out by heating slides in antigen retrieval solution (see 
Table 1) in a microwave for a specific length of time before cooling. Slides were rinsed 
in tris-buffered saline (TBS) before endogenous peroxidise activity was blocked for 10 
minutes at room temperature by incubating with hydrogen peroxidase block. Following 
this, further blocking steps were carried out depending on the primary antibody used 
(see Table 1). Non-specific binding was blocked by incubating the sections with 
Antibody Diluent containing Bovine Serum Albumin (Invitrogen, Camarillo, CA, USA) 
immediately prior to the application of the primary antibody. The sections were 
incubated with 100µl of the primary antibody diluted in Antibody Diluent in a 
humidified chamber. After incubation, slides were washed in TBS containing 10% v/v 
Tween-20 (TBST) (2x5 minutes) and TBS (1x5 minutes) before the application of 2 
drops of labelled polymer-HRP secondary antibody, and then incubated in a humidified 
chamber at room temperature for 1 hour. Following this, slides were again washed in 
TBST (2x5 minutes) and TBS (1x5 minutes). Sections were then incubated with 3,3-
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diaminobenzidine (DAB, DAKO North America Inc, CA, USA) for 10 minutes at room 
temperature, where the horseradish peroxidise breaks down the DAB via an oxidation 
reaction to produce a brown precipitate at the location of the antigen. Sections were 
washed in running tap water for 5 minutes before being counterstained using Mayer’s 
haematoxylin (Sigma Aldrich, St. Louis, MO, USA) for 30 seconds, rinsed in tap water 
for 60 seconds, Scott’s tap water for a further 60 seconds and finally tap water again for 
60 seconds. Sections were then dehydrated using sequential ethanol (1x2mins, 2x1min) 
and xylene (3x1min) series and finally mounted using diphenylxylene (BDH, Dorset). A 
list of all antibodies used and specific conditions of IHC are presented in table 1.  
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Table 1. List of all antibodies used for immunohistochemistry and the specific conditions 
used for antibody incubations, antigen retrieval and blocking procedures. 
Primary Antibody Dilution  Incubat
ion 
Antigen 
Retrieval 
Blocking 
Reagents 
Secondary 
Antibody 
Anti-LC3B antibody 
(APG8B, rabbit 
polyclonal anti-human 
LC3B Ig; Abgent, San 
Diego, CA, USA; 
0.25mg/ml) 
1:100 
 
4
o
C 
Overnig
ht 
None 
 
5min Envision 
H2O2, 
30min Zymed 
Antibody 
Diluent 
 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-Ki-67 antibody 
(B56, mouse anti 
human Ki-67 IgG1,κ; 
BD Pharmingen, NJ, 
USA; 250µg/ml) 
1:100 
 
4
o
C 
Overnig
ht 
10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
3% H2O2 (v/v 
in methanol)  
Normal Horse 
Serum (1:200 
in PBS for 20 
min) 
Labelled 
polymer-HRP 
anti-mouse 
(K4007, 
EnVision Kit, 
DAKO) 
Anti-Cleaved 
Caspase-3 antibody 
(Asp175, rabbit 
monoclonal anti-
human Cleaved 
Caspase-3 IgG; New  
England BioLabs, 
MA, USA) 
1:800 4
o
C 
Overnig
ht 
10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
5min Envision 
H2O2, 
2 hour 4% (v/v 
in TBS) 
Normal Goat 
Serum 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-Beclin 1 
antibody (BECN1, 
rabbit polyclonal anti-
human Ki-67; Novus 
Biologicals, CO,USA; 
0.2mg/ml) 
1:400 4
o
C 
Overnig
ht 
None 60min Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-H2AX antibody 
(20E3, rabbit 
monoclonal anti 
Phospho-Histone 
H2A.X IgG; Cell 
Signalling, MA, USA) 
1:400 1 hour 
RT 
10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
3% H2O2 
block,  
10min Zymed 
Antibody 
Diluent  
Labelled 
polymer-HRP 
anti-rabbit 
(K4006, 
EnVision Kit, 
DAKO) 
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2.12 Immunofluorescence 
HT-29 and DLD-1 cells (2 x 10
4
) were seeded onto 2cm
2
 coverslips and placed into 6 
well plates with 2ml of RPMI 1640 (ATCC, Manassas, VA, USA) media containing 
10% FBS for 24 hours. Media was subsequently removed and replaced with 2ml of 
media containing no serum for a further 24 hours. The starvation media was then 
removed and the coverslips were incubated on ice for 5 minutes with 2ml of ice cold 
methanol to fix the cells. The methanol was removed and non-specific binding was 
blocked by incubating coverslips with 2ml of 2% (w/v) BSA (Bovine Serum Albumin, 
Sigma Aldrich, St Louis, MO, USA) in PBS (Phosphate Buffered Saline, Sigma 
Aldrich, St Louis, MO, USA) for 60 minutes at room temperature. Coverslips were 
washed for 2 x 5 minutes in 2 ml of PBS before incubating for 45 minutes at room 
temperature with 200µl of rabbit anti human LC3-II primary antibody (APG8A, rabbit 
polyclonal anti human LC3B; Abgent, San Diego, CA, USA; 0.25 mg/ml) diluted 1:50 
with 2% BSA in PBS. Coverslips were then washed 3 x 5 minutes with PBS before 
application 200µl of the secondary fluorescent antibody (Alexa Fluor
®
 546, goat anti-
rabbit, IgG; Invitrogen, Camarillo, CA, USA, 2mg/mL) diluted 1:50 in 2% BSA in PBS. 
Coverslips were incubated at room temperature for 45 minutes before washing for 3 x 5 
minutes with PBS and then mounted using VECTORSHIELD hard-set mounting 
medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) and kept in the 
dark at 4
o
C until examination under the microscope.  
2.13 Preparative Fluorescence Associated Cell Sorting (FACS) 
Upon growing to an average diameter of 1500µm, HT29 spheroids were incubated with 
1µM Hoechst 33342 (Invitrogen, Camarillo, CA, USA) for 30mins at 37
o
C before 
gently washing in medium. Spheroids were then incubated in 0.25% (w/v) trypsin for 
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15mins at 37
o
C before transferring to medium and vigorously pipetting until a single 
cell suspension was achieved.  
The cells were sorted into different populations (necrotic core and viable rim see Figure 
1) based on their cell size (FSC) and granularity (SSC). These two populations were 
then further sorted by the intensity of Hoechst staining using an excitation wavelength 
of 350-360nm and emission monitored at 488nm. Each population was split into 3-4 
different groups with roughly 25-30% of the population in each. A total of 7 fractions 
were collected, 3 derived from the necrotic core population and 4 from the viable rim 
population. The fractions were collected on ice in McCoy's 5A Modified Medium with 
20% FBS and 10% Penicillin Streptomycin (Sigma Aldrich, St Louis, MO, USA) . 
Acknowledgements go to Dr Andrei Mardaryev for his knowledge and expertise in this 
experiment. 
2.14 Analysis of Fractions 
 
Figure 1. A HT-29 MCTS Haematoxylin and Eosin stained section showing the location of 
the viable rim and necrotic core. 
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2.14.1 Plating Efficiency 
To determine the viability of the cells from each fraction the plating efficiency (PE) was 
determined. A number of concentrations (1000, 100, 50 and 10 cells/ml) of cells were 
plated onto six-well plates with 3mls medium and incubated at 37
o
C, 5% CO2, 95% 
humidity. After 10 days colonies containing more than 50 cells were counted, and PE 
was determined using the following formula 
PE (%) = (Number of colonies formed /Number of cells plated) x 100  
2.15 Formation of Necrotic Core Clones 
Cells from the least fluorescent (hence most central to the spheroid) necrotic core 
fraction were plated onto six-well plates at various low concentrations (10-100 cells/ml) 
and allowed to grow for 2-3 weeks. In wells where only a single colony had formed it 
was transferred into a T25 cell culture flask with fresh media and allowed to grow 
further. Cell lines derived from these clones were given the notation NCC to denote 
necrotic core clone. Control clones were also established from the parental cell line 
using the same method only with more dilute cell concentration (1-20 cells/ml). These 
were given the notation CC. 
2.16 Necrotic Core Clone Growth Curves 
Monolayer cultures in the exponential phase of growth were washed with Hanks 
Balanced Salt Solution, and incubated with 0.25% Tryspin for 5-15 minutes until a 
single cell population was achieved. Once the cells were detached, the trypsin was 
diluted with 10ml medium and the cells collected and centrifuged at 1000g for 5 
minutes. Cell pellets were then re-suspended in medium, and a cell count determined 
using a haemocytometer. Cells (10
3
) were then added to 15 T25 flasks, and left to 
incubate at 37
o
C in 95% humidity, 5% CO2. On Day 1, 2, 3, 4 and 7, the above process 
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was repeated in order to get an average cell count for that day. Doubling Times were 
established (determined) from the log phase of the growth curves. 
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3 Results 
The findings of this chapter of work will be presented in the next section detailing the 
isolation of living cells from within the necrotic core of MCTS and their 
characterisation . 
3.1 HT-29 and DLD-1 multicellular tumour spheroid growth curves. 
HT-29 cell line readily formed spheroids when single cell suspensions were added 
directly to medium in spinner flasks and constantly stirred at a rate of 50rpm. There was 
no need to use standard liquid overlay techniques to ‘seed’ spheroids and this also 
removed the need to select spheroids of a defined size prior to transfer to spinner flasks. 
Small spheroids were visible to the naked eye after 72 hours and spheroid diameter was 
determined using an inverted microscope fitted with a calibrated eyepiece graticule. The 
DLD-1 cell line required 24-72 hour liquid overlay incubation prior to transfer to the 
spinner flask to induce the MCTS to form. The growth of DLD1 and HT-29 spheroids is 
presented in figure 1. DLD1 spheroids reached a maximum diameter of 800-1000µm 
after 14-17 days, HT-29 spheroids reached an average size of 1500µm after 21 days, 
with individual spheroids reaching a maximum diameter of in some cases 2000µm (see 
Figure 2). The growth of the spheroids was biphasic, in the first 6 days of growth the 
spheroids grew exponentially, doubling in size every 31.4 hours (HT-29) and 40.2 hours 
(DLD-1), after this time period the growth slowed down to give a doubling time of 
201.7 hours (HT-29) and 189.6 hours (DLD-1). The first phase of MCTS growth 
coincides with the period of growth prior to development of the necrotic core. The 
second slower phase of growth begins around the time of necrotic core formation 
(~500µm). Continued culture after both cell lines have reached their maximal sizes 
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resulted in the loss of structure and eventually breakdown of the spheroids even in the 
presence of fresh, nutrient rich medium.  
 
Figure 2. Graph showing the respective growth of HT-29 spheroids (shown in black) and 
DLD-1 spheroids (shown in red) grown in spinner flasks where the medium is changed as 
required. Three separate experiments were carried out in order to calculate an average and 
standard deviations for the spheroid growth. Cells were transferred to the flask on Day 0. 
3.2 Growth of HCT116 as MCTS.  
HCT-116 cells were unable to form MCTS directly from single cell suspensions. 
Culturing the cells using liquid overlay techniques (1% agar in T-75 flasks) for 24-72 
hours also failed to encourage them to form MCTS prior to transfer to a spinner flask. 
When introduced to culture conditions in the spinner flasks, the cells stopped growing. 
The method which was found to be successful for this cell line involved seeding a 
number of cells (7.5 x 10
3
 in 200µl medium) into agar coated (1%) wells of a 96 well 
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plate and incubating them for several days before transfer to a spinner flask. The result 
of this was the formation of one MCTS per well. At the time of transfer to spinner 
flasks, MCTS can be as big as 600-700µm in diameter. Once transferred to the spinner 
flasks, HCT-116 MCTS will continue to grow until a maximal diameter of 
approximately 1000µm is reached. This final growth phase take 5 days upon transfer to 
spinner flask.  
3.3 Morphology of MCTS 
All three cell lines formed spheroids that had a similar morphology characterised by the 
presence of a viable rim and a centralised necrotic core. 
 
Figure 3. Cross sections through HCT116, HT-29 and DLD-1 MCTS stained with 
Haematoxylin and Eosin.  
HT-29, HCT-116 and DLD-1 cell lines all formed large spheroids, particularly HT-29s 
which grew in some cases to over 2000µm in diameter. As the spheroids grew a 
necrotic core formed (Figure 3) when the spheroid reached approximately 500µm in 
400µm 400µm
200µm
HCT116 HT-29 
DLD-1 
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diameter. The formation of a necrotic core occurs when the diffusion distance from the 
outer layer of cells to the innermost cells is too far for sufficient nutrients and oxygen to 
penetrate. As the spheroid is observed to grow larger in diameter the necrotic core itself 
expands as more cells are too far from the surface layer to survive. DLD-1 spheroids 
were harvested at various different time points within a 15 day period then fixed, 
embedded, sectioned and stained with haematoxylin and eosin in order to examine how 
the morphology of MCTS changes are they grow larger. The results are presented in 
Figure 4. 
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Figure 4. DLD1 MCTS sections stained with haematoxylin and eosin, depicting the growth 
curve of DLD1 spheroids. Scale bar represents 200µm.  
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Measurements of the diameter of the necrotic core and the viable rim as a function of 
overall spheroid diameter are presented in Figure 5. As the spheroid grows, the necrotic 
core increases in size but the width of the viable rim tends to stay a relatively constant 
thickness after the formation of the necrotic core, ranging from between 100-250µm. 
 
Figure 5. Spheroid Diameter and the relative size of the necrotic core and viable rim. Panel 
A and B show Haematoxylin and Eosin staining of two HT-29 spheroid sections, one showing a 
larger spheroid with a thinner viable rim and larger necrotic core (A), and one smaller spheroid 
with a comparatively thicker viable rim and smaller necrotic core (B). Panel C presents the 
relationship between spheroid diameter and the size of the viable rim and necrotic core in HT-
29 MCTS. For each MCTS 4 readings were taken for VR and NC thickness and used to 
determine an average. In total 20 MCTS were examined per group with serial sections examined 
to ensure the widest part of the MCTS is being examined. Experimental errors were omitted 
from the graph in the interest of clarity.  
As the spheroid increases in size, the diameter of the necrotic core also increases 
(Figure 5 and Figure 6). The graphs show that as the size of the spheroid increases the 
400µm 400µm
0
50
100
150
200
250
300
0 500 1000 1500
V
ia
b
le
 R
im
 (
µ
m
) 
Spheroid Diameter (µm) 
0
200
400
600
800
1000
1200
0 500 1000 1500
N
ec
ro
ti
c 
C
o
re
 (
µ
m
) 
Spheroid Diameter (µm) 
A B 
C 
121 
 
thickness of the viable rim stays relatively constant, in comparison to the necrotic core 
which increases in size. This is seen in both HT-29 (Figure 5) and DLD-1 (Figure 6). 
The implication being that the diffusion distance stays relatively constant and is the 
driving factor behind the formation and size of the necrotic core. The Pearson's product-
moment correlation coefficient (P) was calculated to determine the straight line 
correlation between the size of the spheroid and the necrotic core size. Where 0 = no 
correlation, -1 = negative correlation and +1= positive correlation, the results 
demonstrate that there is a positively correlated relationship between spheroid diameter 
and size of the necrotic core for both DLD-1 (P = 0.927) and HT-29 (P = 0.942) 
spheroids. 
 
Figure 6. Data demonstrating the relationship between spheroid diameter and the 
relative sizes of the viable rim and necrotic core in DLD-1 MCTS. Panel A and B 
show data demonstrating the relationship between spheroid diameter and the relative 
size of the viable rim and necrotic core in DLD-1 MCTS. Panel A showing the necrotic 
core as a function of MCTS size, panel B showing the viable rim as a function of MCTS 
size. 
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3.4 Ki67 staining highlighting cellular proliferation within MCTS. 
HT-29 and HCT116 MCTS sections were stained with an antibody against Ki-67, a 
marker of cellular proliferation (Figure 7). In HT-29 spheroids, only cells in the outer 
half of the viable rim stained positive for Ki67. The subset of cells within the viable rim 
which were proliferating in the HT-29 MCTS were located in the outer 100µm of the 
spheroid rim, whilst cells localised any deeper than this were quiescent (Figure 7A). In 
a large HT-29 spheroid (>500µm) with a well-defined necrotic core, there are no cells 
actively proliferating within the necrotic core. In the smaller HCT-116 MCTS the 
majority of actively proliferating cells were seen in the outer 100µm of the spheroid 
viable rim however a number of proliferating cells were seen in the inner half of the 
viable rim (Figure 7B). The 100µm limit which seems to encompass the majority of 
proliferation cells in both types of MCTS would suggest that 100µm is a crucial 
diffusion distance for nutrients and/or oxygen to support cell replication in both HT-29 
and DLD-1 MCTS. 
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Figure 7. Cellular proliferation within MCTS. Panel A presents the expression of Ki-67 in a 
HT-29 MCTS. Panel B showing Ki-67 expression in a HCT 116 MCTS. Panel C the negative 
control, a HT-29 spheroid incubated without primary antibody.  
3.5 Pore formation in the viable rim of large spheroids. 
As described previously, the viable rim becomes very thin in relation to the necrotic 
core as the spheroid increases in size. When spheroids become large, pores can form in 
the viable rim as illustrated in Figure 8. The characteristic feature of pore formation is 
that whilst the majority of the viable rim remains intact, a focal thinning of the viable 
rim occurs in places and when complete, the necrotic core can be extruded (Figure 8). 
This process mostly occurs in spheroids when they reach a size of between 1500-
2000µm. These events become more visible when large mature MCTS are removed 
from the spinner flasks and placed in static liquid overlay conditions. Under continuous 
stirring conditions in the spinner flasks, MCTS appear to retain their compact structure 
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but when placed in liquid overlay conditions, pore formation becomes more visible and 
the spheroid becomes more fragile. It is not known whether the transfer to liquid 
overlay accelerates the formation of pores or it reflects the fact that constant stirring will 
remove any extruded material making the pores harder to detect visually. This 
phenomenon is more common in the HT-29 cell line and pore formation was not 
common in DLD-1 spheroids. Whether this is just an innate characteristic of this 
particular cell line or caused by its ability to grow to the large sizes needed for the 
process to occur is unclear. A HT-29 MCTS demonstrating the formation of a pore in 
the viable rim and subsequent release of the inner necrotic core cells was also stained 
for Ki-67. The staining shows the cells 'escaping' from within the MCTS are not the 
actively proliferating Ki-67 positive cells from the viable rim but those from the 
necrotic core which have a stronger need to escape the nutrient poor environment in the 
centre of the MCTS. 
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Figure 8. Cross section through HT-29 MCTS focusing on the viable rim and pore 
formation. Panels A and B show different magnifications of a single HT-29 spheroid stained 
with antibodies to Ki-67 with a pore in the viable rim. In panel A NC denotes the necrotic core 
and VR the viable rim of the MCTS and arrows indicate thinning of the viable rim in additional 
places in the MCTS. Panel C shows a close up of a section of Panel A denoted by an asterix, 
where the early stages  of pore formation in the viable rim are visible, the thinking of the viable 
rim is shown by an arrow. Spheroids were cultured in liquid overlay following culture in 
spinner flasks and extrusion of the necrotic core is clearly visible as Ki-67 negative cells. 
3.6 Detection of cells undergoing apoptosis using cleaved caspase 3 staining 
MCTS sections were stained with antibodies against Cleaved Caspase-3, an effector 
protein involved in both the intrinsic and extrinsic apoptotic pathways, to look for the 
distribution of apoptotic cells within different regions of the MCTS. Within the viable 
rim of spheroids, only a few cleaved caspase-3 positive cells were visible with the 
majority of these being found close to the necrotic core boundary (Figure 9A). As 
expected, positively stained cells were abundant within the necrotic core (Figure 9A). 
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At higher magnification however (Figure 9B), a number of negatively stained cells were 
visible. Morphologically, these cells resembled viable cells in that they had a defined 
nucleus that was not fragmented. This suggests that the necrotic core is not made up just 
of dead and dying cells as previously thought but a number of cells have managed to 
adapt and survive in this harsh environment. Either that or the cells are undergoing a 
cleaved caspase-3 independent form of cell death. Viable cleaved caspase 3 negative 
cells were not just seen on the periphery of the necrotic core which would suggest that 
they had recently detached from the hypoxic fraction but were present throughout the 
necrotic core. Viable cells were even in the very centre at depths as deep as 600µm from 
the surface.  
  
 
Figure 9. Immunohistochemical images showing Cleaved Caspase-3 expression in HT29 
MCTS. Panel A shows the expression in the entire MCTS. Panel B shows the expression within 
the necrotic core. Circled in panel B are a cluster of negatively stained cells in the necrotic core. 
Panel C represents HT-29 spheroids stained with secondary antibody only (no primary 
antibody).  
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3.7 Analysis of necrosis in colorectal cancer xenografts 
Xenografts from all three cell lines were also examined histologically to determine 
whether the areas of necrosis seen in MCTS were also seen when the cells were grown 
in vivo, and thus determine how representative MCTS are as a model for studying 
necrosis in vitro. Extensive areas of necrosis were seen in all three xenografts 
surrounded by areas of more viable tissue. 
  
 
Figure 10. DLD-1, HCT-116 and HT-29 xenografts showing evidence of areas of necrosis. 
Necrotic areas are indicated with an N, areas of viable tissue are indicated with a V. 
Once areas of necrotic tissue were seen in haematoxylin and eosin stained HT-29, DLD-
1 and HCT 116 xenografts (Figure 10), these same tissues were also examined 
immunohistochemically to determine their cleaved caspase-3 expression (Figure 11). 
The necrotic regions of multicellular tumour spheroids are symmetrical unlike the areas 
of necrosis seen in the same cells grown as in vivo xenografts. In all three xenografts 
expression of cleaved caspase-3 was seen located in areas of necrotic tumour tissue. 
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Similar to the expression seen in HT-29 MCTS, not all the necrotic cells were positive 
for cleaved caspase-3. In the HCT 116 tissue only a small proportion of cells can be 
seen to be stained whereas in the HT-29 and DLD-1 xenografts a larger proportion can 
be seen to be positive.  
   
 
Figure 11. Immunohistochemical analysis of the expression of cleaved caspase-3 in Panel A 
HCT 116, Panel B DLD-1 and Panel C HT-29 xenografts. 
3.8 Comparison of necrotic tissue in clinical colorectal liver metastases and HT-
29 Multicellular Tumour Spheroids 
In colorectal liver metastases, the morphology resembles that of MCTS with a central 
area of necrotic tissue surrounded by a ring of viable cells (Figure 12). The cells within 
the necrotic centre of the ‘rosette’ (Figure 12B) include those which still retain a 
definite nucleus and those in which the nucleus has broken down into multiple nuclear 
bodies. The combination of whole cells and cellular debris is mirrored in the HT-29 
50µm 50µm
50µm
A B 
C 
129 
 
MCTS. Furthermore as in the MCTS the cell-cell connections in the necrotic areas look 
like they have in some places broken down leaving the cells to exist in a less rigid more 
‘liquid-like’ state. The similarities seen in structure and morphology demonstrate that 
MCTS retain many features observed in clinical disease such as areas of necrotic tissue 
and this further supports the fact that MCTS provide a representative in vitro model for 
metastatic colorectal cancer. 
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Figure 12. Morphological analysis of necrotic tissue in colorectal liver metastases and it's 
similarities to the necrotic core in HT-29 MCTS. Panel A shows a liver section containing 
colorectal metastatic deposits. Inset entire liver section, red square represents the field of view 
in the main image. Panel B shows the morphology of a rosette consisting of a central mass of 
necrotic tissue surrounded by a ring of viable cells. Inset entire liver section. Panel C shows 
higher magnification (x20 objective) of the necrotic centre of the rosette. Inset entire liver 
section, grey line indicates the diameter of the necrotic area. For comparison panel D shows the 
necrotic core of a HT-29 MCTS (x20 magnification). Inset number of MCTS sectioned 
together, grey line represents the same distance seen in the necrotic liver rosette for comparison. 
Images were provided by University of Leeds Institute of Cancer and Pathology, Department of 
Pathology, Anatomy and Tumour Biology.
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3.9 Autophagy in MCTS 
The catabolic process of macroautophagy is known to be involved in cell survival in 
hostile environments. The discovery of cleaved caspase-3 negative cells within the 
necrotic core led to the investigation of whether alternative survival and death 
mechanisms were engaged, including autophagy.  
3.10 Characterising Autophagy inhibitors 
In order to determine the presence of autophagic flux within a cell an appropriate 
autophagy inhibitor must be used. The autophagy inhibitor must inhibit the process of 
autophagy after the formation of the (LC3-II coated) autophagasome, allowing these to 
build up within the cell if it is actively undergoing autophagy. If the autophagy inhibitor 
inhibits the process before the formation of an autophagasome then all results seen will 
be negative regardless of the state of autophagic flux within the cell. It was found that 
the addition of both bafilomycin A1 (10nM) and chloroquine (50mM) significantly 
increased the number of LC3 puncta, and therefore autophagasomes, in the starved 
DLD-1 monolayers, whilst 3-methyladenine had a somewhat reduced effect (Figure 13). 
Therefore both bafilomycin A1 and chloroquine are suitable inhibitors for use in 
measuring autophagic flux.  
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Figure 13. Immunofluorescent images showing the expression of LC3 and the effect of 
different autophagy inhibitors on DLD-1 cells. Red fluorescence represents LC3-II, nuclei are 
counterstained blue. Panel A 24hr starvation, no autophagic inhibitor. Panel B 24hr starvation 
and 10nM bafilomycin. Panel C 24hr starvation and 5mM 3-methylalanine. Panel D 24hr 
starvation and 50µM chloroquine. 
3.11 LC3-11 and Beclin-1 staining in HT-29 MCTS 
To detect autophagy in MCTS, various techniques were used. Spheroids which had 
been pre-treated prior to fixation with bafilomycin A1 (10nM) were sectioned and 
stained with an anti-LC3-B antibody and compared to sections of untreated spheroids to 
look for punctate expression of the protein within the different regions of the spheroid. 
Beclin-1 was also used as an autophagic marker to support the results seen from the 
LC3 staining.  
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As shown in Figure 14, LC3 was found to be expressed in punctate dots in the necrotic 
core (Panel C and D). The number of these puncta were also shown to qualitatively 
increase in the necrotic core when spheroids were treated with autophagy inhibitor 
Bafilomycin A1 for 24 hours (Panel D) This increase means that autophagy is actively 
occurring in some cells within the necrotic core, as more autophagasomes are being 
produced. Beclin-1 expression was also seen located in the necrotic core of the spheroid 
(Panel B), further validating the LC3-II staining and the conclusion that cells in the 
necrotic core of MCTS are actively undergoing autophagy.  
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Figure 14. Immunohistochemical staining of HT29 spheroids for Beclin 1 and LC3-II. 
Panel A shows a whole spheroid stained with anti-Beclin-1 antibody. Panel B shows the 
positive Beclin-1 staining at the viable rim/necrotic core boundary and in the necrotic core. 
Panels C and D show the necrotic core stained with anti-LC3 antibody where panel C shows 
staining of an untreated spheroid and D shows the necrotic core of a spheroid that has been 
treated with the autophagy inhibitor Bafilomycin A1. Panels E and F are primary antibody 
controls (no primary antibody added) for Beclin-1 primary LC3-II respectively.  
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3.12 DNA double strand breaks in cells within the Necrotic Core 
To detect whether the cleaved caspase-3 negative cells within the necrotic core were 
indeed alive and managing to survive, HT-29 MCTS sections were investigated for the 
expression of phosphorylated H2AX, a marker of the DNA damage response 
specifically to DNA double strand breaks, that can also be expressed in senescent cells. 
As shown in Figure 15 a number of cells on the boundary between the necrotic core and 
viable rim were stained positive for phorphorylated H2AX (p-H2AX). When examined 
closely it was found that some cells within the necrotic core were also positive. As in 
the case of the cleaved caspase-3 negative cells, p-H2AX positive cells were seen at 
similar depths within the necrotic core. It is not known whether the cleaved caspase-3 
negative cells are positive for p-H2AX. 
  
   
Figure 15. Images showing p-H2AX immunohistochemical staining on HT-29 MCTS 
sections. Panel A represents a low magnification (X10 objective) covering the entire MCTS, 
whereas panels B and C focus on the necrotic core using a X10 and a X20 objective lens 
respectively. Panel D represents the primary antibody control (no primary antibody added). 
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3.13 Phosphorylated-H2AX expression in vivo. 
To see whether the same expression of H2AX could be seen in vivo as well as in vitro, 
sections from HT-29, DLD-1 and HCT 116 xenografts were stained with antibodies 
against H2AX. As seen in Figure 16 positive expression of p-H2AX was seen in all 
three xenografts in or adjacent to areas of necrosis. This is consistent with the pattern of 
p-H2AX expression observed in MCTS in vitro. 
   
 
Figure 16 Expression of p-H2AX in DLD-1 Panel A, HT-29 Panel B and HCT 116 Panel C 
xenografts. V represents areas of viable tissue, N denotes areas of necrosis. Positive staining for 
p-H2AX is indicated where the nuclei of cells is brown/dark brown in appearance. 
3.14 Inhibition of Autophagy in HT-29 MCTS and its effect upon cell death and 
senescence. 
To determine what effect the inhibition of autophagy had on the cellular characteristics 
and the morphology of spheroids, MCTS were treated with an autophagy inhibitor 
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Bafilomycin A1 (10nM) for 24 hours before fixation and histology. In spheroids where 
autophagy has been inhibited there is a larger necrotic core and thinner viable rim, 
compared to size matched, untreated MCTS. As a spheroid (both treated and untreated) 
increases in size the ratio between the size of the necrotic core and the thickness of the 
viable rim increases (Figure 17). In spheroids where autophagy has been inhibited the 
NC/VR ratio is larger. Specifically the viable rim in untreated spheroids becomes 
thinner in size as the spheroids grow but it rarely goes below a thickness of 150µm for 
spheroids with an overall diameter of 1300µm. In contrast, when autophagy is inhibited, 
the viable rim of these MCTS was thinner with values as thin as 90µm recorded. A 
thinner viable rim could be representative of a decreased survival ability of the HT-29 
cells at a shallower depth within the MCTS than previously seen. Inhibition of 
autophagy using Bafilomycin A1 therefore sensitises cell within the regions of the 
viable rim of spheroids where hypoxic cells are expected to reside leaving a thinner 
viable rim and an extended necrotic core.  
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Figure 17. Data demonstrating the relationship between MCTS diameter and the relative 
sizes of the viable rim and necrotic core. Comparing two populations of HT-29 MCTS where 
one has been treated with the autophagic inhibitor Bafilomycin A1.  Panel A shows cleaved 
caspase-3 stained HT-29 MCTS treated with BA1 with a thinning VR, Panel B shows a size 
matched unstained, untreated MCTS for comparison. Panel C shows the data relating to 
spheroid diameter and its relationship with the relative sizes of the necrotic core and viable rim.  
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In order to statistically analyse the two populations and determine whether they are 
significantly different, an ANOCOVA (analysis of covariance) was performed. This test 
enables the comparison of two lines of regression and determines whether the 
population means for the dependant variable (size of the necrotic core and viable rim 
respectively) differ across the levels of the independent variable (normal autophagic 
flux versus inhibited autophagic flux) taking into account and adjusting for the 
differences in the covariate (total spheroid diameter). Which in summation determines 
whether the adjusted group means differ significantly. The ANOCOVA performed upon 
this data was significant for both necrotic core and viable rim size, F > F crit ( Necrotic 
core,18.84 > 4.2; viable rim, 60.25>4.2), with p <0.001 for the necrotic core and 
p<0.0001 for the viable rim (Table 2). The adjusted mean for the normal MCTS 
necrotic core size was 631µm while for the autophagy inhibited MCTS the adjusted 
mean was higher, at 713µm (Table 3). The adjusted means for the viable rim sizes were 
188µm for normal MCTS and 117µm for the autophagy inhibited MCTS. The 
assumptions for the tests were met such that the covariate was linearly related to the 
dependant variable. Therefore the null hypothesis is rejected and the MCTS in the 
autophagy inhibition group have a significantly larger necrotic core and smaller viable 
rim than normal MCTS. 
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Table 2. ANOCOVA Results.  A summary of the ANOCOVA results detailing the sum of 
squares (SS), degrees of freedom (df), mean square (MS), F value and P value. The F crit 
value (the inverse of the F probability) was calculated to 4.20. 
Necrotic Core      
Source SS df MS F P 
Adjusted means 44184 1 44184 18.84 <.001 
Adjusted error 68007 29 2345 - - 
Adjusted total 112191 30 - - - 
Viable Rim      
Source SS df MS F P 
Adjusted means 33597 1 33597 60.25 <.0001 
Adjusted error 16170 29 558 - - 
Adjusted total 49767 30 - - - 
 
Table 3. Detailing the adjusted means of the dependant variable (Necrotic Core and 
Viable Rim diameter (µm)) for the two groups of data analysed in the ANOCOVA. 
Necrotic Core    
 
Normal MCTS 
Autophagy 
Inhibited MCTS 
Total 
N 20 12 32 
Observed Means 670 649 662 
Adjusted Means 631 714 662 
Viable Rim    
 
Normal MCTS 
Autophagy 
Inhibited MCTS 
Total 
N 20 12 32 
Observed Means 190 114 161 
Adjusted Means 188 117 161 
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3.15 Cell death and senescence in autophagy inhibited MCTS 
Comparison of the expression of cell death and senescence markers in HT-29 spheroids 
treated with autophagy inhibitor Bafilomycin A1 showed that in the treated MCTS, 
cleaved caspase-3 positive cells are seen throughout the viable rim as opposed to solely 
in the necrotic core in untreated spheroids (Figure 18, Panel A and B). This appearance 
of a number of dead cells at shallower depths supports the morphological appearance of 
the MCTS and cells. p-H2AX expression is also altered by the inhibition of autophagy. 
There is, similar to the cleaved caspase-3 staining, presence of p-H2AX at shallower 
depths within the viable rim including cells in the outmost surface layer (Panel D). 
These positive cells located at the surface of the spheroid contrast with the p-H2AX 
positive cells in the untreated spheroids where expression is confined to the necrotic 
core and the first few cell layers surrounding this (Panel C). Therefore inhibition of 
autophagy appears to have a major impact on the fate and survival of cells grown as 
MCTS. These results demonstrate that autophagy is a crucial mechanism used by cells 
to survive poor nutrient and oxygen conditions in MCTS. 
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Figure 18. Immunohistochemical analysis of the differential expression of cleaved caspase-
3 (CC3) and p-H2AX in untreated HT-29 MCTS and MCTS treated with autophagy 
inhibitor Bafilomycin A1 (10nM). Panel A shows CC3 expression in a untreated MCTS and 
panel B shows CC3 expression in Bafilomycin A1 treated MCTS. Panel C shows p-H2AX 
expression in a untreated MCTS and panel D shows expression of p-H2AX in a Bafilomycin A1 
treated MCTS.  
3.16 Separation of cell populations within the MCTS using Flow Cytometry 
HT-29 MCTS were stained with Hoechst 33342 (1µM) for 30 minutes to generate a 
gradient of fluorescence. Following trypsinisation, cells were separated based on 
fluorescence intensity and cell size as described below. Control unstained cells (Figure 
19) were analysed first to determine levels of auto fluorescence associated with the 
cells. When the unstained HT-29 spheroids were disaggregated into a single cell 
population and sorted using FACS, two distinct populations were seen (Figure 19). One 
consisted of larger, less granular cells from the viable rim of the spheroid that were 
identified with a low SSC (side scatter indicating cell granularity) and high FSC 
50µm 50µm
A B 
C D 
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(forward scatter indicating cell size). The other population made up the necrotic core 
fraction and included smaller more granular cells, with high SSC and low FSC. Both 
viable rim and necrotic core populations showed low levels of fluorescence.  
          
 
Figure 19. Control unstained MCTS FACS. Graphs representing a control unstained 
population of cells derived from HT-29 MCTSs showing their FSC, SSC and fluorescent 
signal. Panel A illustrates that MCTSs are made up of two major populations; small granular 
necrotic core cells characterised by their low FSC and high SSC (the population of cells in red) 
and large less granular viable rim cells characterised by their high FSC and low SSC (coloured 
blue). Panels B and C represent the low fluorescent signal observed with unstained cells. 
The validity of these two groups as separate populations was supported by using the 
same separation parameters on a population of HT-29 MCTS which had first been 
stained with Hoechst 33342. Once staining was complete the MCTS were disaggregated 
A B 
C 
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into a single cell population. The staining was carried out so that then cells residing in 
the outermost layers of the MCTS would be most strongly stained and the innermost 
cells would be least strongly stained. Once the single cell population was separated by 
SSC and FSC into the necrotic core and viable rim populations the relative fluorescent 
intensities from each population could be measured. The smaller more granular necrotic 
core population had a uniformly low fluorescent signal (see Figure 20), similar to that of 
unstained spheroid cells (see Figure 19). This indicated that the cells were derived from 
deep inside the spheroid furthest away from the source of fluorescent dye. Their 
fluorescent signal was expected to be low as the Hoechst would have to diffuse though 
many layers of cells to reach them. The larger less granular population had a range of 
fluorescent intensities with the highest being more than 2 orders of magnitude greater 
than that of unstained cells. This is consistent with this being the viable rim population 
with the most intensely stained cells being located in the outer most regions of the 
viable rim and the lesser fluorescent cells from the inner viable rim where the hypoxic 
cells reside.  
Using the fluorescent signal of the two populations, it was possible to further spit the 
two groups (NC and VR) into more fractions (Figure 20). The most intensely 
fluorescing cells in the viable rim population were derived from the outer most layer of 
the spheroid, hence being the most strongly stained by the Hoechst 33342. As the 
fluorescent intensity decreased this corresponded to cells derived from deeper within the 
spheroid.  
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Figure 20. Hoechst 33342 stained MCTS and cell sorting. Whole intact MCTSs were stained 
and then disaggregated into a single cell population before analysis by flow cytometry. Cells 
were sorted via size, granularity and intensity of fluorescence. The blue population consists of 
cells from the viable rim, and as such contains the most intensely fluorescent cells. The red plot 
shows the cells derived from the necrotic core which in turn are the least fluorescence as it takes 
longer for the Hoechst to penetrate to the very centre of the spheroid. 
3.17 Characterising the growth of cell populations isolated from different 
regions of MCTS.  
The different fractions were transferred into standard cell culture conditions to 
determine whether they could re-establish growth when environmental conditions 
became favourable again and if so, could clones be generated so that the biological 
properties of cells derived from the necrotic core could be compared to the parental cell 
A B 
C 
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line. Their plating efficiencies were measured, showing that the deeper into the spheroid 
from which the cells were derived, the lower their plating efficiency ( 
Table 4). Contrary to the perceived view that cells within the necrotic core of MCTS are 
dead, a significant number retain the ability to re-grow when returned to normal cell 
culture conditions. A plating efficiency of 5.00+/- 0.52% indicates that a substantial 
number of cells retain viability such that when conditions revert back to 'ideal' growth 
conditions, they are able to proliferate and form colonies of cells again. While the 
plating efficiency of cells isolated from the necrotic core is significantly lower than that 
of the cells taken from the viable rim the surface of the spheroids, it nevertheless 
confirms that viable cells exist within the necrotic core and these have the ability to re-
grow when conditions becomes favourable. 
Table 4. Showing the plating efficiency of the different fractions of the HT29 cells 
separated from a MCTS by Flow cytometry. While it is not possible from this experiment to 
determine the exact depths inside the MCTS from which each fraction is derived the fractions 
order of depths is known. R5 being derived from the surface with the most highly fluorescent 
population (see Figure 20) and each following fraction being derived deeper until R10 which is 
the innermost population of cells (R5>R6>R7>R8>R12>R13>R10). 
Increasing distance from 
spheroid rim Fraction Number 
Plating Efficiency 
(% +/- SD) 
Surface Layer R5 43.33 +/- 2.07 
 R6 41.67 +/- 1.67 
 R7 40.00 +/- 2.19 
 R8 38.33 +/- 1.33 
 R12 15.00 +/- 1.05 
 R13 6.67 +/- 0.52 
Inner Necrotic Core R10 5.00 +/- 0.54 
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3.18 Cloning of cells from HT-29 monolayers and the necrotic core of MCTS.  
Cells were cloned from the necrotic core of HT-29 MCTS to enable the characterisation 
of the cells' growth, migration, 'stemness' and chemosensitivity.   
Necrotic clones were formed from the cells collected from the necrotic core of HT29 
spheroids separated via FACS. Once separated, cells were plated out in serial dilutions 
such that only one colony per well was obtained. Colonies formed were holoclone 
(round colonies composed of small compact cells that can be repeatedly passaged) in 
morphology, which is indicative of high replicative potential and a reduced chance of 
undergoing growth arrest and stem cell-like phenotype. These single colonies derived 
from one cell were then used to establish the necrotic core clones. Once placed into a 
cell culture flask these cells started growing in a similar manner to normal HT-29 cells. 
However, one noticeable difference was that the cells tended to grow partly as a 
monolayer and partly in suspension. Furthermore, these cells now had the ability to 
spontaneous form and maintain MCTS under normal culture conditions (i.e. with no 
liquid overlay). These characteristics remained for between 3 and 4 passages before the 
cells returned to their original way of monolayer growth.  
3.19 Monolayer growth characteristics of clones derived from the necrotic core 
of MCTS compared to parental HT-29 cell lines.   
Table 5. Doubling times calculated for the log phase 
of growth for the necrotic core clones and the 
parental cell line, standard deviations are shown and 
significant statistical differences calculated using a 
Student's T test (<0.05) are indicated with an 
asterisk. 
Compared to the parental HT-29 cells there are 
other noticeable differences in the clones, the 
Cell Line Cell Doubling Time 
(Hours) 
HT-29 25.65 +/- 1.91 
NCC1 30.89 +/- 0.36* 
NCC2 30.38 +/- 2.02 
NCC3 26.99 +/- 0.48 
NCC4 29.99 +/- 0.81* 
NCC5 28.43 +/- 1.60 
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necrotic core clones are slower growing monolayers (Figure 21). There is a clear lag 
phase in the growth of all the clones and the parental cell line with the exception of 
NCC4 although the subsequent growth rate of this clone was still less than the parental 
cell line.  
 
Figure 21. Necrotic Core Clone Growth Curves showing the growth of all 5 clones and the 
parental cell line as monolayer cultures. All growth measurements were made on cell 
between passage 4 and 7. Error bars are omitted in the interests of clarity. P values denote 
clones whose growth was statistically significant from the parental cell line as determined by ba 
student's t test.  
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When the doubling time was calculated for the log phase for each of the cell lines it was 
clear that all five of the clones were slower growing than the parental cell line, as all 
doubling rates for the clones were reduced (Figure 21). NCC1 and NCC4 were both 
found to have significantly lower doubling rates than the parental cell line when a 
Student's T test was performed. 
3.20 Growth curves for spheroids derived from a necrotic core clone and the 
parental HT-29 cell line. 
When the growth of NCC1 in spheroidal culture was compared to the parental cell line a 
similar trend as seen with the monolayer growth was found. NCC1 was slower growing 
than the parental cell line, with a statistically significant (p<0.001) doubling time of 
80.98 hours compared to the parental 74.96 hours (see Figure 22). 
 
Figure 22. Growth of Necrotic Core Clone 1 as a spheroidal culture compared to 
the parental cell line. Measurements were taken from 20 spheroids every 2-3 days. 
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4 Discussion  
The aims of this chapter were to establish whether there were any viable cells present in 
the necrotic core of MCTS and to characterise any such cells in terms of proliferative 
capabilities and other cellular characteristics. The key findings that have emerged from 
this study are that there are in fact viable cells in the necrotic core. These cells are 
importantly able to return to a proliferative status once the conditions become 
favourable.  The purpose of this discussion is to interpret the key results of this chapter 
in the context of highlighting the novel; findings and comparing these results with 
previously published studies in the literature. In particular this discussion will focus on 
the characterisation of different cell populations within the MCTS, specifically their 
proliferation status and formation of necrotic areas, and the potential survival 
mechanisms used by the cells within the necrotic core of MCTS, including autophagy 
and senescence. 
4.1 Culture methods for Multicellular tumour spheroid formation  
Both HT-29 and DLD-1 cells lines were chosen due to their ability to form spheroids. 
While there are many ways to grow spheroids the preferred method to produce large 
numbers is to ‘seed’ spheroids using liquid overlay techniques and then transfer small 
spheroids to spinner culture vessels for continued growth.
4
 The use of liquid overlay 
techniques to initially seed spheroids is however problematical in that spheroids of 
different sizes are formed due to clumping or coalescence of spheroids and it is 
therefore necessary to employ a spheroid sizing strategy (differential sedimentation or 
filtration) before transfer of spheroids to spinner flasks. In this study HT-29 cells 
spontaneously formed spheroids after being seeded straight into the spinner flask. As 
this eliminated the need to use liquid overlay followed by sizing of seeded spheroids, 
this represents a significant improvement to the method making it quicker and easier to 
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grow spheroids of a uniform size. DLD-1 cells however required the liquid overlay step 
before transfer to spinner flasks for the successful initiation of MCTS. 
HCT116 cells were also found to form spheroids though using a different method 
involving seeding individual spheroids into 96 well plates base coated with 1% agarose. 
Spheroids were created by placing large numbers of cells in wells and allowing them to 
coalesce to form a spheroid. Using this method, HCT116 spheroids typically formed 
quicker than HT-29 and DLD-1 spheroids as they were not derived from single cells. 
This meant that in the HCT 116 spheroids the necrotic core forms much quicker as the 
spheroid does not have to grow from a single ~20 µm cell into a >500µm spheroid. 
With regards to the growth characteristics of MCTS, different cell lines grow in a 
slightly different manner. In the case of HT-29 and DLD-1 cells, it generally takes 
between 24-72 hours for spheroids to first form. Necrotic cores become visible to the 
naked eye between 10-14 days for DLD-1 spheroids and between 7-10 days for HT-29 
spheroids. The spheroids developed necrotic cores when they reached a diameter of 
roughly 500µm (Figure 3) and this is consistent with the diffusion distance for oxygen 
and nutrients widely reported in the literature.
5, 6, 7
. 
4.2 Characterising MCTS: Proliferation and Necrosis  
The results of this study demonstrated that different cell lines can form spheroids of 
different maximum sizes. Typically, DLD-1 spheroids did not grow above 1000 μm 
before disintegrating whereas HT-29 spheroids grew to over 1500 μm in some cases 
(Figure 2). A common feature of all spheroid growth was the relationship between the 
diameter of the viable rim compared to the necrotic core. As illustrated in Figure 5, the 
ratio of the diameters of the viable rim to necrotic core (NC/VR) increases as the 
diameter of the spheroid increases. Associated with this increase in NC/VR, the 
thickness of the viable rim also decreases as spheroid size increases (Figure 6) and in 
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some regions of the spheroid, considerable thinning occurs leading to pore formation 
(see Figure 8). There was no evidence when the histological analysis was undertaken 
that this phenomenon occurred due to mechanical tearing or any form of physical 
trauma. Pore formation was particularly noticeable in HT-29 spheroids and when large 
spheroids were transferred from spinner flasks to liquid overlay cultures, extrusion of 
the necrotic core through the pores in the viable rim was clearly visible (Figure 8). The 
relationship between the thickness of the viable rim and size of necrotic core and how 
this varies with spheroid size has been extensively studied previously.
8, 9, 10
 The results 
of this study are in general agreement with those reported in the literature. What has not 
been previously reported is the formation of pores in the viable rim and extrusion of the 
necrotic core. One reason why this has not been reported previously is that extrusion of 
the necrotic core is generally only seen in large spheroids (> 1000 μm in diameter). 
Spheroids of this size would be considered too large for experimental work (500 to 800 
μm spheroids are typically used) and would be discarded. It is also possible that some 
cell lines show heterogeneity in their ability to form pores in the viable rim as HT-29 
tended to form pores more readily than DLD-1 spheroids. Whatever the reason, the 
formation of pores and the extrusion of the necrotic core mean that any viable cells that 
remain within the necrotic core now have access to nutrients and oxygen leading to 
reactivation of cell proliferation and growth. The biological and therapeutic significance 
of this observation will be returned to in subsequent chapters of this thesis but for the 
remainder of this chapter, the discussion will focus on further characterisation of the 
multicellular tumour spheroid model.  
When HT-29 MCTS were examined they were found to contain various sub populations 
of cells. By staining for the proliferation marker Ki-67 it is was clear that only the outer 
layers of cells within larger MCTS (>600µm) were actively proliferating (Figure 7) 
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which was consistent with what has been reported in the literature.
11,12,13, 14 
 The other 
cells making up the viable rim were quiescent. From looking at the morphology of the 
cells in the necrotic core it was evident that this area of tissue was largely dead. There 
was a large amount of cell debris and many cells which had become detached from their 
neighbouring cells. 
One of the early significant findings of this study was that the necrotic core of MCTS 
was not made up entirely of dead cells, a finding which had only been reported once 
previously in the literature.
15
 The survival of cells within areas of dead tissue could have 
significant consequences if they ever managed to return to a proliferating state. The first 
evidence for this was initially seen in the negative cleaved caspase-3 staining 
demonstrated by some of the cells found in the necrotic core of HT-29 MCTS (Figure 
9). The histological staining suggested that some cells had managed to avoid cell death, 
or at least caspase-3 dependant cell death.  
4.3 Necrosis in xenografts and human colorectal liver metastases 
Colorectal xenografts from three different cells lines were examined to see whether the 
necrotic areas found in MCTS mirrored the morphology of necrotic tissue in vivo, and 
therefore whether the MCTS were a good model for this area of research. Areas of 
necrotic tissue were seen throughout the xenografts and were surrounded by areas of 
viable tissue similar to that of the MCTS (Figure 10) and in accordance with the 
literature.
16
 However unlike the MCTS, expression of cleaved capase-3 was not as 
extensive in the necrotic areas found in xenografts. HCT 116 xenografts showed 
expression in only a small subset of cells and HT-29 and DLD-1 still showed less than 
in the HT-29 MCTS (Figure 11). Therefore MCTS do reflect xenograft tissue in terms 
of morphology as they both have similar areas of necrotic tissue as seen in Figure 10. 
However the cell death mechanism of the cells grown in MCTSs are different as seen by 
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the differential expression of cleaved caspase-3. When archived clinical tissue was 
examined, it was clear that the structure of MCTS mirrored very closely the structure of 
rosettes found in colorectal liver metastases (Figure 12) and as described in the 
literature.
17
 This further validated the use of MCTS as an in vitro model. 
4.4 Multicellular Tumour Spheroid Cell Sorting 
To support the negative cleaved caspase-3 staining data (Figure 9) and to confirm that 
the negatively stained cells were indeed viable, cells from the different regions within 
MCTS, including the necrotic core were separated and collected using flow cytometry 
(Figure 19 and Figure 20). The Hoechst staining and FACS method used to separate the 
spheroids was found to be a very effective method. Whilst flow cytometry has been 
used previously to demonstrate that spheroids contained two distinct populations of 
cells, the actual process of separating the spheroids was carried out using a serial 
trypsinisation technique.
 18
 The serial trypsinisation technique involves digesting cells 
off the surface of the spheroids a layer at a time. Whilst this technique has definite 
benefits such as being simple to perform it does have some downsides. The technique 
relies on examining the spheroids by eye while trypsinising, and then finally using 
mechanical pressure to disrupt the remaining viable “shell” to release the necrotic core. 
There is a chance that contamination could occur between the different populations if 
for example a spheroid was to accidently burst during the trypsinisation process, 
prematurely releasing the necrotic core cells. Henceforth a more reliable technique was 
required. Flow cytometry is a particularly reliable technique of cell sorting as it 
characterises each cell individually and enables the separation of the cells based on their 
size and granularity. Using cell size and granularity, the population of cells within a 
spheroid can be separated into two groups, cells which make up the viable rim are larger 
and not very granular, necrotic core cells are smaller and more granular.
19
 By staining 
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the spheroids before performing FACS it was possible to add third layer of separation to 
the technique. This made the results more reliable, by examining the fluorescence 
distribution, between the different populations separated by their size and granularity, it 
was possible to further validate FACS as a method of separating spheroids.
20
 
Following the separation of the MCTS, cells their plating efficiency could be measured 
to determine how viable the cells were. The necrotic core cells were found to have a 
certain degree of viability. A plating efficiency of 5% while being significantly lower 
than the other cell populations found in the MCTS is nevertheless highly significant as 
it proves that some cells in the necrotic core are indeed alive.  This is supported by 
similar research using the same cell line which found that there were various enzymes 
which were active within the necrotic core of MCTS.
21
 
Once it was established that there were cells that were managing to survive within the 
necrotic core of MCTS, the next question was how do they manage to survive the poor 
nutrient and low oxygen environment when most other cells cannot and are they 
therefore different to the rest of the cell population?  
4.5 DNA Damage and Senescence 
Whilst it was clear from the Ki-67 staining in Figure 7 that the cells within the necrotic 
core were not proliferating, it was unclear whether the cells were in an active state or 
whether they had become senescent. Expression of the DNA damage marker which has 
also been found to correlate with senescence, p-H2AX, indicated that a number of cells 
at the peripheral edge of the necrotic core on the boundary between the necrotic core 
and the viable rim could be in a senescent state as well as a number of cells throughout 
the necrotic core (Figure 15). Senescence has previously been found to occur in MCTS 
though necrotic core cells have not been the focus of the studies and senescence here 
has not been described before.
22
 Senescence therefore may be a survival mechanism 
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used by the cancer cells to evade cell death. Especially as cancer cells have been shown 
recently to have the ability to re-enter the cell cycle after a period of senescence.
23
 
Furthermore this evidence was mirrored in vivo in colorectal xenografts where similar 
expression was seen in necrotic areas (Figure 16). These results suggest that senescence 
could be used as a mechanism of cell survival in necrotic areas, therefore inhibition of 
the senescent phenotype might sensitise cells to cell death in these regions. Whilst the 
evidence for senescence is not conclusive it is clear that these cells have DNA damage 
which has not been previously described in the different populations within MCTS. 
4.6 Autophagy 
Autophagy was investigated as a mechanism by which the cells could survive the low 
nutrient environment within the necrotic core. Autophagy has been found to be involved 
in various different aspects of tumour cell biology, from drug resistance to 
tumourigenesis, but as an evolutionary conserved catabolic process its main role is to 
recycle old, damaged or unnecessary proteins in order to provide the building blocks to 
sustain further growth and/or survival.
24
 Autophagy has been discovered to have a role 
in cancer stem cell maintenance in various different cancer types including pancreatic, 
liver and colorectal. What was found is that the cancer stem cell resistance to certain 
drugs such as Paclitaxel is reliant on autophagy and when this degradation pathway is 
inhibited the cells are sensitised to the chemotherapeutic.
 25
 It has also been seen that 
cancer stem cells, along with normal cancer cells, use autophagy to help withstand poor 
nutrient and low oxygen conditions. The following sections describe and discuss several 
key aspects related to the role autophagy plays in the necrotic core of MCTS. 
4.6.1 Characterising autophagy inhibitors 
A range of different autophagy inhibitors were trialled on DLD-1 cells grown on glass 
cover slips to determine which was the most appropriate. It was necessary to find an 
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autophagy inhibitor that halted the autophagic pathway in the most appropriate place, in 
order to measure levels of LC3-II conversion and hence autophagic flux without LC3 
degradation altering protein levels. Both Chloroquine and Bafilomycin A1 increased 
LC3-II levels; this was expected as both Bafilomycin A1 and Chloroquine are known to 
inhibit the autophagic pathway downstream of autophagosome formation. In contrast 3-
Methyladenine is a PI3K inhibitor that inhibits the formation of the autophagosome, 
leading to a reduction in the amount of punctate LC3 staining seen (Figure 13).
26
 
Bafilomycin A1, a V-ATPase inhibitor, prevents maturation of autophagic vacuoles.
27
 It 
does this by blocking the fusion of the autophagosome and lysosome hence preventing 
the degradation of LC3. Treatment of cells undergoing autophagy with Bafilomycin A1 
lead to its accumulation of LC3 in the cytoplasm, the difference in punctate LC3 
staining between cells treated with and without the inhibitor indicates the extent of 
autophagic flux. Therefore Bafilomycin A1 was deemed suitable for determining levels 
of autophagic flux within cells, and this is consistent with other methods of autophagy 
detection described in the literatutre.
28
 Chloroquine, a lysosomotropic compound which 
preferentially accumulates in the lysosomes preventing the fusion of the autophagosome 
and the lysosome similar to Bafilomycin A1, also caused an increase in LC3 levels in 
the cytoplasm (Figure 13). Both Bafilomycin and Chloroquine are suitable inhibitors to 
use for measuring autophagy. 
4.6.2 Autophagy in the Necrotic Core 
When the spheroid necrotic core was stained for LC3-II it was found that there was an 
active biological process occurring in what was originally thought of as a completely 
dead environment. This was seen clearly by the increase in LC3-II puncta in the 
necrotic core of the MCTS which were treated with an autophagy inhibitor (Figure 14). 
These results were confirmed by staining for a second autophagy marker Beclin-1 
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whose expression was also seen to be up regulated in the necrotic core. Further 
confirming that there were living cells within, and that autophagy was at least one 
possible method the cells used to survive. Active enzyme activity has previously been 
reported in the necrotic core of MCTS, including enzymes involved in autophagy.
29
 The 
staining data described in Figure 14 confirms the results reported in the literature.  As 
autophagy does not occur in normal cells under normal physiological conditions this 
could lead to a relatively selective way to target the cancer cells. Though as yet it is 
uncertain whether autophagy should be inhibited or induced, owing to its contradicting 
roles in cancer.
30
 
4.6.3 Effect of autophagy inhibition on cell viability and DNA damage in MCTS 
The effect of autophagy inhibition on HT-29 MCTS was measured to determine 
whether, as the LC3 staining data suggested, the cells were indeed reliant upon the 
process for survival within the spheroid. What was seen in the MCTS following 
autophagy inhibition did lend further weight to this hypothesis. In HT-29 MCTS where 
autophagy was inhibited the necrotic core was larger and took up a larger proportion of 
the whole spheroid area compared to a normal autophagy capable cell of a similar size 
(Figure 17). This suggests that without the help of autophagy as a survival mechanism 
cells within the MCTS are more sensitive to nutrient derivation. Cells closer to the 
surface were now staining positive for cleaved caspase-3 as the inhibition of autophagy 
reduced the depth threshold for cell death, in fact expression was noted throughout the 
viable rim, which had never been seen before in these particular MCTS (Figure 18). 
These results closely follow other reports of autophagy inhibition in spheroids published 
in the literature. However whilst autophagy inhibition has previously been shown to 
induce cell death in MCTS, the localisation of the cells affected in the MCTS and the 
effects upon viable rim and necrotic core size have not been investigated. Instead the 
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MCTS have been considered as one homologous population of 3D cells rather than 
separate populations.
31
 The results highlight that in this specific situation autophagy has 
cancer promoting effects. Furthermore its inhibition can be used to induce cell death 
under conditions of nutrient deficiency specifically in the inner nutrient deprived 
hypoxic population of cells found surrounding the necrotic core in MCTS. Hypoxia is 
an established biological target in cancer therapy. Hypoxic cancer cells are known to be 
more resistant to radio and chemotherapy.
32
 As such anti-cancer drugs have been 
developed to specifically target hypoxic cells by taking advantage of the specific 
molecular characteristics displayed by these cells. These include bioreductive prodrugs 
which are reduced to their active form through enzymatic reduction, in normoxic cells 
the active drug is then re-oxidised and deactivated, ensuring steady state levels of active 
drug remain low. In hypoxic cells however the active drug is not re oxidised due to the 
low oxygen availability allowing levels of active drug to reach critically lethal levels. 
Whilst these drugs are relatively selective to hypoxic cells they are subject to certain 
problems relating to drug penetration and speed of bioactivation.
33
 Reports in the 
literature using MCTS and multicell layers as an in vitro model found that in some cases 
the speed of the bioreduction of the prodrug to its active form exceeded the rate of drug 
delivery leading to reduced efficacy in larger areas of hypoxia.
34, 35
 Therefore there is a 
need for improved targeting of the hypoxic tumour microenvironment using different 
mechanisms such as that seen with autophagic inhibition. Despite 40 years of research 
since Sartarelli devised the term 'bioreductive activation', no hypoxia selective 
bioreductive drug has been approved for use in humans. Other approaches to target 
hypoxia aim to exploit cellular responses to hypoxia (e.eg. HIF1 and HIF1 activated 
pathways) but no clinically approved therapy has been developed so far. The 
observation here that Bafilomycin A1 kills the hypoxic fraction of cells in MCTS opens 
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up the possibilty of using autophagy inhibitors as hypoxia selective agents, something 
which has been reported previously in the literature.  
As a result of autophagy inhibition DNA damage was also seen to be induced at 
shallower depths inside the MCTS, as shown by the p-H2AX staining (Figure 18). As 
cells closer to the surface are unable to withstand the nutrient and oxygen deprivation 
when autophagy is inhibited, this leads not only to DNA damage and possibly 
senescence but also eventually apoptosis. Targeting autophagy could be a viable option 
for eliminating cancer stem cells that either are located in nutrient poor environments, or 
that use autophagy to mediate a drug resistance mechanism. Inhibition of autophagy has 
also been shown to inhibit stem cells' self-renewal capabilities; therefore by using an 
autophagy inhibitor alongside a cytotoxic drug, the differentiated cells will be 
eliminated leaving stem cells which are no longer capable of re-growing or 
metastasising.
36
 Inhibiting autophagy is also likely to have fewer side effects than other 
classic cytotoxic drugs. Drugs which inhibit autophagy include Chloroquine which is 
already prescribed to treat malaria.
37
 Also from the results it was clear that the 
autophagy inhibitor used (Bafilomycin A1) was clearly capable of penetrating multiple 
cells layers as its effects were seen to be present in cells in the inner viable rim up to 
150µm deep. One of the most important benefits of autophagy as a target for cancer 
therapy is that it would enable relatively specific targeting of cells which are 
traditionally difficult to treat due to their non-proliferative hypoxic status.
38
 
4.7 Necrotic Core Clones 
In order to understand how the cells survived within the necrotic core and to try and 
determine their biological and therapeutic significance, cells isolated from the core were 
cloned. The establishment of clones from within the necrotic core is a significant step 
towards elucidating the mechanism by which cells survive the poor conditions. The fact 
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that cells from within the core were viable enough to be cloned was an unexpected but 
significant result (Table 4). This has not been previously reported in the literature, 
instead the necrotic core has received little interest due to the assumption that it consists 
entirely of dead cells.
39
 
One of the questions to be answered was concerned with how the cells managed to 
survive, and how they were different to the rest of the population. It was important to 
understand whether they were permanently or transiently different, if this make them 
more resistant to chemotherapeutics, and once out of the necrotic core whether they 
begin to behave in a similar manner to the parental cell line? 
The reasoning behind this line of enquiry is to find out whether these cells within the 
necrotic core pose a problem when treating cancer. If an anti-proliferative drug kills the 
viable rim of the tumour leaving only the ‘dead’ cells in the necrotic core, could these 
cells, hidden amongst the dead, help re-grow the tumour and contribute to resistance? 
Also would they become permanently changed by their environment? They obviously 
have to adapt to survive in low oxygen and nutrient conditions but whether this leads to 
a permanent change is unknown. If they are changed by their time in the necrotic core, 
does this lead to a more aggressive phenotype, which in a clinical setting would mean a 
more aggressive secondary cancer? Or conversely would the only cells capable of 
surviving in the necrotic core be the more hardy and aggressive cancer cells, and 
therefore is the necrotic core an environment that selects for more aggressive cells. 
Many of these questions will be addressed in subsequent chapters but from the results 
presented here, there are some noticeable changes occurring in the necrotic core clones 
once they were returned to growing as monolayers. When the clones were first formed, 
their colony formation was holoclone in structure. Holoclone colonies are indicative of 
stem-like cells and their formation has been taken as a surrogate stem cell assay.
40, 41
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Once the clones were out of the necrotic core and had formed colonies, the cells 
continued to grow at a slower rate to normal HT-29 cells (Figure 21). In addition they 
were also slower when grown as MCTS (Figure 22). A slower rate of proliferation is 
advantageous for the survival of cancer cells when treated with many standard 
chemotherapeutic drugs which target actively proliferating drugs. The way in which the 
cells grew in culture was initially different to the parental cell line. At first the clones 
grew in part as a monolayer and in part as a suspension culture and only after several 
passages did they returned to a normal adherent cell line.
 
However it is important to find out whether the permanent changes observed in the 
necrotic core clones affect their response to chemotherapeutics. The fact that there are 
permanent changes in the Necrotic Core Clones compared to the parent HT-29 cells 
does suggest that these changes seen in cells residing in necrotic areas could have 
therapeutic and prognostic consequences. A slower growth/metabolic rate could 
possibly be one of the reasons for the necrotic core cells ability to survive within a 
hypoxic environment with limited nutrient availability, by slowing down cellular 
metabolism the cells are able to reduce their energy demands and this seems to be a 
characteristic that remains with the cells after conditions become favourable again. 
Slower rate of growth is also a characteristic of stem cells. 
In conclusion, this collection of results has established that there are viable cells located 
within the necrotic core of HT-29 MCTS. These cells have the ability to re-grow when 
conditions become favourable. The next question is what are the therapeutic and 
biological consequences of these cells? In addition the results have demonstrated that 
inhibition of autophagy may be a selective way to target the nutrient deficient hypoxic 
cells which inhibit the hypoxic tumour microenvironment in and around areas of tumour 
necrosis. This avenue of research has not been pursued further in this thesis but it will 
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be developed further by others within the Institute of Cancer Therapeutics at the 
University of Bradford.  
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Chapter 2: Biological Implications of viable cells within the necrotic core of 
MCTS 
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1 Introduction 
Following the identification that there are viable cells in the necrotic core of MCTS, 
different survival mechanisms used by the cells were investigated to understand why 
some cells managed to survive. EMT confers a certain survival advantage to cells as it 
makes them resistant to anoikis and therefore could be responsible for the survival of 
cells within the liquid like centre of the necrotic core. Expression of markers associated 
with EMT have, like necrosis, been found to be an indicator of poor prognosis in a 
variety of different cancer types.
1, 2, 3
 Therefore by establishing whether the viable cells 
in the necrotic core have undergone EMT this may help further understand the link 
between necrosis and poor prognosis. Stem cells are also known to survive anchorage 
independent conditions and have increased survival capabilities in response to stress.
4, 5
 
Furthermore stem cells have been implicated in tumour progression, recurrence and 
metastasis.
6
 Senescence is another cellular response to stress, while originally believed 
to be irreversible cancer cells have been shown to be capable of reversing the process 
and returning to a proliferative state.
7, 8 
Senescent cells by the nature of their non-
proliferative status are resistant to many conventional chemotherapeutics, however as 
senescence was not believed to be reversible the senescent cells themselves seemingly 
had no relevance when trying to understand tumour progression. In cancer the cells 
could be using senescence as a survival strategy therefore making it a possible target. 
Tumours are known to contain heterogeneous populations of cells which include cells 
with a variety of different characteristics. It is important to understand whether the 
necrotic core selects for cells which are more aggressive and resistant and if so to find 
ways to eliminate the cells. The specific aims of this chapter are to characterise the 
necrotic core  of HT-29 MCTS and the necrotic core clones in terms of their migration, 
proliferation, senescence, EMT status, stem cell characteristics and in vivo growth.   
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2 Materials and Methods 
Following the growth of MCTS as described in Chapter 1 the different populations 
could then be examined in situ using different cell staining and immunohistochemical 
techniques. Once physically separated the different populations can be analysed by 
western blotting, and the necrotic core clones can be examined using different 
functional assays.  
2.1 Haematoxylin and Eosin Staining of MCTS 
Sections were de-paraffinised with xylene (3x5 minutes) and rehydrated using ethanol 
(3x2 minutes) before being washed in running tap water for 5 minutes. Sections were 
then stained with Mayer’s haematoxylin (Sigma Aldrich, St. Louis, MO, USA) for 10 
minutes. Excess stain was removed from the section by soaking in acid alcohol for 60 
seconds before rinsing in running tap water for 5mins and then immersing in Scott’s 
Tap Water for 60 seconds to allow the colour to develop. Sections were counterstained 
in Eosin (Sigma Aldrich, St. Louis, MO, USA) for 60 seconds before a final wash in 
running tap water. Finally the sections were dehydrated using sequential ethanol 
(1x2minutes, 2x1minute) and xylene (3x1minute) series and mounted using 
diphenylxylene (BDH, Pool, UK).   
2.2 Immunohistochemistry 
Sections were de-paraffinised with xylene (3x5 minutes) and rehydrated using ethanol 
(3x2 minutes) before being washed in running tap water for 5 minutes. If necessary, 
antigen retrieval was then carried out by heating slides in antigen retrieval solution 
(Table 1) in a microwave for a specific length of time before cooling. Slides were rinsed 
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in tris-buffered saline (TBS) before endogenous peroxidise activity was blocked for 10 
minutes at room temperature. Following this, further blocking steps were carried out 
depending on the primary antibody used (Table 1). Non-specific binding was blocked 
by incubating the sections with Antibody Diluent containing Bovine Serum Albumin 
(Invitrogen, Camarillo, CA, USA) immediately prior to the application of the primary 
antibody. The sections were incubated with 100µl of the primary antibody diluted in 
Antibody Diluent in a humidified chamber. After incubation slides were washed in TBS 
containing 10% (v/v) Tween-20 (TBST) (2x5 minutes) and TBS (1x5 minutes) before 
the application of 2 drops of labelled polymer-HRP secondary antibody, and then 
incubated in a humidified chamber at room temperature for 1 hour. Following this, 
slides were again washed in TBST (2x5 minutes) and TBS (1x5 minutes). Sections were 
then incubated with 3,3-diaminobenzidine (DAB, DAKO North America Inc, CA, 
USA) for 10 minutes at room temperature, where the horseradish peroxidise breaks 
down the DAB via an oxidation reaction to produce a brown precipitate at the location 
of the antigen. Sections were washed in running tap water for 5 minutes before being 
counterstained using Mayer’s haematoxylin (Sigma Aldrich, St. Louis, MO, USA) for 
30 seconds, rinsed in tap water for 60 seconds, Scott’s tap water for a further 60 seconds 
and finally tap water again for 60 seconds. Sections were then dehydrated using 
sequential ethanol (1x2mins, 2x1min) and xylene (3x1min) series and finally mounted 
using diphenylxylene (BDH, Dorset). A list of all antibodies used and specific 
conditions of IHC are presented in table 1. 
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Table 1. Listing all antibodies used for immunohistochemistry and the specific conditions 
used for antibody incubation, antigen retrieval and blocking. 
Primary Antibody Dilution  Incubation Antigen 
Retrieval 
Blocking 
Reagents 
Secondary 
Antibody 
Anti-Cleaved 
Caspase-3 antibody 
(Asp175, rabbit 
monoclonal anti-
human Cleaved 
Caspase-3 IgG; New  
England BioLabs, 
MA, USA) 
1:800 4
o
C 
Overnight 
10 min 
Citrate 
Buffer 
(10mM, 
pH 6.0) 20 
min 
cooling 
5min Envision 
H2O2, 
2 hours 4% (v/v 
in TBS) Normal 
Goat Serum 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-H2AX 
antibody (20E3, 
rabbit monoclonal 
anti Phospho-Histone 
H2A.X IgG; Cell 
Signalling, MA, 
USA) 
1:400 1 hour RT 10 min 
Citrate 
Buffer 
(10mM, 
pH 6.0) 20 
min 
cooling 
3% H2O2 block,  
10min Zymed 
Antibody 
Diluent  
Labelled 
polymer-HRP 
anti-rabbit 
(K4006, 
EnVision Kit, 
DAKO) 
Anti-Snail (2G11, 
mouse monoclonal 
anti human snail 
homolog 1 IgG; 
Novus Biologicals, 
CO, USA; 0.1mg) 
1:100 1 hour RT None 3% H2O2 block,  
10min Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-mouse 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-Twist1 
antibody(rabbit 
polyclonal anti 
human Twist related 
protein 1; Merck 
Millipore, MA, 
USA; 1 mg/ml) 
1:500 1 hour RT None 3% H2O2 block,  
10min Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
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Table 1 Continued 
Primary Antibody Dilution  Incubation Antigen 
Retrieval 
Blocking 
Reagents 
Secondary 
Antibody 
Anti- CD24 antibody 
(rabbit polyclonal 
anti human CD24 
IgG; Abcam, 
Cambridge, UK; 
1mg/ml) 
1:200 1 hour RT 10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
0.3% H2O2 
block, 
10min 
Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-CD44 antibody 
(EPR1013Y, rabbit 
monoclonal anti 
human CD44 IgG; 
Abcam, Cambridge, 
UK; 1mg/ml) 
1:100 1 hour RT 20 min 
EDTA 
Buffer (1M, 
pH 8.0) 20 
min cooling 
0.3% H2O2 
block, 
10min 
Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rat (K4010, 
EnVision Kit, 
DAKO) 
Anti-CD133 
antibody (rabbit 
polyclonal anti 
human CD133 IgG; 
Biorbyt, CA, USA; 
1mg/ml) 
1:800 1 hour RT 10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
0.3% H2O2 
block, 
10min 
Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-E-Cadherin 
(EP700Y, rabbit 
monoclonal anti 
human E-Cadherin 
IgG, Merck 
Millipore, MA, USA) 
1:400 1 hour RT 10 min 
Citrate 
Buffer 
(10mM, pH 
6.0) 20 min 
cooling 
0.3% H2O2 
block, 
10min 
Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
Anti-N-Cadherin 
(EPR1792Y, rabbit 
monoclonal anti 
human N-Cadherin 
IgG; Merck 
Millipore, MA, USA) 
1:100 1 hour RT 20 min 
EDTA 
Buffer (1M, 
pH 8.0) 20 
min cooling 
0.3% H2O2 
block, 
10min 
Zymed 
Antibody 
Diluent 
Labelled 
polymer-HRP 
anti-rabbit 
(K4010, 
EnVision Kit, 
DAKO) 
174 
 
2.3 Western Blotting 
The NCCs and cells from HCT 116, DLD-1 and HT-29 MCTS were investigated for 
expression of 3 proteins listed in Table 2. NCC cells were collected by mechanical 
scrapping, washing with PBS then centrifuged at 1000g for 5 minutes to form a pellet. 
MCTS cells were collected using Trypsin to digest the surface layer cells, and a pestle 
to mechanically break open the MCTS to release the necrotic core cells. Cells were then 
washed in PBS and pelleted using centrifugal force as before. 
Table 2. Primary and secondary antibodies and their corresponding experimental 
conditions used in Western Blotting. 
Primary Antibody Antibody dilution and 
experimental 
conditions 
Secondary Antibody 
Anti-E-Cadherin (EP700Y, 
rabbit monoclonal anti human 
E-Cadherin IgG, Merck 
Millipore, MA, USA) 
1 : 30,000; overnight 
at 4
o
C 
HRP-conjugated goat anti-rabbit 
secondary antibody (P0448, 
DAKO, Agilent Technologies, 
CA, USA) 
Anti-N-Cadherin (EPR1792Y, 
rabbit monoclonal anti human 
N-Cadherin IgG; Merck 
Millipore, MA, USA) 
1 : 30,000; overnight 
at 4
o
C 
HRP-conjugated goat anti-rabbit 
secondary antibody (P0448, 
DAKO, Agilent Technologies, 
CA, USA)  
Anti-Snail (2G11, mouse 
monoclonal anti human snail 
homolog 1 IgG; Novus 
Biologicals, CO, USA; 0.1mg) 
1 : 500; overnight at 
4
o
C 
HRP-conjugated goat anti-mouse 
secondary antibody (P0447, 
DAKO, Agilent Technologies, 
CA, USA) 
Anti-β-Actin (rabbit polyclonal 
anti human beta Actin IgG, 
Abcam, Cambridge, UK; 
1mg/ml) 
1 : 15,000; one hour at 
20
o
C 
HRP-conjugated goat anti-rabbit 
secondary antibody (P0448, 
DAKO, Agilent Technologies, 
CA, USA)  
2.3.1 Cell Lysis 
Cell pellets were lysed in protein extraction buffer (7M urea, 4% CHAPS, 0.1% SDS, 
0.05% Sodium Deoxycholate and 1X PIC (Protease inhibitor complex, Roche, 
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Indianapolis, USA) with EDTA) by incubating the cell pellet on ice for 25 minutes in 
approximately 3x the pellet volume of lysis buffer. The pellet was then sonicated twice 
at 50% power for 10 seconds using a SH70A sonicator (Scientific Laboratory 
Supplies,Nottingham, U.K.). with a 2 minute incubation interval on ice. Following this 
the sample was centrifuged at 12,000g for 10 minutes at 4
o
C and the supernatant 
collected. After this the protein concentration was determined using the Bradford assay.  
2.3.2 Bradford Assay 
The Bradford assay (Bradford, 1976) was used to measure the total protein 
concentration in each sample, relying on the linear relationship between the amount of 
Coomassie dye bound to the proteins present in the sample and the absorption.  Before 
the amount of protein in a sample can be calculated a standard curve must first be 
created as follows .Bovine Serum Albumin was dissolved in HPLC (1mg/ml) and this 
stock was then serially diluted 4 times to give 6 decreasing concentrations of BSA 
(including 1 blank). 50µl of BSA sample was then added to the sample tube and 1.5ml 
of Bradford reagent was added and left to incubate at room temperature for 15min. All 
the BSA samples were then analysed on a spectrophotometer using SkanIt software 
(ThermoFisherScientific) to measure the absorbance of the solution at 595nm. The 
concentration of BSA was plotted against the absorbance of the solutions producing a 
calibration curve. 
Once the calibration curve has been created the same procedure is carried out on the 
lysed cell samples. 5µl of sample is added to 45µl HPLC water before 1.5ml of 
Bradford reagent is added and incubated at room temperature for 15 minutes. The 
absorbance of each sample and BSA dilution was measured using a spectrophotometer 
at 595nm and the protein concentration of the samples was then calculated using the 
standard curve. Samples where absorbance values fall outside the linear range of the 
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calibration curve were diluted to ensure that they were within the linear range and the 
values for protein concentration were corrected for the dilution factor.   
2.3.3 Polyacrylamide Gel Electrophoresis  
SDS Loading buffer [5 X, Bromophenol blue (0.25%), DTT (dithiothreitol; 0.5 M), 
Glycerol (50%), SDS (sodium dodecyl sulfate; 10%), Tris-Cl (0.25 M, pH 6.8)] was 
added to all samples (2:1) and loaded onto each lane (equivalent of 50µg of protein per 
well) of an 10% polyacrylamide gel with 5% stacking gel. Then 5µl of protein ladder 
(PageRuler Plus Prestained Protein Ladder, ThermoScientific, Leicestershire, UK) was 
loaded into the final well. Electrophoresis was carried out using a Mini Trans-Blot 
system (Bio-Rad, Hertfordshire, UK) in a tris-glycine electrophoresis buffer (25mM tris 
base, 250mM glycine, 0.1% w/v SDS, pH 8.3) with a voltage of 60V for the first 20 
minutes as the protein moved through the stacking gel after which, the voltage was 
increased to 100V for a further 45 minutes. 
2.3.4 Electroblotting Transfer 
After separation by gel electrophoresis proteins were transferred onto nitrocellulose 
membrane (Amersham Hybond ECL, GE Healthcare Lifesciences, Buckinghamshire, 
UK). The electrophoretic transfer was performed at 80V for 2½ hours using Transfer 
Buffer (39 mM glycine, 48 mM Tris-HCl, 0.037% SDS, 20% methanol) in the Mini 
Trans-Blot system (Bio-Rad, Hertfordshire, UK).  
2.3.5 Protein Detection 
Membranes were then blocked in 5% (w/v) non fate dried milk in TBS for 2 hours then 
incubated with primary antibodies (see Table 2) overnight at 4
o
C. After washing in 
TBST (3x15min) membranes were incubated with HRP-conjugated  secondary antibody 
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(1 in 500 dilution) for 1 hour at room temperature (Sigma Aldrich, St Louis, MO, USA) 
before detection with chemoluminescent HRP substrate (Western Lightening Plus ECL, 
Perkin Elmer, Massachusetts, USA).  Membranes were placed in a plastic envelope and 
exposed to autoradiography film for between 1 and 10 minutes. Blots were then stripped 
with Restore Western Blot Stripping Buffer (ThermoScientific, Leicestershire, UK) for 
20 minutes, washed in TBS (1x15 minutes) and re-probed with β-Actin primary 
antibody to confirm equal protein loading. All experiments were repeated 3 times and 
blots analysed with GelAnalyzer (GelAnalyzer 2010a, http://www.gelanalyzer.com/). 
Band intensities were normalized with regards to the β-Actin band densities. 
2.4 Wound Healing Assay 
In order to determine the individual motilities of the NCCs and parental HT-29 cell line, 
a wound healing assay was performed. Cells were plated in 6 well plates at 
concentrations of 3x10
6
 cells/well and incubated in 5ml of media for 48 hours to allow 
cells to adhere and form a confluent monolayer. The monolayers were then ‘wounded’ 
using a 100µl tip and washed twice with Hanks Balanced Salt Solution before 
incubating in fresh media. Media was changed every 24 hours. The wounds were 
photographed at 0, 24 and 48 hours post ‘wounding’. The width of the wound was 
determined using Image J analysing software. The rate of migration was determined by 
calculating the rate at which the wound grew smaller over time: 
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 =
(𝑤𝑖𝑑𝑡ℎ 𝑎𝑡 0ℎ𝑟𝑠) − (𝑤𝑖𝑑𝑡ℎ 𝑎𝑡 𝑥 ℎ𝑟𝑠)
𝑡𝑖𝑚𝑒(𝑥)
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2.5 Sphere Formation Assay 
To determine the stem cell functionality of the NCCs, a sphere formation assay was 
conducted. NCC and parental HT-29 cells were seeded at a density of 250 cell/well on 
agar coated 24 well plates in 300µl stem cell medium (DMEM/F12 serum free medium 
supplemented with 20ng/ml EGF, 1x B27, 1x N2, 1% sodium pyruvate).
9
 Cells were 
then allowed to grow in anchorage independence in the above medium for 14 days, at 
which point the number of wells containing spherical organoids was counted. Sphere-
forming efficiency (SFE) was calculated using the following formula: 
𝑆𝐹𝐸 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝ℎ𝑒𝑟𝑒𝑠 × 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑝ℎ𝑒𝑟𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 
   
2.6 In Vivo Analysis of HT-29 and Necrotic Core Clone 4 
To determine if any of the NCCs could form a hetergeneous tumour in vivo similar to 
the parental cell line, a xenografts formation experiment was undertaken. HT-29 and 
Necrotic Core Clone 4 monolayers in the exponential growth phase were harvested 
using trypsin. 3 male nude mice for each cell line were injected subcutaneously with 
100µl of a 1x10
7
 cell/ml solution into each flank. The mice were then monitored for 
tumour growth and measurements made using callipers, tumour volume was determined  
using the following formula: 
𝑡𝑢𝑚𝑜𝑢𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 =
(𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ2)
2
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3 Results 
3.2 E-Cadherin and N-Cadherin staining to determine Epithelial-Mesenchymal 
Transition within the Necrotic Core 
To understand how some cells managed to survive and migrate out of the necrotic core, 
expression of markers of the Epithelial-Mesenchymal Transition (EMT) were 
determined. As the necrotic core of the MCTS exists in a ‘liquid like’ state it was 
hypothesised that in order to avoid anoikis, the cells must have undergone the EMT. To 
determine this, HT-29 MCTS sections were stained for E-Cadherin and N-Cadherin 
protein expression. The expression of E-Cadherin was found throughout the MCTS 
(Figure 1, Panel A and B) although some cells within the necrotic core showed no 
staining (Figure 1, Panel A). N-Cadherin expression was seen only in a subset of cells 
within the necrotic core (Figure 1, Panel C), the rest of the MCTS did not express N-
Cadherin (Figure 1, Panel D). The clusters of cells expressing N-Cadherin looked 
similar in terms of morphology to the cells negative for Cleaved Caspase-3 (Chapter 1, 
Figure 8).  These cells appeared intact and had a small, condensed but not fragmented 
nucleus with a clearly defined cytoplasm.   
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Figure 1. EMT marker staining in the necrotic core of HT-29 MCTS. Panel A shows the 
loss of expression of E-Cadherin in a single cell in the necrotic core. Panel B shows the positive 
expression of E-Cadherin throughout the MCTS. Panel C shows the expression of N-Cadherin 
in a cluster of cells in the necrotic core. Panel D shows the lack of N-Cadherin expression in the 
rest of the MCTS. Panel E shows membranous E-Cadherin staining in the positive control 
MCF-7 xenograft. Panel F shows the positive control used for N-Cadherin staining, mouse 
myocardium tissue. Panel G and H show the primary antibody control for E-Cadherin and N-
Cadherin respectively.  
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3.2 Snail and Twist Expression within MCTS 
Snail and Twist are known transcriptional repressors of E-Cadherin and markers of the 
EMT process and their expression was determined in HT-29 MCTS. As shown in 
Figure 2, Snail was expressed in the viable rim but expression was not consistent across 
the viable rim. The expression of Snail was observed in the cells that resided some 
distance (~100µm) from the surface of the MCTS in the inner viable rim (hypoxic 
fraction). When the necrotic core was examined, expression was seen in a small number 
of cells throughout the core. Both the positive cells in the necrotic core and a proportion 
of those in the viable rim were found to have nuclear expression of Snail, which is 
known to be linked to the EMT. Though a number of cells within the viable rim were 
found to have a cytoplasmic distribution of the protein, tumour populations have been 
found to contain cells with  both patterns of protein localisation.
10
 Nuclear rather than 
cytoplasmic localisation of the protein has been found to be a poor prognostic 
indicator.
11, 12
 These necrotic cells share the same morphology as the Cleaved Caspase-3 
negative and N-Cadherin positive cells in that they looked like intact cells albeit with a 
reduced cytoplasm and denser nuclei. This contrasts sharply with the majority of cells in 
the necrotic core that appeared fragmented. Twist was found to be expressed by the 
majority of the cells present in all areas of the MCTS.  
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Figure 2. Expression of Snail and Twist in HT-29 MCTS. Snail expression in the viable rim 
(Panel A) and necrotic core (Panel B). Panel C and D show expression of Twist in HT-29 
MCTS. E and F show negative primary antibody controls for Snail and Twist respectively. 
3.3 Western Blotting analysis of EMT marker expression 
3.3.1 HT-29 MCTS 
The expression of E-Cadherin, N-Cadherin and Snail was analysed by Western blot in 
the necrotic core and viable rim populations of HT-29 MCTS. As seen in Figure 3, full 
50µm
50µm
50µm 50µm
A B 
C D 
F E 
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length Snail expression was only found in the viable rim, while in the necrotic core no 
expression was detected. This supports the immunohistochemical data which showed 
that Snail was expressed by many of the cells in the inner half of the viable rim, but 
only a select few in the necrotic core. Whilst some positive cells were observed in the 
necrotic core by immunohistochemistry (Figure 2), they may have been undetectable on 
Western blots due to dilution by Snail negative cells or debris. 
Full length N-Cadherin was found to be expressed solely in the necrotic core, no 
detectable expression was seen in the viable rim (Figure 3). This is entirely consistent 
with the immunohistochemical results (Figure 1). Similarly, full length E-Cadherin 
expression showed similar results to the immunohistochemistry in the MCTS sections. 
While expression was seen in both the viable rim and the necrotic core, the expression 
within the necrotic core was somewhat reduced compared to the viable rim.  
A                 B
 
Figure 3 Western Blotting data confirming EMT marker expression within the viable rim 
and necrotic core of HT-29 MCTS. Panel A shows blots of HT-29 MCTS split into two cell 
populations, necrotic core and viable rim. Panel B graph displaying the relative expression of 
the EMT in the different cellular populations, after β-actin normalisation, each experiment was 
carried out three times. 
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3.3.2 DLD-1 and HCT-116 MCTS 
Western blotting for N-Cadherin was repeated in two separate cell lines, DLD1 and 
HCT-116, to confirm the results. N-Cadherin was highly expressed within the necrotic 
core. These results are consistent with the results for HT-29. Both cell lines showed 
expression of N-Cadherin in the necrotic but no detectable expression within the viable 
rim. 
 DLD-1           HCT-116  
     VR           NC            VR          NC 
        N-Cadherin      
        β-actin 
Figure 4. Western Blotting data showing the expression of N-Cadherin in DLD-1 and 
HCT-116 within the viable rim (VR) and necrotic core (NC) of MCTS.  
3.4 Cadherin expression in colorectal xenografts  
The qualitative expression of E-Cadherin in a series of human tumour xenografts is 
presented in Figure 5. The DLD-1 E-Cadherin staining (panel A) was seen to be weaker 
than that of HT-29, with faint expression seen in only a small proportion of the cells.  In 
the HT-29 xenograft (panel C) strong expression of E-Cadherin was observed in a large 
number of cells, consistent with the western blotting results for the HT-29 cell line 
grown as MCTS. HCT 116 xenograft also showed some positive expression of E-
Cadherin (panel B), though this xenograft was less strongly stained than HT-29. Faint 
N-Cadherin expression was seen in all 3 of the xenografts with the strongest expression 
seen in the HCT 116 xenograft (panel E). With the exception of the staining seen in the 
HCT 116 cell line, the expression of N-Cadherin was not as wide spread as E-Cadherin 
and was seen only in small clusters of cells rather than uniformly expressed.
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HCT116         DLD-1            HT-29 
      
     
Figure 5 In vivo N-Cadherin and E-Cadherin expression. E-Cadherin expression in (A) DLD-1 (B) HCT 116 and  (C) HT-29 xenografts. N-
Cadherin expression in (D) DLD-1 (E) HCT 116 and  (F) HT-29 xenografts.    
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3.5 Snail expression in colorectal xenografts 
To determine whether the expression of Snail in necrotic cells was confined only to 
cells grown in spheroids or whether it was a common occurrence in colorectal cancer, 
three cell lines were grown as xenografts and examined immunohistochemically for 
Snail expression. Faint expression of Snail was seen in a number of viable cells in the 
DLD-1 xenograft (Figure 6, panel A). HCT 116 xenograft was completely negative for 
Snail expression (Figure 6, panel B). In contrast, the HT-29 xenograft showed positive 
expression of Snail in areas of necrosis (Figure 6, panel C). 
   
   
Figure 6. Immunohistochemical analysis of Snail expression in xenografts. Panel A DLD-1, 
panel B HCT 116 and panel C HT-29, staining in brown. 
3.6 CD133, CD44 and CD24 staining to identify stem cell markers within the 
Necrotic Core. 
Stem cells are known to be resistant to anoikis therefore to determine whether the 
cleaved caspase-3 negative cells in the necrotic core had stem cell characteristics, the 
expression of a number of known colorectal cancer stem cell markers was examined. 
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CD133 was found to be expressed in the cytoplasm of most cells throughout the viable 
rim and necrotic core (Figure 7, panel A). Cytoplasmic expression of CD24 was seen 
only in a small number of cells within the necrotic core (panel B), while the viable rim 
was negatively stained. A similar pattern was seen in the CD44 expression (panel C), a 
small number of cells within the necrotic core were positively stained whilst the rest of 
the cells in the MCTS were negatively stained. 
 
 
  
Figure 7 Expression of cell surface receptors' CD133, CD24 and CD44 within HT-29 
MCTS. Panel A shows expression of CD133 within the viable rim and necrotic core, Panel B 
shows CD24 expression in a number of single cells within the necrotic core. Panel C shows 
expression of CD44 in a cluster of cells in the necrotic core. Panel D, E and F show a negative 
primary antibody controls for CD133, CD24 and CD44 respectively. 
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3.7 Sphere Formation Assay to measure anchorage independent growth of 
Necrotic Core Clones  
To measure the anchorage dependent growth of the clones, the sphere-formation assay, 
which is a functional stem cell assay, was performed. Necrotic Core Clones 1, 2 and 4 
all had similar sphere formation capability compared to that of the parental cell line. 
Two of the clones NCC3 and NCC5 were found to have increased sphere formation 
abilities. Of these two, NCC5 was found to be significantly higher than that of the HT-
29 cells, with a p-value of 0.035. 
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Figure 8. Showing the growth of HT-29 and Necrotic Core Clone 5 in a non-adherent 
environment in the sphere formation assay. Panel A shows the spheres formed in HT-29 
parental cell line, Panel B shows the NCC5 cells. Panel C graph depicting the sphere formation 
factors for the NCCs and parental cell line calculated from the number and size of the spheres 
formed per well. Statistical differences between clones and parental cell line were determined 
using a Student's T Test. Statistical significant differences are denoted with an asterix (p<0.05). 
Error bars were included on the bar to represent the standard error associated with that cell line. 
* p = 0.035 
A HT-29 B NCC5 
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3.8 Wound healing assay to measure the migratory behaviour of Necrotic Core 
Clones 
To assay the migratory phenotype of the necrotic core clones, a wound-healing assay 
was carried out. This assays measures the rate of 'healing' of a scratch to a monolayer 
and qualitative and quantitative analysis of results are presented in Figure 9 and  Figure 
10 respectively. Visually, Necrotic Core Clones 2, 3, 4 and 5 were all shown to be more 
migratory than the parental cell line (Figure 9). In particular Necrotic Core Clones 2 and 
4 were found in some cases to completely close the scratch within 48 hours (see Figure 
9) whereas after 48 hours the parental cell line had closed less than 50% of the scratch. 
Previously completed proliferation assays had showed the clones to be slower growing 
than the parental cell line (Chapter 1, Table 5), hence the increased ability of the clones 
to heal the wound is not due to an increased ability to repopulate the wound by 
proliferation but due to increased migratory behaviour.
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HT-29          NCC1 
   
NCC2          NCC3 
   
NCC4          NCC5 
   
Figure 9. The wound healing assay. Pictures showing the wound made to Parental HT-29 and Necrotic Core Clone (NCC) monolayers at time 0 hours (left) 
and after 48 hours to allow migration of cells (right).  
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To ensure that the increases seen in the necrotic core clones was not the result of innate 
differences in the migratory behaviour of individual cells making up the HT-29 cell 
line, control clones derived from HT-29 monolayer cultures were generated using the 
same method as described in Chapter 1, section 2.16, and tested in the wound healing 
assay. The control clones (CC), while having a range of different migratory behaviours 
were not significantly more migratory than the HT-29 parental cell line (see Figure 10). 
When looking at the results statistically using a student's t-test it was found that only 
Necrotic Core Clone 2 and 4 had significantly different migratory behaviour from the 
parental cell line.  
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Figure 10. Graph showing the motility of the necrotic core clones, control clones and 
parental cell line. Scratch widths were measured in 3 separate areas of the scratch and an 
average derived. Asterix denotes statistically significant difference found through a two tailed 
Student's T test (p<0.05). Both NCC2 and NCC4 were found to have significantly increased 
motility as shown by p-values of 0.0076 and 0.0064 respectively. Error bars denote standard 
errors associated with the individual cell lines. 
3.9 N-Cadherin Western Blotting Analysis of Clones 
To see if the increase seen in the expression of N-Cadherin in the necrotic core of 
MCTS was transient or stable and if the differing motilities measured in the wound 
healing assay were linked to EMT status the expression of N-Cadherin was analysed in 
* * 
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the necrotic core clones. While a band of 140kDa was seen in the spheroid fraction, in 
the clones a band corresponding to a cleaved fragment of N-Cadherin approximately 
35kDa was seen instead. This cleaved fragment was seen present at higher levels in all 
the necrotic core clones compared to the parental cell line. To confirm these differences 
were not down to the heterogenic nature of the cell line, control clones were analysed. 
The expression of cleaved N-Cadherin seen in the control clones was more similar to 
that of the parental cell line than the necrotic core clones, suggesting the necrotic core 
clones stably express N-Cadherin at a higher level than the parental cell line. 
HT29 NCC1 NCC2 NCC3 NCC4 NCC5  HT29  CC1   CC2   CC3   CC4   CC5 
  N-Cadherin 
  β-actin 
Cell 
Line 
N-Cadherin 
Band Density 
β-Actin Band 
Density 
Normalised N-Cadherin 
Band Density 
HT29 10077 7491 1.35 
NCC1 17480 7060 2.48 
NCC2 19094 8225 2.32 
NCC3 20490 8061 2.54 
NCC4 20013 7073 2.83 
NCC5 22301 6264 3.56 
HT-29 10933 9712 1.13 
CC1 12019 9214 1.30 
CC2 13229 11411 1.16 
CC3 15397 11009 1.40 
CC4 13499 10946 1.39 
CC5 18500 11818 2.01 
Figure 11. N-Cadherin Western Blotting Analysis. Panel A Western Blots of NCC and CCs 
probed with N-Cadherin antibody (top) and β-Actin antibody (bottom). Panel B Table of Band 
density data for the western blots, N-Cadherin band density figures are the average of three 
separate blots. Normalised N-Cadherin ban densities have been normalised using the β-actin 
band densities  
~35kD
a 
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Figure 12. Compilation of N-Cadherin western blotting results to show the differing levels 
of normalised cleaved N-Cadherin expression in necrotic core and control clones 
compared to the parental cell line levels.  
3.10 In Vivo Growth of HT-29 and Necrotic Core Clone 4  
On the basis that NCC4 showed more aggressive, invasive behaviour in the wound 
healing assay, this cell line was chosen to determine whether it was capable of growing 
as a solid tumour in vivo and its growth characteristics compared to the parental cell 
line. To compare the tumour forming capabilities of the clones compared to the parental 
cell line, NCC4 and the parental cell line were injected subcutaneously into the flanks of 
mice and the results are presented in Figure 13, 14 and 15. 
In the HT-29 parental cell line group the take rate was calculated as the number of 
xenografts reaching palpable size expressed as a percentage of the initial number of 
inoculations. As all 6 xenografts initially took, the take rate was 100%. Only 2 
xenografts however, both within the same mouse, continued to grow for the full 
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experiment. The other mice were euthanized on days 20 and 22 as the xenografts began 
to ulcerate. The remaining two xenografts continued to grow until they were removed 
for histology. The largest grew to 771mm
3
 and the smallest to 320mm
3
, giving an 
average tumour volume after 50 days of growth of 546mm
3
. 
0
100
200
300
400
500
600
700
800
900
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
T
u
m
o
u
r 
V
o
lu
m
e
 (
m
m
3
)
Time (Days)
M1 L
M1 R
M2 L
M2 R
M3 L
M3 R
 
Figure 13. In vivo growth curve for HT-29 parental cell line in 3 mice each bearing one 
xenograft on each flank (L left, R right). All 6 xenografts initially were seen to grow, giving a 
take rate of 100%. Where the data points end, this represents the point at which the mice were 
euthanized due to the tumours becoming ulcerated.  
In the Necrotic Core Clone 4 group, all 6 xenografts initially took and started to grow 
giving a take rate of 100%. However the growth of 4 of the 6 xenografts stalled and in 
some cases, tumour regression occurred, the unsuccessful NCC4 xenografts stopped 
growing before they reached sizes any bigger than 100mm
3
.The two xenografts that 
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continued to grow for the entire experiment reached sizes of 634 and 446 mm
3
, giving 
an average volume of 540mm
3
.  
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Figure 14. In vivo growth curve for Necrotic Core Clone 4 in 3 mice (M4-6) each bearing 
one xenograft on each flank (L left, R right).  
In both cases of the three mice used for each group only one mouse developed tumours 
which grew successfully. Each mouse developed two tumours, with one growing larger 
than the other in both cases. Whilst the average tumour size was very similar for both 
groups the sample size of one for each group means it is difficult to conclude with any 
confidence whether the similarities seen are true or not. Importantly however NCC4 
cells were shown to be capable of forming a xenograft. This cell population was cloned 
from a colony formed from one single cell and therefore is homogeneous and yet was 
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able to form a xenograft similar in size to the heterogeneous parental cell line (Figure 
15). 
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Figure 15. Direct comparison of the growth rates of HT-29 and NCC4 xenografts. M1 
represents the HT-29 xenografts that successfully took and continued to grow for the entire 
experiment, M6 represents the successful NCC4 xenografts. (L left flank, R right flank). 
3.11 Immunohistochemical Analysis of HT-29 and Necrotic Core Clone 4 
Xenografts 
Following the growth of the HT-29 and NCC4 xenografts in the mice, the tumours 
where excised on day 50, fixed and embedded in preparation for morphological and 
immunohistochemical analysis. The two xenografts were compared to see if there were 
any differences between the two tumours formed, morphologically or in terms of 
marker expression. Markers examined included EMT markers E-Cadherin, N-Cadherin 
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and Snail, senescence marker p-H2AX, and cell death marker Cleaved Capsase-3. The 
results showed that xenografts formed from necrotic core clone 4 cells had similar tissue 
morphology to the parental cell line HT-29, representative images of which are 
presented in Figure 16, panels A and B. This included extensive areas of necrotic tissue 
surrounded by healthy tissue. Cleaved Caspase-3 staining demonstrated that apoptosis 
was occurring in necrotic regions and in areas bordering necrotic regions in both 
parental and NCC4 xenografts (see Figure 16, panels C and D for representative 
examples). In contrast to MCTS where cleaved caspase 3 expression was more or less 
uniform across the necrotic core (see figure 8 in Chapter 1), in the xenografts the 
staining was less consistent. Whilst necrotic regions were similarly stained in the HT-29 
parental xenograft (Figure 16, Panel C) the NCC4 xenografts had regions of strong 
positive staining typically lining the outer edges of the necrotic regions but not 
throughout (Figure 16, panel D).  
H2AX expression was also examined to see whether there would be differential 
expression in the necrotic core clone NCC4. In the HT-29 xenograft expression was 
located in the cells on the periphery of the necrotic regions and in the necrotic regions 
themselves (Figure 16, panels E and F). This was similar to the pattern of expression 
seen with the HT-29 cells grown as spheroids. 
To determine whether the expression of EMT markers seen in the Necrotic Core of HT-
29 MCTS was maintained in the clones the xenografts were examined. Snail expression 
was seen in necrotic regions of both the HT-29 and NCC4 xenografts (Figure 16, panels 
G and H) therefore making Snail expression a characteristic of HT-29 necrotic cells 
when grown in vitro and in vivo. E-Cadherin expression was seen in both the HT-29 and 
NCC4 xenografts, and was found to be expressed by a large number of both necrotic 
and non necrotic cells. Faint N-Cadherin expression was also seen in both xenografts. 
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The expression of N-Cadherin was not as wide spread as E-Cadherin and was seen only 
in small clusters of cells rather than uniformly expressed, though membranous staining 
was seen both in necrotic and necrotic areas of the tissue. 
199 
 
     
Figure 16. Immunohistochemical analysis of the HT-29 Parental and NCC4 cells grown as xenografts. Analysis of sections stained with 
Haematoxylin and Eosin (A) HT-29, (B) NCC4. Cleaved caspase-3 expression (C) HT-29, (D) NCC4. H2AX expression (E) HT-29, (F) NCC4. 
Snail expression (G) HT-29, (H) NCC4. E-Cadherin expression (I) HT-29, (J) NCC4. N-Cadherin expression (K) HT-29, (L) NCC4. 
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4 Discussion 
The aim of Chapter 2 was to characterise the necrotic core clones in order to determine 
their biological significance. By investigating the possible mechanisms by which they 
survived the necrotic core and by determining any unique differences between the 
clones and the parental cell line, new targets may be uncovered. Both the Epithelial 
Mesenchymal Transition and stem cells have been implicated in the necrotic core clones 
survival, the evidence for and significance of it is discussed in the following section.   
4.1 Surviving the Necrotic Core: Epithelial Mesenchymal Transition 
Further to surviving the poor nutrient conditions in the necrotic core the physical 
environment also places another obstacle for the cells to overcome. The tissue structure 
within the necrotic core is not very organised, the cells exist in a liquid like state due to 
the large number of dead cells and cellular debris. The lack of correct cell-cell contacts 
would normally induce anoikis in epithelial cells, when an epithelial cell becomes 
unattached from its local environment it undergoes anchorage dependant cell death.
13
 
Therefore the cells which manage to survive in the necrotic core must have found some 
way to resist the process of anoikis. 
Cells which are capable of bypassing anoikis tend to be those which have undergone the 
EMT.
14
 Hence the necrotic core was investigated for markers of the EMT. What was 
found in the necrotic core when stained for certain EMT makers was that some cells 
were seen to have reduced E-Cadherin expression and gain of N-Cadherin expression, 
this occurred in a number of clusters of cells in the necrotic core only (Figure 1). Loss 
of E-Cadherin and gain of N-Cadherin are the classical signs of the EMT.
15
 Western 
blots wwere carried out to confirm the immunohistochemistry results, and similar 
evidence was seen (Figure 3) N-Cadherin was found to be present in the necrotic core 
201 
 
but not in the viable rim population of HT-29 cells. As frequently research is carried out 
on intact MCTSs, it does not distinguish between the different populations of cells 
within the MCTS. This is the first time that induction of N-Cadherin expression has 
been seen specifically in the centre of MCTS. However gain of N-Cadherin expression 
has been seen in cultures of lung adenocarinoma plural effusions, when grown as 
spheres compared to their monolayer counterparts.
16
 E-Cadherin was found expressed in 
both populations but the expression in the necrotic core was reduced in comparison to 
the viable rim. The expression of E-Cadherin found in the MCTS mirrored xenograft 
expression data reported in the literature where E-Cadherin was found to be lost in areas 
of necrosis in colorectal xenografts.
17
 Furthermore HT-29 cells have previously been 
found to exhibit a loss of E-Cadherin expression when grown in 3D.
18
  
Further markers such as Snail were also investigated (Figure 2), and this staining gave 
evidence which supported much of the literature which was that Snail is up regulated by 
reduced oxygen levels.
19, 20
 Snail expression was seen in the hypoxic areas of the 
MCTS, and in a small number of cells in the necrotic core (Figure 2, Panel B). This is 
consistent with previous studies in breast cancer which have found that hypoxia induced 
a partial EMT by increasing the expression of Snail.
21
 A similar response was seen in 
pancreatic cancer cells where hypoxia induced Snail expression through the binding of 
HIF-1α to the hypoxia response elements of the Snail gene promoter. Both in pancreatic 
and hepatocellular carcinoma this hypoxia induced increase in Snail was associated with 
metastasis.
22,23
 Snail expression has also been reported in the literature to be up 
regulated when HT-29 cells are grown in 3D, though no distinction in expression has 
been made between the separate populations of cells within the MCTS.
 24
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Together this data indicate these viable cells within the necrotic core may have gone 
through the EMT. And that this transition may be a key survival mechanism as it helps 
the cells survive the anchorage independent growth conditions within the necrotic core. 
To confirm that this was not an isolated occurrence and that it was characteristic of this 
particular cell line, two other colorectal cancer cell lines were used to form MCTS. Both 
HCT-116 (p53
+
/
+
) and DLD-1 MCTS showed a similar pattern of N-Cadherin 
expression as shown in Figure 4. No expression was seen in the viable rim but it was 
present in the necrotic core (see Figure 4). This gain of N-Cadherin expression by the 
cells in the necrotic core is therefore not specific to HT-29 cells and seems to be a 
common mechanism of colorectal cells grown as MCTS. This phenomenon has also 
been described in lung adenocarcinoma with similar results reported when monolayer 
were compared to spheroidal cultures. While cells grown in monolayers were found to 
be E-Cadherin positive and N-Cadherin negative, the opposite was seen in cells grown 
in MCTS.
25
 However descriptions of colorectal MCTS and their Cadherin expression 
have yet to contain information of the location of staining within the MCTS instead of 
treating the MCTS as one population.  
Tumour xenografts were examined for Cadherin and Snail expression to see if the 
results seen in the 3D cell culture mimicked the processes happening in vivo. HT-29 and 
DLD-1 xenografts were both seen to have Snail expression within areas of necrotic 
tissue whilst HCT-116 was not (Figure 6). N-Cadherin expression was found 
throughout all the xenografts including in areas of necrotic tissue (Figure 5). 
Together this evidence shows that the necrotic core of MCTS induces a full or partial 
EMT in epithelial cancer cells, and this acquisition gives the cancer cells an increasingly 
metastatic phenotype. Furthermore the changes in expression of EMT markers are 
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mirrored in an in vivo setting which supports the use of MCTS to study this 
phenomenon.  
4.2 EMT in the Necrotic Core Clones 
Once the necrotic core clones had been established in cell culture their metastatic 
potential and EMT status was characterised. This would establish whether the changes 
seen in the necrotic core of the MCTS were retained by the cells once they returned to 
favourable growth conditions. Since living cells have not previously been studied from 
the necrotic core of spheroids their growth characteristics and properties represent novel 
findings. 
One of the first observations made about the clones when they were returned to normal 
monolayer growth conditions in cell culture was that they continued to grow in 
suspension forming small MCTS. The cells maintained their preferences for growth in 
suspension for several passages before returning to fully adherent growth. Spontaneous 
spheroid formation, a characteristic of the EMT,
26,27
 was not seen in the original cell 
line under the same culture conditions suggesting that the shift from epithelial to 
mesenchymal phenotype seen in the necrotic core is maintained in the clones. 
Through wound healing assays, it was clear that some of the clones under normal 
culture conditions had a higher migratory ability than the parental cell line. The 
expression levels of N-Cadherin, an EMT marker found elevated in the necrotic core of 
MCTS, was examined in clones via western blotting and all five of the clones had 
higher levels of the cleaved form of N-Cadherin than the parental cell line. This 
experiment, performed on monolayer cultures of the clones, determined whether the 
clones maintained the increased levels of N-Cadherin seen in MCTS or whether this 
increase was transient. Clearly the results showed that this effect was not transient. 
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While the full length N-Cadherin protein was not present in the cells grown as 
monolayer a shortened part of the protein corresponding to the intracellular and 
transmembrane domains was seen. This cleaved form of N-Cadherin has been reported 
previously to be found upregulated in gliobastoma cells and was shown to be cleaved by 
the disintegrin and metalloproteinase ADAM10. Whilst the function of the cleaved form 
of N-Cadherin has not been conclusively established, in Glioblastoma when ADAM 10 
cleavage of N-Cadherin was inhibited a decrease in cell migration was seen. 
28
  
While an increased migratory ability is not ideal when treating cancer, unless the cell 
can anchor itself into a new environment and use its self renewal properties to form a 
secondary tumour, this ability will not result in successful metastasis. Increased 
migratory behaviour and the ability to grow in suspension, two properties the clones 
have, supports the view that they have undergone the EMT. Generally anchorage 
dependant cells such as epithelial cells will not survive if they become unattached from 
their surrounding, this lack of cellular attachment leads to anoikis. The ability of the 
cells to survive within the ‘liquid like’ environment of the MCTS necrotic core in the 
first place suggests that these cells must have undergone the EMT. But having 
undergone the EMT does not ensure that once the cells have migrated to a new site they 
are capable of forming a metastatic deposit. Recent research into the mode of growth of 
tumours has put forth the hypothesis that stem cells are the seed of tumour growth and it 
is these cancer associated stem cells that drive the proliferation and differentiation of 
tumours. According to the hypothesis migratory stem cells which have an EMT-like 
phenotype are responsible for metastasis.
29
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4.3 The Necrotic Core as a Niche for Stem-like cells 
Other markers known to be up regulated in three dimensional cell cultures are stem cell 
markers. Stem cell markers are known to be up-regulated in cells exposed to hostile 
microenvironments such as those found at the centre of MCTS.
30
 Stem cells themselves 
are known to have increased survival capabilities compared to cancer cells, both in 
response to chemotherapeutics and poor nutrient and oxygen conditions. Hypoxic 
niches have been known to exist which support colorectal cancer stem cells and hypoxia 
as a stimuli has been discovered to enrich stem cell populations.
31,32
 Furthermore the 
EMT marker Snail which was found to be expressed in hypoxic and necrotic regions 
within the MCTS and xenografts has been linked to the acquisition  of a stem cell 
phenotype.
 33, 34 
Because the identification of cancer stem cells can be complicated, several assays were 
used to determine the ‘stemness’ of cells. While normal tissue stem cells are often 
identified by the expression of certain stem cell markers, this is not such a reliable 
method when looking at cancer stem cells due to their intrinsic plasticity. 
Three known colorectal cancer stem cells markers, CD133, CD24, and CD44 were 
examined in MCTS and suggested that the viable cells in the necrotic core were 
expressing stem cell markers. While CD133 was found to be expressed by the majority 
of the cells within the HT-29 MCTS population, cytoplasmic expression of CD24 and 
CD44 was only found in a small number of cells within the necrotic core. All three stem 
cell markers examined have been previously found to be expressed in subpopulations of 
cells within the HT-29 cell line.
35, 36
 Specifically cytoplasmic staining for CD44 and 
CD24 expression has also been found in HT-29 populations.
37, 38, 39 
Furthermore none of 
the cells within the necrotic core were actively proliferating as seen by the absence of 
Ki-67 expression (Chapter 1, section 3.4), which is consistent with cancer stem cells 
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which are known not to rapidly proliferate and tend to exist in a quiescent state.
40
  The 
expression of the two stem cell markers suggested that these viable cells in the necrotic 
core could be cancer stem cell, or had acquired stem-like characteristics. 
To confirm whether the necrotic core clones were also stem-like in their behaviour, 
functional assays were also carried out in order to back up the marker expression data. 
The clones' anchorage independent growth was measured in the sphere formation assay 
which found that one of the clones, Necrotic Core Clone 5 did had a significantly 
greater ability to form spheres than the parental cell line (Figure 8). The final functional 
assay that was carried out was the xenograft assay. The in vivo growth of Necrotic Core 
Clone 4 and the parental cell line were measured, and it was determined that the clone 
was fully capable of forming a heterogeneous xenograft similar to that formed by the 
parental cell line. The NCC4 xenograft managed to recapitulate both the morphology 
and marker expression of the HT-29 parental cell line. The only difference between the 
two was the expression of cleaved capsase-3, the levels of which was reduced in the 
clone and differences in localisation were seen. The lack of staining within the necrotic 
areas could mean that the clone cells are more resistant to cell death or that when grown 
in vivo these cells can be subject to caspase independent cell death mechanisms. 
Altogether the expression of certain stem cell markers found on a subset of cells within 
the necrotic core, along with the evidence for EMT having occurred and the in vivo 
growth assays show these migratory cells have an ability to form tumours in vivo that 
recapitulate the morphology of the original cell line, and hence should be investigated 
further.  
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4.4 Clone Summary 
Overall the clones have different phenotypes than the parental cell line in many 
different ways. They have been shown to be more migratory than the parental cell line 
in the wound healing assay (Figure 9) and they possess the capabilities for anchorage 
independent growth as determined by the sphere formation assay (Figure 8). In addition, 
the clones retain the ability to form heterogeneous tumours in vivo with growth 
characteristics that are similar to the original parental lines. These observations together 
demonstrate that there are viable cells within the necrotic core that can regrow when 
conditions become favourable, have a greater capacity to migrate and are able to form 
tumours when implanted subcutaneously into mice. Certain cancer stem cell makers 
were found on cells within the necrotic core of the MCTS, though the expression of 
stem cell markers exhibits a certain amount of plasticity and is known to be dependent 
upon the cells' current microenvironment. This links into the experimental conditions 
surrounding the formation of the clones. Whilst it was found that necrotic core cells 
could and did return to proliferation once placed in standard culture conditions, this 
does not necessarily mean that if necrotic core cells in vivo or in a clinical setting were 
once again re-introduced to sufficient oxygen and nutrient, the same phenomenon 
would be seen. Henceforth future works into the subject would benefit from looking 
into whether necrotic core cells could re-grow a tumour in vivo when transplanted 
directly into mice without returning to normal cell culture conditions first. 
Whether the necrotic core of MCTS acts to enrich these cell populations or whether 
harsh microenvironmental factors such as severe hypoxia cause a change within the cell 
is not yet known. However the fact remains that the necrotic core of spheroids provides 
a niche for cancer stem cell-like cells which have a phenotype consistent with metastatic 
cells. Furthermore that this differential phenotype, as compared to the parental cell line, 
208 
 
is maintained when the cells are returned to normal culture conditions showing that the 
changes selected for in the necrotic core are not transient. The targeting of these cells 
therefore is crucial to prevent disease recurrence. 
Regardless of whether they are called stem cells, stem-like cell or cancer initiating cells, 
these cells have shown themselves to be more migratory and capable of self renewal. 
Therefore not considering their title, these cells seem likely candidates for disease 
recurrence and are therefore biologically significant. 
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Chapter 3:Therapeutic Implications  
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1 Introduction 
Chemotherapy is one of the main methods used to treat cancer. However development 
of resistance is a major cause of treatment failure in cancer patients. Resistance to both 
conventional chemotherapeutics and more specific targeted therapies share many 
common mechanisms including alterations in target, increased efflux of drug, 
inactivation of cell death signalling and up-regulation in pro survival signalling. 
Survival of resistant cells following treatment can lead to relapse as the resistant cells 
repopulate the tumour resulting in a tumour which is now resistant to treatment.1 The 
existence of viable cells within necrotic regions which are not only less sensitive to 
standard chemotherapeutics due to their non proliferative status but maintain this 
increased resistance once returned to proliferation could well explain the link between 
tumour necrosis and poor prognosis. Furthermore stem cells are known to be more 
resistant to chemotherapeutics through various different mechanisms including 
increased expression of multidrug transporters,2 and the utilisation of autophagy.3, 4 The 
aim of this chapter is the determine the therapeutic responses of the clones to several 
commonly used chemotherapeutics to determine if they are significantly more resistant 
compared to the parental cell line. This research will be carried out using the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay, which 
utilises the conversion of formazan crystals from MTT by living cells to determine the 
number of living cells. This can be used to measure the effects of cytotoxic drugs upon 
cells.  
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2 Methods 
2.1 Chemosensitivity testing using the MTT Assay 
The chemosensitivity of the Necrotic Core Clones and the parental HT-29 cell line was 
examined using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. Initially cells were seeded in round bottom wells of a 96 well plate at 
the seeding density of 2x103 cells per well. Once cells were seeded into wells, they were 
left to adhere for 24 hours at 37oC 5% CO2 and 95% humidity. One lane on each plate 
contained no cells only McCoy's 5a Modified Medium to serve as the blank, and 
another lane contained cells but no drug, the serve as the control. After 24 hours cells 
were treated with increasing concentrations of Doxorubicin (Sigma Aldrich, St Louis, 
MO, USA, stock solution 10mM, dissolved in H2O), 5-Fluorouracil (Sigma Aldrich, St 
Louis, MO, USA, stock solution 100mM, dissolved in DMSO) and Gefitinib 
(Selleckchem, TX, USA, stock solution 100mM, dissolved in DMSO). The cells were 
incubated with the drug for 96 hours. Following this incubation period, 20µl of MTT 
(5mg/ml) was added to each well and left for a further 4 hours. All media containing 
MTT was then removed, leaving the resulting formazan crystals in the bottom of the 
wells. The crystals were then dissolved in 150µl of DMSO (Dimethyl sulfoxide, Sigma, 
St Louis, MO, USA) before absorbance was read using a plate reader at 540nm. Percent 
survival was calculated with the help of the control drug lane (cells but no drug) as 
formation of the formazan product correlates with cell number. The following formula 
was used to calculate percent survival: 
%		 = 											 × 100 
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3 Results 
3.1 Chemosensitivities of clones derived from the necrotic core. 
Once clones from the necrotic core had been established and were growing as 
monolayers the response of cells to chemotherapeutic drugs was determined. Three 
different drugs used to treat colorectal cancer in the clinic were tested (doxorubicin, 5-
fluorouracil (5FU) and gefitinib) and the response of the parental HT-29 and the 
necrotic core clones to each of these drugs is presented below. IC50 values, which 
represent the concentration of drug required to kill 50% of the cell population, for all 
drugs are summarised in Table 4.  
3.2 Response of NCC and HT-29 cells to doxorubicin 
Using doxorubicin, the IC50 value for the clones were all similar to the parental cell line 
with the exception of Necrotic Core Clone 1. NCC1 was found to be significantly more 
resistant to doxorubicin than HT-29 cells, with IC50 values of 144 ± 39µM and 70 ± 
17µM for NCC1 and HT-29 respectively (Figure 1). In contrast, NCC4 was 
significantly (p < 0.05) more sensitive than the parental HT-29 with IC50 values of 36 ± 
9 and 70± 17 µM respectively (figure 1).  
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Figure 1. Doxorubicin Dose Response Curves. Panel A shows the dose response 
curves for the HT-29 parental cells and Necrotic Core Clones in response to 
doxorubicin. Panel B presents the IC50 values for each of the different cells. All 
experiments were carried out in triplicate, error bars denote the standard deviations 
associated with the data. Clones which have statistically significant (p<0.05) IC50 values 
compared to the parental cell line are marked with an asterix. 
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When statistically analysed Necrotic Core Clone 1  was found to be significantly more 
resistant to Doxorubicin than the parental cell line with a p-value of 0.04 which was 
below the significance threshold of 0.05 (Table 1). Necrotic Core Clone 4 was found to 
be significantly more sensitive to Doxorubicin than the parental cell line with a p-value 
of 0.04. 
Table 1. Results of a 2-Tailed Student's T-Test. Calculating the statistical 
significance of the clones' chemosensitivities compared to the parental cell line in the 
case of Doxorubicin. Significance as measured by a p-value of  <0.05 denoted by *). 
Cell Line P-value 
NCC1 0.040338* 
NCC2 0.093746 
NCC3 0.658858 
NCC4 0.043251* 
NCC5 0.152285 
3.3 Response of NCC and HT-29 cells to 5-FU 
Another chemotherapeutic agent used in the treatment of colorectal cancer is 5-FU. 
When the chemosensitivities of the clones to 5-FU was compared to the parental cell 
line a similar result to the doxorubicin chemosensitivity was seen. Again Necrotic Core 
Clone 1 was found to have a significantly decreased sensitivity to the drug. In this case 
exhibiting an IC50 almost three times greater compared to HT-29 (Figure 2). This 
difference in IC50 was statistically significant (p < 0.01, Table 2). In contrast, NCC3 
was more sensitive to 5FU than HT-29 and this difference was statistically significant (p 
< 0.05). The rest of the clones all had statistically comparable IC50 values to the parental 
cell line, despite the fact that the IC50 value for NCC5 was the lowest value observed (p 
> 0.05, Table 2).  
 219 
 
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
H
T-
29
 
Su
rv
iv
a
l (
%
)
5-FU (µM)
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
N
CC
1 S
u
rv
iv
sa
l (%
)
5-FU (µM)
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
N
C
C
2 S
u
rv
iv
a
l (%
)
5-FU (µM)
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
N
C
C
3 S
u
rv
iv
a
l (%
)
5-FU (µM)
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
N
C
C
4 
Su
rv
iv
a
l (%
)
5-FU (µM)
0
10
20
30
40
50
60
70
80
90
100
0.1 1 10 100
N
C
C
5 
Su
rv
iv
a
l (%
)
5-FU (µM)
 
Figure 2. Response of necrotic core clones and the parental HT-29 cell line to 5-FU. 
Panel A shows Dose Response Curves for all 5 clones and parental cell line. Panel B 
shows the calculated IC50 values. Cells were exposed to 5-FU for 96 hours and each 
value represents the mean ± standard deviation for three independent experiments. 
Clones which have statistically significant (p<0.05*, p<0.001**) IC50 values compared 
to the parental cell line are marked with an asterix. 
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Table 2. Results of a 2-Tailed Student's T-Test. Calculating the statistical 
significance of the clones' 5-FU IC50 compared to the parental cell line. (Significance as 
measured by a p-value of <0.05 and 0.001 denoted by * and ** respectively). 
Cell Line P-value 
NCC1 0.000036** 
NCC2 0.057992 
NCC3 0.038351* 
NCC4 0.523350 
NCC5 0.083682 
3.4 Response of NCC and HT-29 cells to gefitinib 
The response of the clones to gefitinib was determined, the results of which are 
presented in Figure 3. Whilst some of the NCC lines showed some increased selectivity 
to gefitinib, there were no statistically significant differences (p > 0.05) in IC50 values 
between NCC and parental HT-29 cell (Table 3). 
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Figure 3. Chemosensitivities to the Necrotic Core Clones and Parental Cell Line to 
gefitinib. Panel A shows individual dose response curves for each of the clones and the 
parental cell line detailing cell death in response to concentration of drug. Panel B 
shows a bar chart presenting the gefitinib IC50s for the necrotic core clones and parental 
cell line.  
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When a statistical analysis in the form of a Student's T-Test was carried out no 
significant differences were found to be present between the clones and the parental cell 
line (Table 3).  
Table 3. Results of a 2-Tailed Student's T-Test. Calculating the statistical 
significance of the clones' Gefitinib IC50 compared to the parental cell line. 
Cell Line P-value 
NCC1 0.801437 
NCC2 0.551095 
NCC3 0.202862 
NCC4 0.202322 
NCC5 0.489259 
3.5 Chemosensitivity Summary 
Certain patterns were seen in the response of the clones to chemotherapeutic agents 
(Table 4 A). In the case of the two drugs which targeted actively proliferating cells 
(doxorubicin and 5-FU), NCC1 was found to be significantly more resistant compared 
to the parental cell line. This clone has a resistance mechanism that the parental cell line 
and other necrotic core clone do not. This resistance mechanism was not of use when 
the cells were treated with the EGFR inhibitor gefitinib suggesting that the mechanism 
is independent of this receptor. 
In order to try and understand the differences in chemosensitivity of NCC1 to 5-FU and 
doxorubicin the doubling rates of the clones grown as monolayers (Table 4B, as 
presented in Chapter 1, Table 4) were examined. NCC1 had the largest doubling time, 
30.89 ± 0.36 hours compared to the parental cell line's (25.65 ± 1.91 hours). The 
reduced rate of cellular proliferation could explain the reduced sensitivity to 5-FU and 
doxorubicin.  
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Table 4. A Chemosensitivities of the necrotic core clones and the parental HT-29 
cell line. Cells were exposed to each drug for 96 hours and cell survival was determined 
using the MTT assay. Each value represents the mean ± standard deviation for three 
independent experiments and significance at p values of < 0.01 and  <0.05 are denoted 
by ** and * respectively). B Measurement of cellular proliferation of the clones 
grown as monolayers (Chapter 1, Table 4). Statistically significant differences 
between the clones and parental cell line were determined using a Two Tailed Student's 
T Test, significance (<0.05) is denoted by an asterix. 
 
Cell Line 
 
5FU  
(µM) ± SD 
Doxorubicin  
(nM) ± SD 
Gefitinib  
(µM) ± SD 
  HT29 5.7 ± 0.6 70 ± 17 8.4 ± 2.6 
NCC1 15.2 ± 0.5** 144 ± 39* 8.0 ± 0.6 
NCC2 4.6 ± 0.3 45 ± 9 7.4 ± 0.7 
NCC3 4.0 ± 0.7* 64 ± 11 6.0 ± 0.8 
NCC4 6.4 ± 1.8 36 ± 9* 6.0 ± 0.7 
NCC5 3.3 ± 1.7 51 ± 5 7.2 ± 0.7 
 
  
Cell Line Cell Doubling 
(hours) 
HT-29 25.65 ± 1.91 
NCC1 30.89 ± 0.36* 
NCC2 30.38 ± 2.02 
NCC3 26.99 ± 0.48 
NCC4 29.99 ± 0.81* 
NCC5 28.43 ± 1.60 
A B 
 224 
 
4 Discussion 
Previous chapters in this thesis have demonstrated that within the necrotic core of 
MCTS, there are cells that retain viability and these can form new cell lines when 
returned to favourable growth conditions. Furthermore, these cells can also show 
increased motility and have gone through the EMT leading to the possibility that these 
cells could be more aggressive when they re-grow upon their return to favourable 
conditions. This chapter has focused on whether the cell lines derived from the necrotic 
core have differential response to chemotherapeutic agents that are typically used to 
treat colorectal cancer.  
Drugs used to treat cancer which are targeted against actively proliferating cells will 
target cells in the viable rim (of MCTS) and tumour areas closest to blood vessels. 
Necrotic areas by the virtue of their proliferation status are not affected.5 This was not 
considered to be an issue when they were believed to only contain dead cells. However 
now it seems that some cells can survive in this hostile environment and retain 
permanent changes this may present a problem.  
When looking at the chemosensitivity of the clones, two of the five were seen to react to 
all three chemotherapeutics in a similar manner to the parental cell line. However one of 
the clones, NCC1, showed a significantly decreased sensitivity in response to both 
doxorubicin and 5-floururacil (5-FU). Whilst NCC3 was also significantly more 
resistant to 5-FU, NCC4 was found to be more sensitive to doxorubicin (Table 4). As 
both doxorubicin and 5-FU target actively proliferating cells,6 the proliferation rates of 
the clones were examined alongside their response to the drugs in order to determine 
whether rate of proliferation correlated with chemoresistance. NCC1 and NCC4 had 
significantly decreased rates of proliferation compared with the parental cell line, 
though only NCC1 was found to have increased resistance to the any of the drugs 
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tested. Whilst NCC3 did not have significantly altered rate of proliferation compared 
the parental cell line. From the small number of clones it is difficult to confidently 
suggest that the rate of cellular proliferation is linked to the cells' sensitivity to the anti 
proliferative drugs. Though it does seem to be a difference that all the necrotic core 
clone cell lines share, as all 5 of the clones exhibit slower doubling times than the 
parental cell line. A slower metabolic/proliferative rate may be a protective mechanism 
for the cell, there is much information published in the literature regarding the resistance 
mechanisms for 5-FU and doxorubicin which supports this hypothesis. Slow cycling 
cancer cells were found to be more resistant to 5-FU in colon carcinoma patients.7 
Cellular proliferation rates in tumours have been linked to clinical response in breast 
cancer patients.8 More specifically expression of cell cycle related genes, especially 
genes involved in G1 to S phase transition were found to be attenuated in 5-FU resistant 
colorectal and breast cancer cells. The resistant cells were characterised as slower 
growing with a higher proportion of the cells in GO/G1 and lower proportion in S-
phase.9 Further supporting evidence found in the literature also linked increased 
doubling time with increased 5-FU resistance in colon cancer cell lines.10 The 
mechanism behind this is believed to be explained by attenuated cell cycling resulting in 
a slower incorporation 5-FU into the cell's DNA thereby giving the cell longer to repair 
to misincorporated nucelotides.11Similar results have been described in response to 
doxorubicin where fast growing breast cancer cells were shown to be more sensitive 
than slower growing cell lines,12 and within cell lines slower growing, stem cell marker 
positive cells were also found to be more resistant than their faster growing stem cell 
marker negative counterparts.13 
Both 5-FU, an anti-metabolite and doxorubicin, a DNA intercalator14, have both been 
found previously to be less effective on cancer stem cells. In the case of 5-FU this 
 226 
 
resistance was found to involve Wnt signalling, in CD133+ DLD-1 colorectal cancer 
stem cells. 5-FU was found to cause an increase in Wnt signalling, whereas in normal 
DLD-1 cells, caused a decrease in Wnt signalling. Furthermore the resistance seen in 
the CD133+ cells was reduced by the inhibition of Wnt signalling.15 Increased 
chemoresistance is a characteristic of cancer stem cells, as described in Chapter 2 there 
is evidence to suggest that the clones may have stem like characteristics. Doxorubicin, 
which also inhibits the activity of topoisomerase II,16, 17 has also been linked to 
increased Wnt signalling and over expression of multidrug resistance  transporters, both 
of which are characteristics of cancer stem cells.18 Together doxorubicin and 5-FU have 
been used in research to help select for cancer stem cells by taking advantage of the 
stem cells increased resistance to both drugs.19Chemoresistance of cancer stem cells has 
been given as the reason for tumour recurrence.20 In fact by treating the tumour with an 
agent to which cancer stem cells are resistant or less sensitive than the rest of the tumour 
population could act to enrich the cancer stem cell population within this tumour and 
therefore leads to recurrence this time of an even more chemoresistant tumour.21 If 
indeed cancer stem cells are able to survive within harsh microenvironments and avoid 
chemotoxicity then new targets must be found in order to eliminate them. 
The final conclusion is that whilst some cell lines derived from the necrotic core have a 
similar chemosensitivity profile to parental lines, others have a more resistant 
phenotype that could have significant therapeutic implications. Not only may these cells 
go on to form secondary tumours but due to the conditions within the necrotic core this 
may contribute towards the evolution of a resistant population of cells. Whether they 
acquire this increased resistance through mutations gained within the necrotic core or 
whether the necrotic core selects for them, the end result is a cell which is harder to kill 
with conventional chemotherapy. Furthermore resistance to the two drugs 5-FU and 
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doxorubicin is commonly found in stem cells, lending further weight to the argument 
that the living cells found in the necrotic core of MCTS could be stem-like cells. 
Therefore by targeting stem cell resistance mechanisms it may be possible to target 
these cells. This discovery could help explain why high levels of tumour necrosis have 
been linked to increased tumour aggression. The evolution of an increasingly resistant 
sub population within areas of necrotic tissue is a hypothesis that could explain this. 
While it might seem counterintuitive, there have been many scenarios put forward to 
explain the relationship between necrosis and tumour aggression. For instance highly 
angiogenic tumours are seen to have higher levels of necrosis and this is due to areas of 
the highly proliferating tumour constantly outgrowing the angiogenic capacity of the 
tumour’s vasculature leading to necrosis. However while there are theories explaining 
the relationship between necrosis and aggression none have yet been confirmed. By 
looking closely at the necrotic core in MCTS and necrotic core clones it may be 
possible to determine a mechanism for this phenomenon. Though what is certain from 
the piece of research is that the Necrotic Core Clones have therapeutic significance 
which could lead to therapeutic implications for the necrotic core. 
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Chapter 4: Proteomic analysis of the Necrotic Core Clones 
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1 Introduction 
Whilst the Human Genome Project was completed in 2003, the Human Proteome 
Project only began in 2010.1 Genomic investigations in cancer provide huge volumes of 
information which have lead to many new targets for cancer research. Proteomics 
however can be argued as being a better tool to understand disease as it looks at the 
functional unit of the cells. While a genetic change may not lead to any change in 
function, a proteomic change will often make a functional difference at the cellular 
level.2  Investigations into the proteomic profile of cancer cells began over five decades 
with the discovery of patterns of globulin expression using the newly developed starch 
gel electrophoresis technology. 3 Since then the development of new technologies have 
allowed the quantitative analysis of large numbers of proteins within cells. Progress thus 
far has included the characterisation of multiple types of cancer from tissues, cells and 
serum with the goal of elucidating signalling pathways and the aberrant expression. 
In the previous three chapters it has been demonstrated that the cells cloned from the 
necrotic core of MCTS are different from the parental cell line and hence may have 
biological and therapeutic implications. Therefore it is important to develop therapeutic 
strategies to target these cells. As a first step in the process this chapter examines the 
proteome of the cells derived from the necrotic core with the aim to identifying any 
potential targets for drug development.  
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2 Methods 
2.1 Overview 
To examine the proteome of the NCCs in comparison to the parental cell line, protein 
was extracted from the relevant cell pellets and concentrated before being digested with 
trypsin and labelled with iTRAQ labels. Once the individual samples were labelled they 
were combined into one sample and separated into 11 elutions using strong cation 
exchange. The eluate where then applied to the Reverse Phase Nano HPLC to separate 
them further onto MALDI plates. Following this MALDI TOF/TOF analysis was 
performed on the mass spectrometer, before the data was transferred to ProteinScape 3.0 
for protein identification and further analysed using Gene Ontology software (Figure 1).   
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Figure 1. Workflow diagram to highlight the key steps in the proteomic experiment 
(modified from WARP-LC user manual, Version 1.2 2008) 
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2.2 Cell Lysis 
Monolayers grown to 80% confluence were harvested via mechanical scrapping, 
washed 3 x with PBS before being pelleted by centrifugation (1000rpm, 5 minutes) and 
stored at -80oC. Pelleted cells were thawed on ice and then re-suspended in 2x pellet 
volume of protein extraction buffer (7M urea, 2M thiourea, 4% CHAPS (3- ((3-
cholamidopropyl)dimethylammonio)-1-propanesulfonic acid), 0.1% w/v SDS, 0.05% 
w/v sodium deoxycholate in PBS). Cells were then homogenised by sonication using 6 
cycles, repeated 3 times and incubated on ice for 30 seconds between cycles. The 
sample was then centrifuged at 13,000rpm for 15 minutes at 4oC after which the liquid 
phase was collected and stored at -20oC. The Bradford assay was performed as 
described previously (Chapter 2, section 2.3.5) to measure the total protein 
concentration in each sample (see Appendix). 
2.3 Acetone Precipitation 
Once the protein concentration has been determined, 250µg of protein from each sample 
was added to 1ml of chilled acetone, briefly vortexed, centrifuged at 12,000rpm for 1 
minute at room temperature, and incubated at -20oC overnight. Following the overnight 
incubation samples were centrifuged again at 13,000rpm for 20 minutes at 4oC before 
the supernatent was removed and pellets lyophilised at 40oC. Once completed the 
acetone precipitated samples were re-suspended in 8M urea in 400mM ammonium 
bicarbonate and re-analysed with the Bradford assay to determine how much protein 
had been lost through acetone precipitation.  
2.4 Protein Digestion 
Dithiothreitol (1µl of 50mM) was added to the re-suspended samples (80µg of protein) 
before vortexing and centrifuging. The samples were incubated in a water bath at 60oC 
for 15 minutes and then allowed to cool on ice for 5 minutes. Iodoacetamide (1µl of 
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100mM) was added before another brief vortex and centrifugation. The samples were 
then incubated in the dark at room temperature for 20 minutes before a final addition of 
13µl of trypsin buffer (360mM ammonium bicarbonate, 10% acetonitrile) and 2µl 
trypsin (1mg/ml in trypsin buffer) Samples were left to incubate at 37oC overnight. 
Controls 
Several controls were also included in the experiment. These consisted of the 
following:- 
• Myoglobin and Trypsin- 18µl myoglobin, 2 µl trypsin, 2µl trypsin buffer. 
• Trypsin alone-2 µl trypsin, 20µl trypsin buffer. 
• Myoglobin alone-18µl myoglobin, 4µl trypsin buffer. 
Trypsin was added at the same time to both the controls and the samples. After 
incubating at 37oC for 20 hours an aliquot (0.5µl) of each reaction (sample and controls) 
was diluted 1 in 10 (in 10% acetonitrile), and analysed by manual MALDI MS (see 
section Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry). 
2.5 Manual MALDI MS sample preparation 
To determine whether trypsin digestion had been successful, samples were analysed 
manually on the Mass Spectrometer (MALDI-TOF/TOF UltraFlex II mass 
spectrometer, Bruker Daltonics, Bremen, Germany). The plate was first primed with 
matrix on each spot, followed by addition of 0.5µl of sample then 0.5 µl of matrix was 
added. Once the plate was dry it was analysed on the mass spectrometer. 
2.6 Desalting the Samples 
The samples were desalted on a C18 bond elution column (Kinesis Ltd, UK) using the 
following protocol. Methanol (1 ml) was first pushed through the column with a 10ml 
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syringe, followed by 2x1ml of Buffer A (2% acetonitrile, 0.05% trifluoroacetic acid) 
and then the sample. After this another 2x 1ml of Buffer A was used to remove non-
bound buffer components. Finally the sample was eluted using 1x 1ml of Buffer B (80% 
acetonitrile, 0.05% trifluoroacetic acid). The samples were then vortexed and 
centrifuged (1000rpm, 1 minute) before lyophilization for 1hr at ~48oC. Subsequently, 
the samples were re-suspended in 10µl of TEAB (triethylammonium bicarbonate with 
0.1% SDS) 
2.7 4-plex iTRAQ Labelling 
The samples were labelled with iTRAQ labels for relative protein quantification. The 
labels are a set of 4 isobaric reagents which enables the multiplexing of up to 4 different 
samples within one LC/MS/MS run. The iTRAQ labels consists of 3 parts, a reporter 
group, a balance group and a peptide reactive group (Figure 2).  
 
Figure 2. Structure of the iTRAQ reagents.4 
Once the 4 iTRAQ labels (Applied Biosystems, ThermoFisherScientific, Leicestershire, 
UK) had defrosted, 40µl of ethanol was added to each tube and the contents of each 
added to the corresponding sample. 
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HT-29 (control) - iTRAQ 114 
Necrotic Core Clone 1 - iTRAQ 115 
Necrotic Core Clone 4 - iTRAQ 116 
Necrotic Core Clone 5 - iTRAQ 117 
A further 10µl of ethanol was added to each iTRAQ tube before vortexing, 
centrifugation and transfer to the appropriate samples. This was to ensure no reagent 
was lost. The pH was then tested to ensure it fell between pH7-10. The labelled samples 
were then incubated at room temperature for 2 hours before testing the pH again. If it 
had fallen outside the desired range it was adjusted with 1M TEAB. HPLC water (50µl) 
was then added to each labelled sample before combining all samples in one tube. 
Again to ensure no sample was lost, 25µl of HPLC water was added to each empty tube, 
vortexed, centrifuged (1000rpm, 1 minute) and then transferred to the combined 
samples. The combined sample was then lyophilised at ~50oC (aqueous) and stored at -
20oC. 
2.8 Strong Cation Exchange 
Strong Cation Exchange (SCX) was used to separate the sample into fractions using the 
following protocol. The Isolute SCX column (Kinesis Ltd, UK) was washed by adding 
1ml HPLC water, then 2x 1ml of cation exchange loading buffer (25% acetonitrile 
10mM KH2PO4 in 25% acetonitrile, 0.01% sodium azide adjusted to pH 3.0 with HCl) 
was added and pushed through using a syringe. The sample was re-suspended in 600µl 
of cation exchange loading buffer and the pH measured and adjusted to pH 2.5-3.0 with 
10% TFA (trifluoroacetic acid). Then the sample was added to the column and allowed 
to flow through using hydrostatic pressure. 
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The flow through was collected in an Eppendorf tube. The sample tube was washed 
with cation exchange buffer to minimise sample loss, the wash solution added to the 
column and flow through collected in the same Eppendorf tube. This first fraction was 
referred to as Flow Through 1 (FT1). Another 1ml of cation exchange loading buffer 
was added to the column and the flow through collected in a separate Eppendorf tube 
(FT2). To elute the peptides a range of elution buffers (cation exchange buffer + KCl) 
of differing potassium chloride concentrations were used to collect 11 separate fractions 
designated E01-11 as illustrated in Table 1 below: 
Table 1. Potassium Chloride concentrations of the elution buffers and their corresponding 
elutions.  
Eluate 
Fraction 
Number 
Potassium Chloride 
Concentration 
(mM) 
E01 30 
E02 60 
E03 90 
E04 120 
E05 150 
E06 180 
E07 240 
E08 300 
E09 500 
E10 700 
E11 1000 
To elute the different fractions, 500µl of the corresponding elution buffer was added to 
the column, allowed to pass through via hydrostatic pressure and the eluate collected. 
To each collected fraction 1.5ml of C18 bond elution Buffer A was added to dilute the 
acetonitrile in the fractions before each fraction was again desalted on C18 cartridges 
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using the previously described method (section 2.6). All desalted fractions were then 
lyophilised and stored at -20oC.  
2.9 Reverse Phase Nano HPLC  
Each fraction (E1-11) was re-suspended in 13µl of 10% acetonitrile and vortexed for 15 
seconds, 12µl transferred to an LC vial and 5µl of this applied for LC-MALDI on an LC 
Packings Ultimate 3000 capillary HPLC system (Dionex, Camberley, Surrey, UK). The 
residual sample in the vial was then recovered and added to the 1µl of left over fraction, 
lyophilised and stored at -20oC for future analyses. The sample was injected into the 
system using a 1µl sample loop and washed onto a C18 300µm x5mm, 5µm diameter, 
100 Å Pep-Map column (LC Packings, Sunnyvale, CA, USA) using carrier solvent 
(0.05% TFA), before being transferred to a C18, 75m x15cm, 3µm 100 Å PepMap 
Column (LC Packings) equilibrated with 2% CH3CN with 0.05% TFA (mobile phase 
A). Peptides were eluted over 105 minutes by modifying the mobile phase A to 
incorporate an increasing percentage (10-40%) of mobile phase B (80% acetonitrile, 
0.05% TFA). The linear elution gradient produced 384 fractions of peptides (75nl each) 
which were collected, via a Proteineer FC Collector (Bruker Daltonics, Bremen, 
Germany), onto a MTP AnchorChip 800/384 target plate (Bruker Daltonics). Fractions 
were co-deposited with 1.2µl of a saturated solution of CHCA Matrix (α-cyano-4-
hydroxy cinnamic acid, Sigma Aldrich, St. Louis, MO, USA).  Matrix consists of 
1.056ml 2:1 ethanol:acetone, 120µl CHCA saturated stock solution, 12µl 100mM 
ammonium phosphate and 12µl of 10%TFA. After the LC-MALDI run had finished 
0.4µl of calibrant was hand-pipetted onto the plate between each group of four fractions 
before 1.5µl of matrix was added on top. The calibrant comprises of 5µl Peptide 
Calibration Standard II (Bruker Daltonics) diluted in 70µl 80% acetonitrile. 
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Table 2. List of all peptides comprising the Peptide Calibration Standard II and their 
molecular weights.  
Peptide Molecular Weight (Da) 
Bradykinin fragment 1−7 757.86 
Angiotensin II 1047.19 
Angiotensin I 1297.49 
Substrate P 1348.64 
Bombesin 1620.86 
Renin Substrate Tetradecapeptide porcine 1760.03 
ACTH clip 1−17 2094.43 
ACTH clip 18−39 2466.68 
Somatostatin 28 3149.57 
The plate was then analysed using MALDI mass spectrometry. Each SCX fraction was 
analysed twice on the HPLC creating two MTP Anchorchip target plates to be analysed 
on the mass spectrometer. 
2.10 Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-
MS) 
MALDI MS analysis was carried out using a MALDI-TOF/TOF UltraFlex II mass 
spectrometer (Bruker Daltonics, Bremen, Germany) with a 200Hz smartbeam laser in 
reflectron positive ion mode. MS Data Acquisition was carried out using WarpLC 
software (v1.3) which was fully automated and included data acquisition (Flex Control 
v1.3) and data analysis (Flex Analysis v1.3 Snap peak detection algorithms). Initially 
MS analysis was performed which involved the accumulation of 500 shots in 100 shot 
steps within a 700-4200 Da mass range (minimum signal to noise of 7) to create a non 
redundant list of peptides for MS/MS analysis. External calibration was carried out 
during MS analysis once for every 4 spots on the plate. Once a non-redundant list of 
peptides had been created each individual peptide was subjected to MS/MS analysis 
241 
 
using LIFT mode (Flex Control v1.3) to acquire 1500 laser shots per spectrum. The 
fragment mass lists (Flex Analysis v1.3 using TopHat baseline subtraction and 
Savitzky-Golay smoothing) were compiled into a batch file before transfer to 
ProteinScape for database searching.  
2.11 Protein Identification 
Proteins were identified in ProteinScape v3.0 (Bruker Daltonics) using Mascot v2.4 
(Matrix Science, UK) software, the MS/MS data was automatically compared against 
the 2013_02 SwissProt human protein database  containing 20278 sequences (using the 
Bruker Biotools interface (v3.2 SR4). The Mascot search parameters included were 
trypsin digestion, two missed cleavage, no fixed modifications, fixed modifications of 
the carbamidomethylated cysteines, methionine oxidation and iTRAQ labelling on 
lysines and N-termini and possible iTRAQ side ractions. Peptide mass tolerance  was 
set at 100ppm (parts per million) with a MS/MS tolerance of +/- 0.7 Da. A 95% 
confidence interval was included (p<0.05, Mascot score ≥28.0) for the purpose of 
searching the MS/MS data against SwissProt.   
2.12 Data Analysis 
ProteinScape was used to combine all 22 (11 fractions analysed in duplicate) LC-
MALDI runs to create a single non-redundant protein list. The protein list was filtered 
manually to include only proteins identified by more than two first ranked unique 
peptides, at least one of which has a Mascot Score ≥28.0. All peptides not ranked first 
were removed from the list, all 1st ranked proteins regardless of Mascot score were 
included to provide additional iTRAQ values for quantitative analysis. In order to 
compare protein expression between the different groups, iTRAQ reporter ion ratios 
were determined for each protein NCC1/HT-29 = 115/114, NCC4/HT-29 = 116/114, 
NCC5/HT-29 = 117/114. For each group the mean ratio was determined and used to 
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normalise the data set by dividing each individual ratio by the mean to compensate for 
experimental variation in the preparation, trypsin digestion and iTRAQ labelling of the 
protein extracts. The standard deviations for each normalised group were then 
calculated and used to determine significance of the ratios (Table 3). 
Table 3. Calculated Standard Deviations and subsequent Significance Ranges for iTRAQ 
reporter ion ratios for the three Necrotic Core Clones compared to the Parental Cell Line. 
The range of significant ratios includes values which are more than or equal to 1 standard 
deviation greater than 1, and equal to or less than the reciprocal of this first value. The lower 
range is derived from the reciprocal of the upper level of significance. 
Ratio Standard Deviation Range of Significance 
115/114 0.163 1.163≥x≤ 1/1.163 (0.860) 
116/114 0.123 1.123≥x≤1/1.123 (0.890) 
117/114 0.114 1.114≥x≤1/1.114 (0.898) 
A ratio was deemed significant if they were greater or lesser than one standard deviation 
from the mean. The significant proteins were then transferred to Ingenuity Pathway 
Analysis (Ingenuity Systems, CA, USA) software for gene ontology analysis. 
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3 Results 
3.1 Acetone Precipitation 
Preliminary proteomic analysis using 8-plex iTRAQ yielded a low number of proteins 
(results not included) due limited quantities of sample and protein loss within the 
experimental procedure. The procedure was modified by (a) using 4-plex iTRAQ with 
fewer samples, (b) measuring the protein amount before and after acetone precipitation, 
(c) using a larger amount of starting material (250µg) to allow for protein loss during 
acetone precipitation 
After the first Bradford assay 250µg of protein for each sample was acetone 
precipitated. Following this the Bradford Assay was repeated and a large percentage of 
the proteins were lost. The % yield ranged from 37.2% to 53.6% (Table 4).  
Table 4. Amount of protein was measured in all four samples before and after acetone 
precipitation to determine the efficiency (yield) of the protein precipitation procedure. 
Sample Amount of protein pre 
acetone precipitation (µg) 
Amount of protein post 
acetone precipitation (µg) 
Yield 
(%) 
HT29 250 103 41.2 
NCC1 250 93 37.2 
NCC4 250 116 53.6 
NCC5 250 115 53.1 
3.2 Trypsin Digestion 
MS results from the 4 samples (HT-29, NCC1, NCC4, NCC5) show that trypsin 
digestion has taken place successfully and that the samples were ITRAQ labelled 
(Figure 3). In each sample, a complex mixture of signals was observed between m/z= 
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760 and 3522. Each was dominated by a strong signal at m/z= 1229.8 which was 
subsequently identified as the nondenaturing zwitterionic detergent CHAPS. 
 
Figure 3. MS spectra of the individual trypsin digested protein extracts from HT29 parent 
cell line and clones NCC1, NCC4 and NCC5. The presence of multiple peaks demonstrates 
that effective trypsin digestion occurred in each of the 4 samples.  
3.3 ITRAQ Labelled Proteins 
Once the proteins from each of the four samples were labelled, the four samples were 
combined and the combined sample fractionated into 12 fractions (named elution (E)1-
11, based on the order they were eluted from the column and FT1 collected from the 
flow through from the column) using strong cation exchange before each fraction 
underwent LC-MALDI. Each fraction was analysed twice and the results combined. 
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Table 5 shows the number of compounds found in each sample and the number of 
proteins these relate to for both LC-MALDI runs of each fraction.  
Table 5. LC-MALDI results for each fraction separated by strong cation exchange. Each 
fraction was run twice and the results combined in Proteinscape. 
 1st Run 2nd Run 
Fraction Compounds 
for MS/MS 
Background 
Compounds 
Proteins Compounds 
for MS/MS 
Background 
Compounds 
Proteins 
E1 3019 430 786 4337 61 974 
E2 4492 424 1178 6856 174 3295 
E3 4724 207 1634 6471 318 1796 
E4 5935 360 1998 6856 174 3295 
E5 6258 331 1783 6977 78 3655 
E6 5902 224 1746 8591 95 3885 
E7 6066 30 1544 8034 87 3490 
E8 6836 48 1804 7284 66 3219 
E9 6767 40 1621 6669 167 1412 
E10 6477 28 1330 7084 29 1390 
E11 6419 11 1023 3652 0 597 
FT1 2380 14 438 1694 59 320 
The results of all LC MALDI data were combined to give a non-redundant list of 1432 
proteins. Each protein was identified by at least 2 peptides one of which had a mascot 
score of >28.0. To identify any differences in expression of protein between the 
different samples, the ratios of the iTRAQ reporter ions were established for each 
protein.(HT29/NCC1, HT-29/NCC4 and HT-29/NCC5). Mean ratios were calculated 
for each of the three comparisons, and data was normalised using the calculated 
average. After normalisation of the results 134 proteins were found to be changed 
significantly in NCC1 compared to the parental cell line, with 61 found to be up-
regulated and 73 down-regulated. In NCC4 222 proteins were found to be changed with 
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101 up-regulated and 121 down-regulated. And in NCC5 264 proteins were found at 
significantly different levels compared to the parental cell lines, of these 117 were found 
at higher levels and 147 were found at lower levels. Of these proteins 49 were found to 
be altered in all three of the clones (Figure 4) of which 21 were up-regulated and 28 
were down-regulated. All proteins calculated to be significantly changed were analysed 
using Ingenuity Pathway Analysis software to look for commonly altered molecular 
pathways and networks. 
 
Figure 4. Venn Diagrams showing the overlap of the proteins found altered in all three 
necrotic core clones analysed in comparison to the parental cell line. Panel A details all the 
up-regulated proteins, panel B represents the down regulated proteins.  
3.4 Necrotic Core Clone Analysis 
The changed proteins in each of the individual clones was analysed in order to link any 
proteomic changes with the different functional capabilities the different clones possess. 
Following this the changed proteins common to all three clones were analysed in order 
to look for common mechanisms of cell survival, chemoresistance, metastasis and 
metabolism. 
B A 
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3.4.1 Necrotic Core Clone 1 
As expected cancer was the top disease associated with the proteins found to be changed 
in NCC1 compared to the parental cell line with p-values ranging from 0.00000355 to 
0.0157 for all different cancer types included. The top molecular functions found to be 
associated with the significant proteins included the following:- 
1. Cellular Movement (p-value 0.00000835 - 0.0145) 29 proteins  
2. Cell Death and Survival (p-value 0.00000933 - 0.0148) 46 proteins 
3. Cell-To-Cell Signalling and Interaction (p-value 0.0000309E-05 - 0.0146) 14 proteins 
4. Cellular Development (p-value 0.0000465E-05 - 0.0146) 30 proteins 
5. Cellular Growth and Proliferation (p-value 0.0000659E-05 - 0.0137) 46 proteins 
Using Ingenuity Pathway Analysis (IPA) nine networks were found to be significantly 
altered in Necrotic Core Clone 1 compared to HT-29 parental cells (Table 6).  
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Table 6. Networks found to be altered in Necrotic Core Clone 1 compared to the parental cell line. Number of molecules within the network found to be 
altered in the clone are shown, those in bold with either a green downwards arrow representing decreased expression, or a red upwards arrow representing 
increased expression. For each network a number of diseases and functions associated with the pathway are listed. 
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Of the nine networks found to be changed network 5 and 6 were found to interact 
(Figure 5). These were the pathways involved in drug metabolism and DNA repair and 
replication and involved the up regulation of various proteins known to be involved in 
chemoresistance such as sulfhydryl oxidase 2 (QSOX2), glutathione s-transferase 
(GST) and putative oxidoreductase (GLYR1). 
 
Figure 5. Diagram showing the interaction between Network 5 (Drug Metabolism, 
Developmental Disorder, Gastrointestinal Disease) and Network 6 (RNA Damage and 
Repair, DNA Replication, Recombination, and Repair, Nucleic Acid Recombination). 
Green shapes indicate proteins that are down-regulated, red shapes indicate proteins which are 
up-regulated. Pink lines indicate the point at which the two networks connect. For a key to what 
the different shapes represent refer to the appendix (Figure 4). 
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3.4.2 Necrotic Core Clone 4 
As seen with NCC1, cancer was found to be one of the top diseases associated with the 
proteins found altered in NCC4 with a p-value between 0.000358 and 0.0219. Also 
similar to clone NCC1 the top molecular and cellular functions found to be altered 
included one of the same functions, cell death and survival. A summary of the cellular 
functions that may be altered as a result of differential protein expression are listed 
below. 
1. RNA Post-Transcriptional Modification (p-value 0.000000000117 - 0.00866) 16 
proteins 
2. Cell Death and Survival (p-value 0.0000168 - 0.0219) 70 proteins 
3. Free Radical Scavenging (p-value 0.0000502 - 0.0130) 18 proteins 
4. Amino Acid Metabolism (p-value 0.000107 - 0.0219) 7 proteins 
5. Cellular Growth and Proliferation (p-value 0.000107 - 0.0219) 63 proteins 
Twelve networks were found to be altered in NCC4 (Table 7), within this group a theme 
was found. Several networks involved altered metabolism, including lipid metabolism 
and amino acid metabolism.  Specific proteins involved in these networks, which were 
found at differing levels in NCC4 included SPINK1 also known as Tumour-associated 
Trypsin Inhibitor. This protein also found to be up-regulated in NCC1, is associated 
with increased invasion in multiple cancer types. 
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Table 7. Networks found to be altered in Necrotic Core Clone 4. Number of molecules within the network found to be altered in the clone are shown, 
those in bold with either a green downwards arrow representing decreased expression, or a red upwards arrow representing increased expression. For each 
network a number of diseases and functions associated with the pathway are listed.  
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3.4.3 Necrotic Core Clone 5 
As with the previous two clones, cancer was seen as a top disease associated with the 
changed proteins in NCC5, with a p-value of 0.000263E-04 - 0.0264. The top molecular 
and cellular functions shown to be altered in NCC5 showed commonality with the other 
two clones in that it included Cell Death and Survival. Cellular movement was also 
found to be altered in this clone, something that could be related to increased migration 
seen in the NCC5 wound healing assay results. In particular proteins such as Basal- cell 
adhesion molecule (B-CAM) and Aldehyde Dehydrogenase 1A1 (ALDH1A1) were 
found to be up-regulated in not only NCC5 but also NCC4, whilst no significant 
difference in levels were seen in the least migratory clone NCC1.  
RNA Post-Transcriptional Modification (p-value 0.00000569 - 0.00259) 15 proteins 
Cellular Growth and Proliferation (p-value 0.00000598 - 0.0264) 91 proteins 
Protein Synthesis (p-value 0.0000142 - 0.0144) 35 proteins 
Cell Death and Survival (p-value 0.0000478 - 0.0264) 85 proteins 
Cellular Movement (p-value 0.000110 - 0.0220) 36 proteins 
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Table 8. Networks found to be altered in Necrotic Core Clone 5. Number of molecules within the network found to be altered in the clone are shown, 
those in bold with either a green downwards arrow representing decreased expression, or a red upwards arrow representing increased expression. For each 
network a number of diseases and functions associated with the pathway are listed. 
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Table 8 Continued.  
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3.5 Common Analysis 
There were many similarities between the analyses of the three clones. All three had 
alterations in cellular growth and proliferation, which correlated with growth 
characteristics observed when clones were grown in culture (Chapter 1, Figure 20). A 
large number of proteins found altered in all of the clones were found to be related to 
cell death and survival (Table 9). In total 49 proteins were found to be changed in all 
three clones (21 up-regulated and 28 down regulated see Figure 4) and these proteins 
were analysed using ingenuity pathways analysis software to determine the top cellular 
and molecular functions associated with the proteins: 
Cell Death and Survival (p-value 0.0000376 - 0.0471) 22 proteins 
Cellular Compromise (p-value 0.000440 - 0.0387) 8 proteins 
Cellular Assembly and Organization (p-value 0.000872 - 0.0492) 11 proteins 
Cellular Movement (p-value 0.000995 - 0.0456) 11 proteins 
Lipid Metabolism (p-value 0.00109 - 0.0492) 9 proteins 
The top function that all three clones had in common was cell death and survival 
(involving 22 out of the 49 proteins). There were 4 networks found to be altered in all 3 
clones, the individual proteins involved and their exact effort (positive or negative) on 
the described function while be expanded upon subsequently. 
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Figure 6. Top network identified by IPA analysis. Network 1: Cell Death and Survival, 
Renal Damage, Renal Tubule Injury. Solid arrows represent known interactions, dotted 
arrows represent indirect interactions. Red shapes are proteins seen at increased levels, green 
shapes are proteins found at decreased levels compared to the parental cell line. For a key to 
what the different shapes represent refer to the appendix (Figure 4). 
Figure 6 shown above presents the cell death and survival network which was found to 
be altered in all three of the clones. In order to understand whether the network was 
altered in a beneficial way which may help explain the survival of the clones within the 
necrotic core the individual proteins within the network were investigated for relevance. 
TGM2 (Tissue Transglutaminase 2) was found to be increased in the clones, this protein 
has previously been shown to be elevated in CD44 cells and the inhibition of which 
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increased cell death in glioma patient derived tissues.5 Also involved in the cell death 
and survival pathway was Cathepsin B (CTSB) a thiol protease, up-regulated in all three 
clones. Cathepsin B has been linked to poor prognosis and increased metastatic and 
invasive phenotype in human tumours. Metastasis associated protein 2 (MTA2) was 
also found at increased levels in all three clones. Increased expression of this protein is 
associated with invasion and metastasis in gastric cancer.6 Sequestosome-1 (SQSTM1) 
also known as p62 is involved in autophagy, but was found to be down regulated in all 
three clones. 
 
Figure 7. Network 2: RNA Damage and Repair, Hereditary Disorder, Cell Cycle. Solid 
arrows represent known interactions, dotted arrows represent indirect interactions. Red shapes 
are proteins seen at increased levels, green shapes are proteins found at decreased levels 
compared to the parental cell line. For a key to what the different shapes represent refer to the 
appendix (Figure 4). 
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The Cell cycle pathway was also found to be altered (Figure 7), with a total of 13 
proteins found to be up- or down-regulated. Quiescin sulfhydryl oxidase 2 (QSOX2) an 
enzyme involved in the oxidation of sulfhydryl groups, was seen at higher levels in all 
three clones compared to the parental cell line. Glyoxylate reductase 1 (GLYR1) was 
also found to be up regulated in this pathway and is known to be involved in regulating 
p38 MAP kinase a key protein involved in the regulation of the cell cycle in response to 
stress.7 
 
Figure 8. Network 3: Lipid Metabolism, Molecular Transport, Small Molecule 
Biochemistry. Solid arrows represent known interactions, dotted arrows represent indirect 
interactions. Red shapes are proteins seen at increased levels, green shapes are proteins found at 
decreased levels compared to the parental cell line. For a key to what the different shapes 
represent refer to the appendix (Figure 4). 
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The network involved in lipid metabolism and small molecule biochemistry was also 
found to be altered in all three clones (Figure 8). Proteins involved in a variety of 
different metabolism related processes were shown to be altered. These included up-
regulation of Palmitoyl-protein thioesterase 1 (PPT1) involved in lysosomal degradation 
and Alanine aminotransferease (ALAT2) also known as glutamic pyruvate transaminase 
a protein involved in glutaminolysis.8 
 
Figure 9. Network 4: Cellular Assembly and Organization, Cellular Compromise, Drug 
Metabolism . Solid arrows represent known interactions, dotted arrows represent indirect 
interactions. Red shapes are proteins seen at increased levels, green shapes are proteins found at 
decreased levels compared to the parental cell line. For a key to what the different shapes 
represent refer to the appendix (Figure 4). 
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In the Cellular Assembly and Organisation, Cellular Compromise and Drug Metabolism 
pathway shown in Figure 9 a number of proteins were also found to be altered. 
DNAJC15 also known as MCJ (methylation-controlled J protein) resides on the inner 
mitochondrial membrane and is involved in negatively regulating mitochondrial 
membrane potential and the production of ATP. 9  
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Table 9 List of all up- or down-regulated proteins found common to all 3 clones. Green 
ratios represent the cases where the protein was found at increased levels in the clones 
compared to the parental cell line, and red represents the cases where the clones' expression was 
decreased compared to the parental cell line. 
Acces
sion 
Protein MW Scor
e 
# 
Pept
ides 
Ratio 
NC1/HT
-29 
Ratio 
NC4/HT
-29 
Ratio 
NC5/HT
-29 
Cell Death and Survival 
STRN
4 
Striatin-4 80.5 88 2 0.400 0.830 0.633 
MRP MARCKS-related protein 19.5 87 1 0.416 0.820 0.568 
RPB2 DNA-directed RNA 
polymerase II subunit 
RPB2 
133.
8 
234 4 0.714 0.773 0.680 
S10A
A 
Protein S100-A10 11.2 109 2 0.745 0.868 0.829 
DD19
A 
ATP-dependent RNA 
helicase DDX19A 
53.9 81 2 0.761 0.859 0.587 
MAP4 Microtubule-associated 
protein 4 
120.
9 
153 5 0.831 0.820 0.829 
SQST
M 
Sequestosome-1 47.7 336 6 0.831 0.878 0.838 
ZYX Zyxin 61.2 305 7 0.831 0.878 0.875 
POP7 Ribonuclease P protein 
subunit p20 
15.6 66 1 0.847 0.859 0.773 
MUC
5A 
Mucin-5AC (Fragments) 526.
3 
150 5 0.847 0.754 0.838 
ALBU Serum albumin 69.3 102 3 0.855 0.735 0.810 
SERC Phosphoserine 
aminotransferase 
40.4 147 3 1.458 1.202 1.210 
HSPB
1 
Heat shock protein beta-1 22.8 361 6 1.396 1.269 1.322 
CATB Cathepsin B 37.8 45 2 1.396 2.719 2.104 
RABP
2 
Cellular retinoic acid-
binding protein 2 
15.7 588 11 1.309 1.212 1.155 
SPB5 Serpin B5 OS=Homo 
sapiens GN=SERPINB5 
PE=1 SV=2 
42.1 113 3 1.255 1.164 1.304 
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PSD1
3 
26S proteasome non-
ATPase regulatory subunit 
13 
42.9 85 2 1.278 1.154 1.155 
MTA2 Metastasis-associated 
protein MTA2 
75 196 5 1.231 1.126 1.145 
TGM2 Protein-glutamine gamma-
glutamyltransferase 2 
77.3 563 15 1.215 1.231 1.182 
SNCG Gamma-synuclein 13.3 283 4 1.207 1.231 1.117 
CMC2 Calcium-binding 
mitochondrial carrier 
protein Aralar2 
74.1 313 6 1.192 1.126 1.238 
PLAP Phospholipase A-2-
activating protein 
87.1 82 3 1.184 1.154 1.164 
Cellular Assembly and Organisation, Cellular Compromise and Drug Metabolism 
GPR3
7 
Probable G-protein coupled 
receptor 37 
67.1 145 6 0.196 0.200 0.242 
DHRS
2 
Dehydrogenase/reductase 
SDR family member 2 
27.4 111 1 0.274 0.286 0.810 
TIM5
0 
Mitochondrial import inner 
membrane translocase 
subunit TIM50 
39.6 119 2 0.721 0.782 0.633 
PDE1
2 
2',5'-phosphodiesterase 12 67.3 141 4 0.855 0.849 0.894 
NUB1 NEDD8 ultimate buster 1 70.5 101 1 1.200 1.240 1.276 
DNJC
2 
DnaJ homolog subfamily C 
member 2 
72 231 4 1.184 1.126 1.201 
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 
HTSF
1 
HIV Tat-specific factor 1 85.8 199 5 0.627 0.782 0.698 
RBM8
A 
RNA-binding protein 8A 19.9 73 1 0.690 0.668 0.661 
SNTB
1 
Beta-1-syntrophin 58 117 1 0.776 0.859 0.652 
WFS1 Wolframin 100.
2 
98 1 0.831 0.811 0.838 
ALAT
2/ 
Alanine aminotransferase 2 57.9 216 6 1.356 1.355 1.294 
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GPT2 
PPT1 Palmitoyl-protein 
thioesterase 1 
34.2 175 3 1.168 1.154 1.229 
RNA Damage and Repair, Cell Cycle 
NOL1
1 
Nucleolar protein 11 81.1 82 1 0.165 0.191 0.149 
CL04
5 
Uncharacterized protein 
C12orf45 
20.1 91 1 0.721 0.830 0.894 
ZN42
8 
Zinc finger protein 428 20.5 89 3 0.745 0.716 0.717 
AAM
P 
Angio-associated migratory 
cell protein 
46.7 72 1 0.761 0.868 0.782 
BLVR
B 
Flavin reductase (NADPH) 22.1 126 7 0.761 0.868 0.885 
KRT3
5 
Keratin, type I cuticular 
Ha5 
50.3 174 4 0.815 0.878 0.875 
K1324 UPF0577 protein 
KIAA1324 
111.
3 
113 2 0.823 0.859 0.819 
UTP1
8 
U3 small nucleolar RNA-
associated protein 18 
homolog 
62 94 3 0.847 0.878 0.708 
MPPB Mitochondrial-processing 
peptidase subunit beta 
54.3 200 6 0.847 0.868 0.857 
MTN
D 
1,2-dihydroxy-3-keto-5-
methylthiopentene 
dioxygenase 
21.5 67 1 1.694 1.269 1.313 
RT25 28S ribosomal protein S25, 
mitochondrial 
20.1 29 1 1.349 1.240 1.536 
QSOX
2 
Sulfhydryl oxidase 2 77.5 153 4 1.247 1.231 1.248 
GLYR
1 
Putative oxidoreductase 
GLYR1 
60.5 44 1 1.207 1.145 1.285 
RRMJ
3 
pre-rRNA processing 
protein FTSJ3 
96.5 93 2 1.278 1.297 1.406 
PAP1
M 
Polyadenylate-binding 
protein 1-like 2 
22.8 186 3 1.184 1.154 1.266 
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Further analysis was also performed on the list of changed proteins to look at their 
downstream effects. Two similar processes were found to be activated as a result of the 
changes seen in the proteome of the necrotic core clones (Figure 10). Changes in 
migration was shown to be a downstream effect caused by increased expression of 
Cathepsin B, Heat shock protein beta-1, Protein-glutamine gamma-glutamyltransferase 
2 and Synuclein gamma, and the decreased expression of inhibitory proteins MARCKS 
related protein and Zyxin. Similarly, metastasis was also calculated to be up-regulated 
as a downstream effect of the protein changes seen. This also involved the increased 
expression of Cathepsin B and Synuclein gamma with the addition of Tissue 
Transglutaminase 2. The combination of these results is consistent with the clones 
possessing a more migratory and metastatic phenotype as shown by the wound healing 
assay results presented previously. 
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Figure 10. Diagrams showing the downstream effects of some of the proteins found to be 
common to all three clones. For a key to what the different shapes represent refer to 
supplementary Figure 4. 
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4 Discussion 
The purpose of chapter 4 was to determine whether the characteristics shown by the 
clones that lead to an increase in survival, migratory behaviour and chemoresistance 
(Chapters 1-3) could be explained by changes seen in their proteome. Overall a number 
of proteins known to be related to metabolism, increased invasive phenotype, metastatic 
behaviour, drug resistance, stemness and evasion of cell death were found to be altered 
in all three clones. Showing that these cells, which managed to survive within the 
necrotic core of MCTS, may have done so as a result of their differential proteomic 
profile compared to the parental cell line. By characterising the changes seen in the 
clones new targets for therapeutic intervention could be identified. This discussion aims 
to highlight the key results obtained in the context of target identification. To start with 
however methodological aspects will be discussed as these inform the design of 
subsequent experiments. 
4.1 Experimental Procedures: Acetone Precipitation 
During the preparation of the protein samples it was necessary to precipitate the protein 
using acetone, a commonly used protein concentration technique in iTRAQ proteomics. 
To ensure that enough protein was being precipitated to continue the experiment and 
that the same amounts of protein were carried forward in each sample the protein 
concentration was measured before and after acetone treatment. Over half of the total 
protein in each sample was lost during acetone precipitation (Appendix, Table 4). This 
reduction in protein yield explains the low number of proteins detected in the initial 8-
plex iTRAQ experiment. Because so much protein is lost during the precipitation 
reaction, it was necessary to start the experiment with an increased amount of sample to 
account for the loss. Furthermore the protein losses were not the same in each sample 
therefore it was necessary to measure the protein concentration after acetone 
precipitation to ensure that for each sample the same amount of protein was being 
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labelled. Many methodologies do not call for protein measurements post acetone 
precipitation but to ensure that an equal amount of protein is being labelled from each 
sample the results of this study found that it was in fact necessary. Omission of this step 
would therefore invalidate the quantitative nature of the results. 
4.2 Necrotic Core Clones 
To investigate the proteomic differences seen in the clones compared to the parental cell 
line; the proteome of three of the clones was investigated alongside the parental cell 
line. While a proteomics analysis can produced a large volume of data, many different 
proteins involved in the various process previously investigated such as migration, 
metastasis, chemoresistance, evasion of cell death, and stem cell resistance pathways  
can be identified using gene ontology software. In the previous Chapters, the 
phenotypic changes seen in the clones compared to the parental cell line were described 
and analysed. The clones were originally found to be slower growing (Chapter 1, Figure 
21), have increased migration abilities (Chapter 2, Figure 10), increased 
chemoresistance (Chapter 3, Table 5) and stem-like and EMT characteristics (Chapter 2, 
Figure 8 and Figure 11). Many of these characteristics were found to correlate with the 
proteomic analysis, details of which are discussed in the subsequent sections. 
4.2.1 Stem Cell Markers 
The identification of cancer stem cells is a contentious issue as discussed in the 
Introduction. In order to confidently define a cancer stem cell a combination of different 
markers and assays are required. Several known colorectal stem cell markers were 
found in the necrotic core of HT-29 MTCS, where the clones were derived from 
(Chapter 1, Figure 7). Analysis of stem cell functionality through the sphere formation 
assay found that NCC5 had an increased sphere formation capability Chapter 2, Figure 
8). Proteomic analysis found up regulation of a further colorectal cancer stem cell 
268 
 
marker Aldehyde Dehydrogenase (ALDH1) in Clone 4 and 5. ALDH1 is a cytosolic 
enzyme which oxidises aldehydes to their corresponding carboxylic acids.10 Expression 
of Aldehyde Dehydrogenase has been used extensively to identify colorectal cancer 
stem cells.11,12 ALDH1+ cells have been found in the base of crypt in the colon 
epithelium, and during tumourigenesis these cells have been seen to move up through 
the crypt and increase in number. When implanted into immunocompromised mice, 
they formed a xenograft whereas ALDH1- cells were unable to.13 Long before ALDH1's 
association with stem cells was discovered, ALDH1 was found to be crucial to drug 
resistance capabilities in the case of certain drugs such as cyclophosphamide as the drug 
is a substrate for the cytosolic enzyme.14, 15  Later on it was implicated in the increased 
chemoresistance qualities seen in stem cells.16 
The identification of increased ALDH1 levels in NCC4 and NCC5 further validates the 
data discussed in Chapter 2 regarding the functional stem cell like properties of the 
Necrotic Core Clones. Due to the contention surrounding the identification of stem cells 
discussed previously, different stem cell markers are used for different subtypes of 
cancer, and marker expression is not stable but can change depending on the 
environment the cell is placed in. Therefore combinations of marker expression and 
functional assays such as sphere formation and xenotransplanatation are required.17 
These clones while showing certain marker expression and sphere formation capabilities 
along with the ability to form tumours in vivo certainly have increased stem-like 
capabilities, though further characterisation would be required before the title 'stem cell' 
could be used with confidence. 
4.2.2 Metastasis and Invasion 
All three clones were found to have increased levels of proteins involved in invasion 
and metastasis of cancer cells. SPINK1 a serine protease inhibitor Kazal type 1 is also 
269 
 
known as Tumour-associated Trypsin Inhibitor or Pancreatic Secretory Inhibitor (PSTI) 
since this peptide is secreted together with trypsinogen by pancreatic acinar cells and in 
the gastrointestinal and urinary tract. SPINK1was one of the proteins found to be up 
regulated in NCC4, the most migratory clone (Table 10) and is known to be associated 
with metastasis in cancer cells. In particular it was found in the medium of HT-29 cells 
and was found to increase invasion.18 Increased SPINK1 expression in liver metastasis 
has been reported and this was associated with poor prognosis in colorectal cancer.19 B-
CAM, a glycoprotein which functions as a laminin receptor and is believed to play a 
role in cellular adhesion,20 was discovered to be up regulated in both NCC4 and NCC5 
but not in the least migratory clone, NCC1. This protein has been found to be involved 
in increased migration in epithelial skin cancers.21 Cathepsin B a thiol protease was also 
up-regulated and again this protein is associated with an increased metastatic and 
invasive potential in cancer cells.22 Its expression has been found to be particularly up-
regulated at the invasive edge of tumours.23 Cathepsin B plays a role in enabling the 
degradation of the ECM, through proteolytic cleavage further supporting its role in 
invasion.24 
Metastasis associated protein 2 (MTA2) is part of the metastasis associated family of 
proteins. It is found expressed in solid tumours, where its expression is associated with 
increased stage of cancer and metastasis. Furthermore, knock down of the MTA2 gene 
with shRNA in gastric cancer cells caused an in vitro reduction in migration and 
invasion.25 MTA2 has chromatin remodelling capabilities and is known to be an integral 
part of the histone deacetylase complexes (HDAC).26, 27 The HDAC1-containing 
complex, known as PID, which contains MTA2 is involved in mediating the 
deacetylation of p53. PID specifically interacts with p53, and reduces the levels of the 
acetylated protein thereby repressing p53's transciptional activity.28 MTA2 was found at 
increased levels in all three of the clones. 
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Quiescin sulfhydryl oxidase 2 (QSOX2) is an enzyme involved in the oxidation of 
sulfhydryl groups. QSOX2 is known to be up-regulated under hypoxic conditions and 
its increased expression has been found to correlate with metastatic potential in 
pancreatic cancer.29 Its pro-invasive role has been shown to be mediated through its 
ability to activate MMP-9.30,31 In the clones it's expression was found to be up-regulated 
in all three of the clones.  
In summary there were a number of proteins involved in the migration, metastasis and 
invasion of cancer which were found to be up-regulated in the clones. Further 
investigation into the reliance of the cells upon these proteins could lead to the 
discovery of therapeutic targets for preventing or curbing metastasis.  
4.2.3 Chemoresistance 
The chemoresistance shown by several of the clones discussed in Chapter 3 is a key 
issue to investigate. Once the cells which manage to survive the low nutrient oxygen 
conditions found in necrotic tissue are once again able to access oxygen and nutrients 
and return to a proliferative state any acquired or innate chemoresistant properties could 
have a significant bearing upon the outcome of therapy. By elucidating some of the 
mechanisms involved in the increased chemoresistant phenotype this could lead to 
further targets for chemotherapeutic intervention.  
Two pathways, of particular relevance in NCC1 were drug metabolism and DNA repair. 
These were important findings as NCC1 was found to be the most chemoresistant clone 
(Table 10). Individual proteins found at higher levels included zeta-crystallin a 
NAPDH:quinone oxidoreductase.32 Also increased was Glutathione S-transferase a 
detoxification enzyme involved in the phase two metabolism of many different types of 
drug including Chlorambucil, Melphalan,  Nitrogen mustard,  Phosphoramide mustard,  
Acrolein,  Carmustine,  Hydroxyalkenals,  Ethacrynic acid,  and various steroids.33 
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Importantly Glutathione S- transferase is also thought to be involved in Doxorubicin 
resistance in colorectal cancer.34, 35 When cell lines were transfected to overexpress GST 
their resistance to Doxorubicin was increased.36, 37 This could indeed explain NCC1's 
decreased response to Doxorubicin in the MTT assay described in Chapter 3 (Figure 1).  
QSOX2, an oxidoreductase also implicated in invasion, metastasis and extracellular 
matrix formation, was found up regulated in all three clones.38 It is a protein capable of 
generating disulfide bonds which enables it to oxidise a wide range of thiol compounds.39 It 
has been found to regulate the response of neuroblastoma cells to IFN-gamma radiation.40 
4.2.4 Cell Death and Survival 
DNAJC15 also known as MCJ (methylation-controlled J protein)  is a protein located 
inside the mitochondria. Its function involves negatively regulating mitochondrial 
membrane potential and the production of ATP. This protein was found up regulated in 
all three clones and can function as a protective mechanism for tumour cells particularly 
those under metabolic or chemotherapeutic stress. By down-regulating the activity of 
the mitochondria the cells are more resistant to mitochondria mediated cell death 
(namely apoptosis stimulated by the intrinsic pathway).41, 42, 43 
Other proteins in the cell death and survival pathway that were found to have altered 
expression in the clones include Heat shock protein beta-1 (HSPB1). HSPB1 has many 
functions including thermo tolerance, chaperone abilities, regulation of cell 
differentiation and development and most importantly, inhibition of apoptosis.44, 45 
HSPB1 is also involved in activation of the proteasome and can help increase the 
degradation of damaged proteins and organelles by binding to ubiquitinated proteins. 
Furthermore HSPB1 also functions to activate the NF-κβ pathway which subsequently 
can have effects upon cellular proliferation and inflammation and stress responses.46 It 
is this modulation of the NF-κβ pathway along with HSPB1's ability to modulate 
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reactive oxygen species and increase glutathione levels that is thought to account for its 
cell survival and anti-apoptotic effects. 
4.2.5 Metabolism  
Other pathways which were altered in the clones included pathways involved in 
metabolism and cell survival. As the clones were formed from the cells which managed 
to survive the harsh environment in the necrotic core, it is likely that alterations would 
occur in their metabolism or cell survival pathways which enabled them to survive. The 
metabolism of lipids was found to be changed in all three clones. Up-regulation of 
proteins such as alanine aminotransferase 2 (ALAT2), a protein involved in 
glutaminolysis was seen. ALAT2 is responsible for catalysing the reversible transfer of 
amino groups from L-alanine to α-ketoglutarate, a key substrate for prolyl hydroxylases 
and HIF1α regulation,47, 48 to produce pyruvate and L-glutamate. 49 This protein 
amongst others is found up regulated in a number of different cancers and the inhibition 
of which has been shown to decrease cell survival50 and inhibit cellular proliferation and 
growth.51, 52 Palmitoyl-protein thioesterase 1 (PPT1) is another protein found up-
regulated in the clones which has been found to have protective effects. PPT1 is 
responsible for removal of palmitic acid (a process called depalmitoylation) from 
various signalling proteins known to be deregulated in cancer such as Src- and Ras-
related proteins. The process of depalmitoylation is required before such proteins can 
degraded by lysosomal proteases.53  This protein was found to be important for cell 
survival in cancer cells, it's over expression has been shown to have a protective effect 
for cells against cell death whereas its inhibition has shown to induce apoptosis.54 
4.2.6 Autophagy 
Several proteins known to be involved in autophagy were found to have altered 
expression in the necrotic core clones. These include Cathepsin B, Sequestosome-1 and 
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Tissue tranglutaminase 2. Cathepsin B is a proteolytic enzyme involved in many 
different processes associated with cancer including invasion and metastasis and 
autophagy. Increased expression has been shown to increase the invasive and metastatic 
potential of the cancer cells.55 Cathepsin B is also known to have a role in autophagy, 
the degradation pathway which has been found to be up regulated in the necrotic core of 
MCTS.56 Increased levels of Cathepsin B have been shown to protect cells from cell 
death during times of nutrient deprivation.57 Increased expression of this protein was 
found in all three clones and could go some way towards explaining their survival 
within the necrotic core. 
Sequestosome-1 was found to be down regulated in the clones, this protein also known 
as p62 is involved in many different signalling pathways, including autophagy, 
activation of Nuclear Factor-KB, oxidative signalling,58 the extrinsic apoptosis pathway 
and tumourigenesis.59 Increased tumour autophagy has been shown to decrease protein 
levels of Sequestosome-1 which is an autophagy substrate itself as it acts as a molecular 
adaptor between the autophagic machinery and its substrates for degradation.6061 It is 
also involved in the extrinsic apoptotic pathway through its role in the aggregation of 
caspase-8.62 
Tissue Transglutaminase 2 (TGM2) is another protein which has links to autophagy that 
was found to be up regulated in the clones. TGM2 is a key component in the maturation 
of the autophagolysosome. 63 Increased levels of the proteins have been found in 
numerous different cancer types, and is associated with increased tumour aggression, 
poor prognosis, invasion and metastasis and drug resistance. 64 Its drug resistance 
abilities are thought to be mediated through its modulation of survival pathways, 
apopotosis, ECM formation, EMT and autophagy.65 Recently TGM2 has been found to 
induce EMT and stem like characteristics in epithelial cells.66 This supports much of the 
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proteomic data presented here as many stem cell and migratory related proteins have 
been found to be altered in the clones. 
Table 10. Table of characteristics applying to the Necrotic Core Clones which have been 
measured in vitro. Green indicates up-regulated or increased activity, and red indicates a 
decrease. Characteristics were determined using the following assays: MTT assay, wound 
healing assay, proliferation assay and the sphere formation assay. All changes shown were 
statically significant (p<0.05)  
Clone Chemosensitivity Migration Proliferation Anchorage 
Independent 
Growth 
Necrotic Core 
Clone1 
    
Necrotic Core 
Clone 2 
    
Necrotic Core 
Clone 3 
    
Necrotic Core 
Clone 4 
    
Necrotic Core 
Clone 5 
    
4.3 Conclusion 
The proteomic analysis of the necrotic core clones in comparison to the parental cell 
line has shown that there are obvious differences in the expression of proteins. Many of 
these differentially expressed proteins have roles in a number of different processes 
which were found phenotypically to be altered in the clones. For example the clones, in 
particular NCC4, were found to have increased migratory behaviour and numerous 
different proteins found to be involved in migration, invasion and metastasis and the 
275 
 
EMT were up regulated in the clones compared to the parental cell line. NCC1 was 
found to be more chemoresistant to Doxorubicin and 5-FU in vitro, when the proteome 
of NCC1 was examined it was found that there was up regulation of Glutathione S-
transferase an enzyme that has in fact been linked to Doxorubicin resistance in 
colorectal cancer. Moreover NCC5 was found to have a more stem like phenotype in 
vitro compared to the parental cell line, the proteomic analysis found increased 
expression of Aldehyde dehydrogenase (ALDH1A1) a colorectal stem cell marker in 
NCC5 as well as NCC4.  
By looking at the changed proteins which were common to all three clones, clues as to 
the possible mechanisms by which these cells managed to survive within the necrotic 
core of the HT-29 MCTS can be elucidated. The top molecular function identified by 
the gene ontology software was cell death and survival, and involved 22 out of the 49 
changed proteins. This was expected as the one main difference between the parental 
cell line and the clones is that the clones are capable of escaping cell death under 
conditions which kill the parental cells. Proteins involved in the regulation of the cell 
cycle were also found changed in of the clones; this was not unexpected for two main 
reasons. The proliferation status of the clones was found to be significantly lower than 
the parental cell line when returned to normal culture conditions, a change which 
seemed to be stable in the cells, and when the proliferation status of the MCTS cells in 
situ was examined the living cells within the necrotic core were not found to be actively 
proliferating. 
Metabolism was a further function which was found to be altered in the clones, again 
this was not unexpected because in order to survive the low nutrient conditions of the 
necrotic core, cells would have to have undergone some sort of metabolic adaptation. 
Lipid metabolism and various proteins involved in autophagy were shown to be altered. 
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In particular the expression of autophagy related proteins was indicative of an increased 
level of autophagic flux within the cells. These results are consistent with the 
observation that autophagy was found to be actively occurring in the necrotic core when 
the MCTS were examined immunohistochemically, Furthermore this suggests that these 
cells have a higher level of basal autophagy and therefore are better equipped to survive 
poor nutrient conditions. This also proves that the increased levels of autophagy seen in 
the necrotic core was not a transient change only seen while the cells were within the 
necrotic core but seems to be a stable change. 
One of the most valuable things learnt from the proteomic analysis of the clones was 
that the changes induced or selected for by the necrotic environment seem to have been 
memorised and remain as stable changes even when the cells are returned to favourable 
conditions. An important question this raises is whether the necrotic core induces these 
changes in the cells or merely selects for cells which already possess the ability to 
survive the hostile conditions. Regardless of the answer if this scenario was applied to a 
clinical situation, the end result is still an enriched population of cells which have 
increased metastatic potential, survival ability and stem like characteristics. By their 
very nature, they may be resistant to most chemotherapies and can therefore contribute 
to poor clinical outcome. 
4.3.1 Potential Targets 
The analysis of the proteome of the necrotic core clones has given rise to a number of 
possible targets, some of which have been targeted previously. One of these possible 
targets is Cathepsin B found up regulated in the clones. Inhibitors of this protein have 
been tested both in vitro, in vivo and in the clinic and while they have been found to be 
effective in reducing tumour cell motility and invasiveness they have had issues with off 
target effects and toxicities.67 Another autophagy related target is TGM2, inhibition of 
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this protein has been found to reverse drug resistance in multiple cancer types including 
glioblastoma68 and breast.69 Specifically in breast cancer it was found to be responsible 
for Doxorubicin resistance, similar to NCC1. Therefore inhibition of this protein in the 
necrotic core clones would be very interesting to look into. PPT1 inhibitors have also 
been tested in cancer cells. In neuroblastoma the inhibition of PPT1 was found to 
selectively kill the cells, although this work has yet to progress to in vivo or clinical 
testing PPT1 could be a valid target. Gluathione S-transferease which was found up-
regulated in NCC1 the most chemoresstant clone could also be a possible target to 
sensitise cells to Doxorubicin treatment. ALAT2 which is involved in cellular 
metabolism has also been suggested as a target for cancer therapy. Inhibition of the 
protein has been found to reduce cancer cell proliferation growth and survival. 
Furthermore in vivo research has found that ALAT2 inhibition exerts this effect by 
stimulating mitochondrial activity, cancer growth is therefore impaired as ALAT2 
inhibition counteracts the Warburg effect by up regulating mitochondrial metabolism.70 
MTA2 is another target which has been tested in vivo. Inhibition of this metastasis 
associated protein was found to reduce xenograft growth and lung metastasis in 
immunocompromised mice. Inhibiting this protein therefore could have effects on not 
only the primary tumour but this supposedly would also inhibit those cells with 
metastatic potential which would otherwise be able to metastasise and from new 
metastatic deposits. However all these targets need to be validated in colorectal cancer. 
Though the fact that work has been carried out previously in other tumour types and has 
shown good results is beneficial and provides further evidence that they are valid cancer 
targets. 
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1 Discussion 
Tumour necrosis has been linked to poor patient prognosis since the early 1990s,1 yet no 
conclusive mechanism has been discovered to explain the relationship. Many 
hypotheses have been proposed yet scarce research has been carried out to support 
them, possibly due to necrotic tissue not being considered a necessary target for 
chemotherapeutic intervention. To date the proposed hypotheses include, the presence 
of necrotic tissue correlates with hypoxia which is linked to decreased radiosensitivity,2 
and chemosensitivity.3 Tumour necrosis occurs in fast growing aggressive tumours 
which quickly outgrow their blood supply and therefore necrosis occurs as a result of 
the tumour cells' aggressive nature.4, 5 And finally the idea that the process of necrotic 
cell death itself stimulates inflammation leading to an environment conducive to 
mutagenesis, cell proliferation and subsequent immunosuppression.6 The discovery of 
living cells within the necrotic core of MCTS highlights the importance of 
understanding the link between tumour necrosis and patient prognosis, especially as 
tumour necrosis is a common feature of many different types of solid tumour. 
The aims of this thesis were to understand how and why tumour necrosis was linked to 
poor prognosis by focussing on the necrotic core of multicellular tumour spheroids and 
the cells which reside there. The major finding of this thesis is the identification and 
isolation of viable cells from the necrotic core, which provides an alternative 
explanation for why necrosis is associated with poor prognosis. This discussion will 
evaluate the work done in this thesis to characterise these cells in order to determine 
their biological and therapeutic significance. 
As stated above the primary conclusion to be made from this thesis is that the necrotic 
core of multicellular tumour spheroids contains living cells. To date necrotic tissue has 
largely been overlooked when examining the tumour microenvironment. The first 
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indication of this discovery presented in this thesis occurred when the MCTS were 
immunohistochemically stained for cleaved capase-3 and a number of cells within the 
necrotic core showed negative expression. These negatively stained cells were found to 
be viable when the necrotic core cells were separated from the rest of the cells within 
the MCTS using flow cytometry and cells were found to grow from this population. 
When these cells were examined in situ it was discovered they had an altered cellular 
metabolism, namely they were actively undergoing autophagy and they showed 
different expression of EMT and stem cell markers compared to the other cells in the 
MCTS. This then lead to the next important conclusion, not only were there living cells 
in the necrotic core but these cells were phenotypically distinct from the rest of the cells 
in the MCTS. The changes in EMT and stem cell markers lead to the hypothesis that 
these cells could explain why tumours with high levels of necrosis are more aggressive 
and result in a poor prognosis for the patient. From their expression of EMT and stem 
cell markers it is possible that they are more migratory and metastatic and have other 
stem cell properties. Cells such as these have been implicated in the formation of 
metastases as the tumour cell of origin. Necrotic areas form due to lack of nutrients and 
oxygen; these surviving cells therefore are more resistant to these conditions as many 
stem cells have shown to be.7  
The survival of clones within the necrotic core of MCTS was the first indication that 
there may be another possible hypothesis to explain the link between tumour necrosis 
and poor patient prognosis. The survival and possible enrichment of these cells in the 
tumour population following a spatial and/or temporal decline of oxygen and nutrients 
may hold the key for how to target these cells for destruction. The formation of necrotic 
core clones themselves from the living cells within the MCTS necrotic core was an 
important development in the project. It not only enabled the characterisation of these 
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cells, specifically their migration and stem cell characteristics through functional assays 
but allowed the determination as to the state of changes in the cells, were they transient 
or stable? Transient changes would not explain fully how the viable necrotic core cells 
were the cause of metastasis if once out of the necrotic tissue they returned to their 
original state. A stable change on the other hand would allow for the theory that these 
cells were the cells which cause secondary tumours and relapse. Due to their different 
properties the cells could be able to survive within the hostile environment, and once 
conditions became favourable again their metastatic capabilities would allow them to 
migrate to a new location where stem cell qualities could enable them to form new 
micro metastases. Whilst these changes were seen to be stable within the clones as 
functional analyses were carried out several months post isolation from the MCTS, stem 
like cells are known for their plasticity. Upon attachment to a new location the cell 
would have to undergo the MET in order to attach and begin to grow. To be more 
accurate it seems that the necrotic core selects for characteristics that are useful at the 
current time for the cell and for the future of the tumour.  
When analysed functionally, the clones demonstrated their differences compared to the 
parental cell line. Increased migration seen in the wound healing assay, increased sphere 
formation capabilities, and increased resistance to chemotherapeutics were 
characteristics seen in a number of different clones. These observed characteristics were 
further supported by the proteomic data which showed distinct changes in the proteome 
of the clones. Altered expression was found in proteins involved in migration, invasion 
and metastasis, cell survival, cell metabolism and resistance to chemotherapeutics, 
specifically one of the drugs on which clones response was tested (Doxorubicin). This 
change in protein expression was seen once the clones had returned to two dimensional 
cell culture for a substantial amount of time. An interesting discovery from this work 
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has been that the five necrotic core clones whilst being phenotypically distinct from the 
parental cell line are also phenotypically distinct from each other. In the various 
different functional assays they have shown different responses. Cloned stem cell lines 
from the same tumour as well as from different but histologically similar tumours are 
known to show a variety of different responses to both chemotherapeutics and 
radiation.8,9, 10 Phenotypic stability of these cells is believed to be dependent on the 
stability of the different environmental selective pressures.11 The necrotic core clones 
established in this work mimics the heterogeneous nature of stem-like cell populations 
found in tumours. When tumour populations have been examined, genetically similar 
cells were shown to be functionally heterogeneous. Hence proteomic analysis of the 
cellular heterogeneity might be more accurate in terms of phenotyping the cells 
accurately.  The differing functional capabilities of genetic clones are believed to 
provide increased survival potential during times of stress and occur as the result of 
gene expression noise, epigenetic and tumour microenvironment drivers.12, 13, 14 There is 
increasing amount of evidence to suggest that diversity generating systems are 
evolutionarily selected for.15, 16, 17, 18  Research into single cell prokaryotes found that in 
homogenous populations a small number of cells showed drug resistance which was 
independent of genetic change or acquisition of antibiotic resistance containing 
plasmids. This difference is instead explained by reduced proliferation and entrance into 
a dormant non-dividing state similar to that of the living cells in the necrotic core.19. 
Colorectal cancer is known to involve a comparatively dormant cell population, which 
suggests that cancer cells may have taken advantage of this evolutionary conserved 
process in order to survive in times of hardship. Dormant cells have been extracted from 
colorectal tumours and found to still retain tumour initiation potential, a phenomenon 
which was demonstrated using the MCTS. These dormant cells were shown to become 
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enriched in tumours following the administration of chemotherapeutic drugs. 20 When 
examined in situ the viable cells surviving in the necrotic core of MCTS were positive 
for a marker of senescence. What needs to be taken into account is that even cells in 
homogenous populations don't all respond in a identical matter to stress, this often 
unstated supposition when using cells in bulk two dimensional monolayer populations 
means that when cell responses are averaged single cell heterogeneity can be concealed. 
Separating the MCTS cells into different populations allowed the individual 
characterisation of the fractions, the results of which highlighted the level of variability 
seen over very small distances. By investigating the surviving necrotic core fraction for 
further mechanisms of dormancy and reliance upon certain survival mechanisms, new 
potential targets could be discovered to specifically target this population. 
The metabolic adaptation was investigated with regards to the importance of autophagy 
for cell survival within the necrotic core. Autophagy was found to be up regulated in the 
necrotic core cells in situ, and proteins involved in the process of autophagy were later 
found to still be up-regulated in the proteomic analysis of the clone monolayers. 
Inhibition of autophagy in MCTS was found to increase cell death at depths previously 
found to be survivable by the cells. The role of autophagy in cancer is complicated; the 
autophagy paradox means that autophagy has both pro tumour and tumour suppressive 
effects,21 effects which change depending on the stage of tumour formation. In a tumour 
in the early stages of formation, the inhibition of autophagy can enhance tumourigenesis 
as it functions to increase cellular stress in the absence of nutrient deprivation (as the 
tumour has yet to outgrow the local circulation). As cellular stress increases so do the 
chances of mutations, some of which could be beneficial to the development of the 
tumour. Conversely in an established tumour, specifically one with areas of necrotic 
tissue, autophagy can be used as a survival mechanism by the tumour to endure the low 
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nutrient environment. In the case of established solid tumours therefore, inhibiting 
autophagy could be a valid target for decreasing the tumour mass and for specifically 
targeting cells managing to survive in the harshest microenvironments within the 
tumour. Reducing the number of these metabolically adapted resilient cells such as the 
necrotic core clones, which have been shown to be more aggressive in vitro, would 
hopefully reduce the chances of post treatment relapse. Furthermore autophagy have 
been seen previously to be used by cells as a mechanism of survival when treated with 
chemotherapeutics,22 therefore autophagy inhibitions in combination with other 
cytotoxic drugs could improve the cell kill. 
Research in this project has found that autophagic inhibitors have the potential to target 
and kill hypoxic cells such as those bordering the necrotic core in MCTS. Necrotic 
cores were found to become enlarged as the critical depth within the MCTS where 
necrosis is induced was reduced. By inhibiting autophagy in these oxygen and nutrient 
deprived cells its reduces their survival potential. This demonstrates a way in which to 
treat non proliferating cancer cells. Inhibiting autophagy has been found to target cells 
in the hypoxic, nutrient deprived microenvironment in several cancer types including 
liver23 and pancreatic cancer.24 Though as yet no data has been published on the use of 
autophagy inhibitors to selectively target the tumour microenvironment in colorectal 
cancer as a single agent.  
The colorectal cancer stem cell marker ALDH1 was found to be up regulated in two of 
the three clones evaluated in the proteomic assay. Specifically in one clone (NCC5) 
which was shown to have increased anchorage independent growth, a known stem cell 
characteristic, in the sphere formation assay. And in the other clone (NCC4) which was 
found to be able to form a similarly heterogeneous tumour in vivo compared to the 
parental cell line. The general consensus with identifying cancer stem cells is that 
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cancer stem cells can be definitively defined experimentally by their ability to 
recapitulate the generation of a continuously growing tumour".25 Regardless of title 
however it is clear some of the necrotic core clones have an increased stem-like 
behaviour compared to the parental cell line. In addition NCC4 was found to be capable 
of initiating a fully heterogeneous xenografts with a similar structure to the parental cell 
line. This is regarded as the gold standard of stem cell assays. When the clones were 
first formed their holoclone morphology was consistent with that of stem-like cells 
which have the ability to produce differentiated progeny and a high proliferative 
potential. Clones with this specific compact round morphology are believed to be 
enriched in carcinoma stem cell populations.26  Cancer stem cells or tumour initiating 
cells as they are sometimes known have been found previously in cervical MCTS.27 The 
hypoxic necrotic tumour microenvironment found in many solid tumours could be an, 
albeit harsh, stem cell niche.  
The findings from this research have lead to the identification of a number of possible 
targets as it has discovered certain proteins to be over expressed in the Necrotic Core 
Clones. These proteins have been found to be involved in some of the mechanisms used 
by the cancer cells to survive within the necrotic environment. The altered metabolism 
found in the cells can be targeted, specifically autophagy as discussed previously. The 
cell's cell cycle status could also be a possible target. The living cells within the necrotic 
core are not actively proliferating and express certain senescence markers. Senescence 
is known to be reversible in some cancer cells making these cells potentially dangerous. 
Targeting senescent cells could therefore be a relatively selective way to target the cells 
surviving in necrotic areas. Different methods have been suggested to target senescent 
cancer cells previously due to the observation that senescent tumour cells have 
detrimental properties which warrant their elimination. Mechanisms of targeting include 
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utilising the senescent cell's metabolic phenotype which has been described as hyper 
catabolic. Senescent cells are known to have increased endoplasm reticulum stress and 
glucose consumption, in combination with the up regulation of unfolded protein 
response and protein ubiquitination which leads to the increased targeting of proteins 
for autophagic degradation. Therefore synthetic lethal metabolic targeting has been 
proposed as a way to specifically eliminate these cells.28  
Dormancy has previously been implicated in the survival of some populations of cells 
within a tumour. Cells induced to become quiescent from signals in the 
microenvironment have been implicated of acting like stem cells to cause re growth of 
the tumour at later time. 29 Therefore targeting these cells which are normally immune to 
chemotherapeutics due to their proliferative status has the potential to improve long 
term treatment outcome.  Similarly the differences that stem cells exhibit can be 
targeted as well. Cancer stem cells themselves are not known to be homogeneous; many 
different types of cancer stem cell can be present in the same tumour mass each with 
differing characteristics. This heterogeneous population therefore is not straightforward 
to target. Not only are cancer stem cells not all alike but they themselves can express 
different markers and up regulate different signalling pathways depending on their 
current environment, so a stem cell will not be consistently expressing the same markers 
for its whole life. However by identifying signalling networks which are deregulated in 
cancer stem cells or by finding a key molecule on which the stem cells rely on for a 
critical process such as self-renewal, senescence, chemoresistance, or evasion of cell 
death, these cells may be targeted. Differentiation therapy can also be used to force the 
pluripotent cells to terminally differentiate, thereby extinguishing their potential to form 
new metastatic deposits. Drugs such as retinoic acid have been used to force stem cells 
to differentiate in leukaemias,30 squamous cell carcinomas31 and melanoma,32 causing 
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effects ranging from reduced colony formation33 to increased differentiation and 
apoptosis and reduced proliferation.34 
1.1 Critical Appraisal and Future Works 
Spheroids are considered a model of intermediate complexity between standard two 
dimensional cell culture in vitro and tumour growth in vivo in terms of complexity. Due 
to their structure, the cells inside are at the mercy of different diffusion gradients of 
oxygen and nutrients, just as normal tumour cells would be. The production of 
extracellular matrix by the cells within the MCTS only furthers to improve the 
suitability of the model.35 Like solid tumours, MCTS develop subpopulations of 
quiescent and necrotic cells in the centre which are similar to regions observed in 
tumours that are inadequately supplied by the local vasculature.  They enable the study 
of different cell sub populations within the same MCTS and the effects of the different 
microenvironments' upon them. The cells found within the MCTS also have similar 
growth kinetics to tumours grown in vivo. Similar maximal diffusion distances were 
also seen in the spheroids as have been recorded in clinical tumour tissue.36 Essentially 
MCTS enable the characterization of various sub populations of cells with a variety of 
microenvironments which could lead to new ways of targeting these populations by 
taking advantages of the molecular differences or by normalizing these differences.  
Isolation of different populations of cells from within the MCTS enabled the individual 
study and characterisation of these populations in vitro. Populations which have been 
found to be distinct from each other with regards to the proteome in general,37 and 
specifically cyclin dependant kinase inhibitors.38 However much work has looked into 
MCTS as a model without taking advantage of the differing populations, instead 
combining them all together and masking any potential variations. 
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This body of work has established there are biological differences in cells found capable 
of surviving in areas of necrosis. Furthermore through identification of possible survival 
mechanism and functional differences, and the proteomic investigation of these cells, 
possible targets for further investigation have been established. As yet the reliance of 
the cells upon these aberrantly expressed proteins is not understood, but in order to take 
this work further research would need to be carried out to validate these targets. The 
proteomic analysis provided a starting point for further investigation into identifying 
markers for these viable cells within necrotic tissue. Further work could include 
validating many numbers of these proteins in order to determine their expression in situ 
(within the necrotic core of MCTS). Specifically assays to measure active enzyme 
activity would be imperative in order to determine whether the proteins highlighted in 
the proteomic experiment had functional activity within the cells in the necrotic core.  
Specifically investigating the proteins which are linked to the functional biological data 
presented in Chapters 1, 2 and 3 such as proteins involves in migration and metastasis, 
chemoresistance and cell survival. Focussing further work on the differences between 
NCC1 and NCC3 may also be useful. Both were found to be more resistant to 5-FU 
than the parental cell line yet only NCC1 was found to have a slower rate of 
proliferation. By investigating this further a drug resistance mechanism independent of 
the relationship between proliferation and drug sensitivity may be uncovered. 
Modelling these processes in MCTS has many advantages; however the next stage of 
research would need to be concerned with moving from in vitro to in vivo. Isolating 
cells from within necrotic regions in xenografts and then clinical tissue would serve to 
provide proof of principle for using MCTS as an in vitro model for this area of research. 
Furthermore understanding whether this phenomenon is seen only in colorectal cancer 
or in other cancer types would be important future work.   
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1.2 Concluding Statement 
The aim of this body of research was to examine the necrotic core of MCTS, 
characterise the cells it comprised of and ultimately determine the existence of any 
viable cells with biological and therapeutic significance. The final conclusions to be 
made from this body of work are that within the necrotic core, there is a subpopulation 
of cells that remain viable. Once returned to favourable growth conditions, they retain 
the ability to grow and form colonies. These clones have different characteristics to the 
parental HT-29 cell line and this includes attenuated cellular proliferation, increased 
chemosensitivity and migration and stem-like characteristics. The biological 
implications of these findings could be profound as these studies have identified a 
subset of cells that are traditionally ignored but have the ability to reform tumours once 
growth conditions become favourable. Therapeutically, some of these cells have a 
resistant phenotype and although the mechanism of resistance isn’t known, it could 
represent a novel route to generate the resistant phenotype that typically leads to 
treatment failure in patients. Taken together, the results presented in this thesis provide 
a novel hypothesis to explain the reason why the extent of tumour necrosis described by 
several studies is a poor prognostic factor. Tumour necrosis contributes to poor 
prognosis for patients by providing a microenvironmental niche for the survival of non 
proliferating metabolically adapted aggressive cells which once conditions becomes 
favourable again could be capable of reforming a more aggressive secondary tumour. 
Understanding the biology and exploring the potential mechanisms identified in this 
thesis could lead to novel targets for therapeutic intervention. 
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